


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 9

September 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	.vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	viii
1.7 Cumulative Supplement Legend	ix
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 9
September 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS) (ABBOTT)	ABBVIE INC (ABBVIE) (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ABRAXIX PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)

APP PHARMACEUTICALS (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
APP PHARMACEUTICALS LLC (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
NEXUS PHARMACEUTICALS (NEXUS PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)
ROSS LABORATORIES DIV ABBOTT LABORATORIES (ROSS LABS)	ABBVIE INC (ABBVIE)
SOLVAY PHARMACEUTICALS (SOLVAY)	ABBVIE INC (ABBVIE)
UNIMED PHARMACEUTICALS INC (UNIMED PHARMS)	ABBVIE INC (ABBVIE)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001

SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834	15160	
SINGLE SOURCE	2451	2446	2428	2429	
	(16.9%)	(16.6%)	(16.4%)	(16.0%)	
MULTISOURCE	11953	12187	12328	12653	
	(82.5%)	(82.8%)	(83.1%)	(83.5%)	
THERAPEUTICALLY EQUIVALENT	11792	12037	12187	12509	
	(81.4%)	(81.8%)	(82.2%)	(82.5%)	
NOT THERAPEUTICALLY EQUIVALENT	161	150	141	144	
	(1.1%)	(1.0%)	(1.0%)	(0.9%)	
EXCEPTIONS ¹	76	78	78	78	
	(0.5%)	(0.5%)	(0.5%)	(0.5%)	
NEW MOLECULAR ENTITIES					
APPROVED	6	8	7	9	
NUMBER OF APPLICANTS	810	826	826	836	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
	ZIAGEN					
AB	+ VIIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

+ MIKART 325MG;50MG

A089987 001 Oct 26, 1992 Jun CRLD

PHRENILIN

@ VALEANT 325MG;50MG

A087811 001 Jun 19, 1985 Jun DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	LANNETT HOLDINGS INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012	Aug	NEWA
----	----------------------	-----------------	-------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

NEXGEN PHARMA INC 300MG;50MG;40MG;30MG

A076560 002 Jul 19, 2012 Jul NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
----	---------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

CAPITAL AND CODEINE

+ VALEANT 120MG/5ML;12MG/5ML

A086024 001 Jan CTEC

+ VALEANT PHARMS LLC 120MG/5ML;12MG/5ML

A086024 001 Jun CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ NESHER PHARMS 500MG/15ML;7.5MG/15ML

A040366 001 Jan 23, 2002 Jun DISC

AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
----	------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
----	---------------------	-----------	-------------	--------------	-----	------

AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
----	--	-------------	-------------	--------------	-----	------

AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA
----	--	------------	-------------	--------------	-----	------

>D>	@ ENDO PHARMS	500MG;5MG	A040281 001	Sep 30, 1998	Sep	CAHN
-----	---------------	-----------	-------------	--------------	-----	------

>D>	@	500MG;7.5MG	A040280 001	Sep 30, 1998	Sep	CAHN
-----	---	-------------	-------------	--------------	-----	------

>D>	@	650MG;7.5MG	A040280 002	Sep 30, 1998	Sep	CAHN
-----	---	-------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	@	ENDO PHARMS	650MG;10MG	A040280	003	Sep 30, 1998	Sep	CAHN
>D>	@		750MG;7.5MG	A040281	002	Sep 30, 1998	Sep	CAHN
>A>	@	VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998	Sep	CAHN
>A>	@		500MG;7.5MG	A040280	001	Sep 30, 1998	Sep	CAHN
>A>	@		650MG;7.5MG	A040280	002	Sep 30, 1998	Sep	CAHN
>A>	@		650MG;10MG	A040280	003	Sep 30, 1998	Sep	CAHN
>A>	@		750MG;7.5MG	A040281	002	Sep 30, 1998	Sep	CAHN

VICODIN

>D>	AA	+	ABBOTT	500MG;5MG	A088058	001	Jan 07, 1983	Sep	CAHN
>A>	AA	+	ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983	Sep	CAHN

VICODIN ES

>D>	AA	+	ABBOTT	750MG;7.5MG	A089736	001	Dec 09, 1988	Sep	CAHN
>A>	AA	+	ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988	Sep	CAHN

VICODIN HP

>D>	AA		ABBOTT	660MG;10MG	A040117	001	Sep 23, 1996	Sep	CAHN
>A>	AA		ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996	Sep	CAHN

ZYDONE

>D>	+	ENDO PHARMS	400MG;5MG	A040288	001	Nov 27, 1998	Sep	CAHN
>D>	+		400MG;7.5MG	A040288	002	Nov 27, 1998	Sep	CAHN
>D>	+		400MG;10MG	A040288	003	Nov 27, 1998	Sep	CAHN
>A>	+	VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998	Sep	CAHN
>A>	+		400MG;7.5MG	A040288	002	Nov 27, 1998	Sep	CAHN
>A>	+		400MG;10MG	A040288	003	Nov 27, 1998	Sep	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	@	ENDO PHARMS	500MG;5MG	A040303	001	Dec 30, 1999	Sep	CAHN
>A>	@	VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999	Sep	CAHN

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03, 2012	Mar	NEWA
AA			325MG;10MG	A040800	002	Apr 03, 2012	Mar	NEWA
AA		ALVOGEN INC	325MG;7.5MG	A202677	001	Jul 26, 2012	Jul	NEWA
AA			325MG;10MG	A202677	002	Jul 26, 2012	Jul	NEWA

PERCOCET

>D>	AA	+	ENDO PHARMS	325MG;2.5MG	A040330	001	Jun 25, 1999	Sep	CAHN
>D>		@		325MG;5MG	A085106	002		Sep	CAHN
>D>	AA	+		325MG;5MG	A040330	002	Jun 25, 1999	Sep	CAHN
>D>	AA	+		325MG;7.5MG	A040434	001	Nov 23, 2001	Sep	CAHN
>D>	AA	+		325MG;10MG	A040434	002	Nov 23, 2001	Sep	CAHN
>D>	AA	+		500MG;7.5MG	A040341	001	Jul 26, 1999	Sep	CAHN
>D>	AA	+		650MG;10MG	A040341	002	Jul 26, 1999	Sep	CAHN
>A>	AA	+	VINTAGE PHARMS LLC	325MG;2.5MG	A040330	001	Jun 25, 1999	Sep	CAHN
>A>		@		325MG;5MG	A085106	002		Sep	CAHN
>A>	AA	+		325MG;5MG	A040330	002	Jun 25, 1999	Sep	CAHN
>A>	AA	+		325MG;7.5MG	A040434	001	Nov 23, 2001	Sep	CAHN
>A>	AA	+		325MG;10MG	A040434	002	Nov 23, 2001	Sep	CAHN
>A>	AA	+		500MG;7.5MG	A040341	001	Jul 26, 1999	Sep	CAHN
>A>	AA	+		650MG;10MG	A040341	002	Jul 26, 1999	Sep	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Mar	NEWA
AB	ZYDUS PHARMS USA INC	325MG;37.5MG	A090460	001	Sep 06, 2012	Aug	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Apr	NEWA
AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD
	DIAMOX						
	@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990	Apr	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA INC	20%	A203853	001	Jun 21, 2012	Jun	NEWA
----	----------------	-----	---------	-----	--------------	-----	------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

	+ FOREST LABS INC	0.375MG/INH	N202450	001	Jul 23, 2012	Jul	NEWA
--	-------------------	-------------	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@ HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997	May	CAHN
--	-----------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

	@ HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	May	CAHN
--	-----------------------	-------	---------	-----	--------------	-----	------

	@	800MG	A074891	002	Oct 31, 1997	May	CAHN
--	---	-------	---------	-----	--------------	-----	------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB	TOLMAR	0.3%	A200298	001	Jun 14, 2012	Jun	NEWA
----	--------	------	---------	-----	--------------	-----	------

DIFFERIN

AB	+ GALDERMA LABS LP	0.3%	N021753	001	Jun 19, 2007	Jun	CFTG
----	--------------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

	+ GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	Apr	CAHN
--	--------------------	------	---------	-----	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

	@ TEVA PARENTERAL	3MG/ML	A078676	001	Jul 31, 2008	Mar	DISC
--	-------------------	--------	---------	-----	--------------	-----	------

	@	3MG/ML	A076564	001	Jun 16, 2004	Jan	DISC
--	---	--------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	AN	TEVA PARENTERAL	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Sep	CAHN
>A>	AN	TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Sep	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>A>	AN	RITEDOSE CORP	EQ 0.083% BASE;0.017%	A202496	001	Oct 01, 2012	Sep	NEWA
		@ SANDOZ INC	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Apr	DISC
>D>	AN	TEVA PARENTERAL	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007	Sep	CAHN
>A>	AN	TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007	Sep	CAHN

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+		MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012	Mar	NEWA
---	--	----------------	--------------	---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	10MG	A079060	001	Aug 30, 2012	Aug	NEWA
AB		INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
AB		WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Jul	NEWA

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@		GENZYME	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC
---	--	---------	-------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>D>	AB	ALPHAPHARM	0.25MG	A074046	001	Oct 19, 1993	Sep	CAHN
>D>	AB		0.5MG	A074046	002	Oct 19, 1993	Sep	CAHN
>D>	AB		1MG	A074046	003	Oct 19, 1993	Sep	CAHN
>D>	AB		2MG	A074046	004	May 07, 1997	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993	Sep	CAHN
>A>	AB		0.5MG	A074046	002	Oct 19, 1993	Sep	CAHN
>A>	AB		1MG	A074046	003	Oct 19, 1993	Sep	CAHN
>A>	AB		2MG	A074046	004	May 07, 1997	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@		SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
@			1MG	A077777	002	Jun 30, 2006	Mar	DISC
@			2MG	A077777	003	Jun 30, 2006	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC	3MG	A077777 004	Jun 30, 2006	Mar	DISC
@ VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007	Jul	DISC
@	1MG	A078442 002	Oct 15, 2007	Jul	DISC
@	2MG	A078442 003	Oct 15, 2007	Jul	DISC
@	3MG	A078442 004	Oct 15, 2007	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726 001	Jan 19, 2005	Jan	CAHN
AB		0.5MG	N021726 002	Jan 19, 2005	Jan	CAHN
AB	+	1MG	N021726 003	Jan 19, 2005	Jan	CAHN
AB		2MG	N021726 004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+	CUBIST PHARMS	12MG	N021775 001	May 20, 2008	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065 001	May 15, 2003	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

AMCINONIDE

+	FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096 001	Nov 19, 2002	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@	HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC
---	---------	-----------------	-------------	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15% (150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA
	15% (300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
-----------------	------------------	-------------	--------------	-----	------

NOVAMINE 15%

@	HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT
---	-------------	------------------	-------------	--------------	-----	------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@	CLOVER PHARMS	250MG/ML	N015229 002		Mar	CAHN
---	---------------	----------	-------------	--	-----	------

SYRUP; ORAL

AMICAR

AA	+	CLOVER PHARMS	1.25GM/5ML	N015230 002		Mar	CAHN
----	---	---------------	------------	-------------	--	-----	------

TABLET; ORAL

AMICAR

AB		CLOVER PHARMS	500MG	N015197 001		Mar	CAHN
	+		1GM	N015197 002	Jun 24, 2004	Mar	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ BEDFORD	50MG/ML	A076018	001	Oct 15, 2002	Jun	DISC
@ BEDFORD LABS	50MG/ML	A076299	001	Oct 24, 2002	Jun	DISC
@ TEVA PARENTERAL	50MG/ML	A076163	001	Sep 05, 2003	Jan	DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MURTY PHARMS	200MG	A077069	001	Apr 08, 2005	May	CAHN
AB		400MG	A077069	002	Apr 08, 2005	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CARACO	10MG	A040816	002	Jun 27, 2008	Apr	NEWA
AB		50MG	A040816	003	Jun 27, 2008	Apr	NEWA
AB		75MG	A040816	004	Jun 27, 2008	Apr	NEWA
AB		100MG	A040816	005	Jun 27, 2008	Apr	NEWA
AB		150MG	A040816	006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Feb	CTEC
+		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Feb	CRLD
	LIMBITROL						
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001		Feb	DISC
	LIMBITROL DS						
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380	002	Apr 13, 2012	Mar	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012	Aug	NEWA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

>D>	NOVARTIS	5MG;12.5MG;160MG	N022314	001	Apr 30, 2009	Sep	CFTG
>A>	AB	5MG;12.5MG;160MG	N022314	001	Apr 30, 2009	Sep	CFTG
>D>		5MG;25MG;160MG	N022314	002	Apr 30, 2009	Sep	CFTG
>A>	AB	5MG;25MG;160MG	N022314	002	Apr 30, 2009	Sep	CFTG
>D>		10MG;12.5MG;160MG	N022314	003	Apr 30, 2009	Sep	CFTG
>A>	AB	10MG;12.5MG;160MG	N022314	003	Apr 30, 2009	Sep	CFTG

TABLET; ORALEXFORGE HCT

>D>		NOVARTIS	10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
>A>	AB		10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
>D>		+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG
>A>	AB	+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTANTABLET; ORAL

>A>		AMLODIPINE,VALSARTAN AND HYDROCHLOROTHIAZIDE					
>A>	AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435 001	Sep 25, 2012	Sep	NEWA
>A>	AB		5MG;25MG;160MG	A200435 002	Sep 25, 2012	Sep	NEWA
>A>	AB		10MG;12.5MG;160MG	A200435 005	Sep 25, 2012	Sep	NEWA
>A>	AB		10MG;25MG;160MG	A200435 003	Sep 25, 2012	Sep	NEWA
>A>	AB		10MG;25MG;320MG	A200435 004	Sep 25, 2012	Sep	NEWA

AMOXICILLINTABLET, FOR SUSPENSION; ORALDISPERMOX

@	RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
---	------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUMFOR SUSPENSION; ORALAMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORALAMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORALADDERALL XR 10

AB	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG	
AB		ADDERALL XR 15					
AB	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG	
AB		ADDERALL XR 20					
AB	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG	
AB		ADDERALL XR 25					
AB	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG	
AB		ADDERALL XR 30					
AB	+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
AB		ADDERALL XR 5					
AB	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG	

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA
----	-------------------	-------------------------	-------------	--------------	-----	------

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

	INDEPENDENCE PHARMS	5MG	A200166 001	Aug 09, 2012	Jul	NEWA
+		10MG	A200166 002	Aug 09, 2012	Jul	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Aug	CAHN
AP		EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Aug	CAHN
AP		EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Aug	CAHN
AP		EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Aug	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
----	-----------	---------------	-------------	--------------	-----	------

ANAGRELIDE HYDROCHLORIDE

>D>	AB	ALPHAPHARM	EQ 0.5MG BASE	A077613 001	Jun 27, 2006	Sep	CAHN
>D>	AB		EQ 1MG BASE	A077613 002	Jun 27, 2006	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A077613 001	Jun 27, 2006	Sep	CAHN
>A>	AB		EQ 1MG BASE	A077613 002	Jun 27, 2006	Sep	CAHN
	@	SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
	@		EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
AB	IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA

APREPITANT

CAPSULE; ORAL

APREPITANT

>A>	AB	SANDOZ	40MG	A090999 001	Sep 24, 2012	Sep	NEWA
>A>	AB		80MG	A090999 002	Sep 24, 2012	Sep	NEWA
>A>	AB		125MG	A090999 003	Sep 24, 2012	Sep	NEWA
		EMEND					
>D>		MERCK	40MG	N021549 003	Jun 30, 2006	Sep	CFTG
>A>	AB		40MG	N021549 003	Jun 30, 2006	Sep	CFTG
>D>			80MG	N021549 001	Mar 26, 2003	Sep	CFTG
>A>	AB		80MG	N021549 001	Mar 26, 2003	Sep	CFTG
>D>	+		125MG	N021549 002	Mar 26, 2003	Sep	CFTG
>A>	AB	+	125MG	N021549 002	Mar 26, 2003	Sep	CFTG

APROTININ

INJECTABLE; INJECTION

TRASYLOL

@ BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
------------------	--------------	-------------	--------------	-----	------

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP + PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
-------------	------------------------	-------------	--------------	-----	------

ARGATROBAN

AP HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA
-----------------------	------------------------	-------------	--------------	-----	------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
---------------------	------	-------------	--------------	-----	------

AB	150MG	A200043 002	Jun 01, 2012	May	NEWA
----	-------	-------------	--------------	-----	------

AB	250MG	A200043 003	Jun 01, 2012	May	NEWA
----	-------	-------------	--------------	-----	------

WATSON LABS INC

100MG	A200156 002	Aug 29, 2012	Aug	NEWA
-------	-------------	--------------	-----	------

200MG	A200156 004	Aug 29, 2012	Aug	NEWA
-------	-------------	--------------	-----	------

NUVIGIL

AB CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
-------------	------	-------------	--------------	-----	------

AB	150MG	N021875 003	Jun 15, 2007	May	CFTG
----	-------	-------------	--------------	-----	------

AB +	250MG	N021875 004	Jun 15, 2007	May	CFTG
------	-------	-------------	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
-------------------	--	-------------	--------------	-----	------

MOVIPREP

AA + SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG
-------------------	--	-------------	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

ORGANON SUB MERCK	EQ 5MG BASE	N022117 001	Aug 13, 2009	Jul	CAHN
-------------------	-------------	-------------	--------------	-----	------

+	EQ 10MG BASE	N022117 002	Aug 13, 2009	Jul	CAHN
---	--------------	-------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>D>	@ ENDO PHARMS	325MG;50MG;40MG;30MG	A075351 001	Mar 05, 1999	Sep	CAHN
-----	---------------	----------------------	-------------	--------------	-----	------

>A>	@ VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351 001	Mar 05, 1999	Sep	CAHN
-----	----------------------	----------------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN
----------------	-------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	---------	-----	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Jun	DISC
@		25MG	A079017	002	Sep 17, 2010	Jun	DISC
@		40MG	A079017	003	Sep 17, 2010	Jun	DISC
@		60MG	A079017	004	Sep 17, 2010	Jun	DISC
@		80MG	A079017	005	Sep 17, 2010	Jun	DISC
@		100MG	A079017	006	Sep 17, 2010	Jun	DISC

STRATTERA

LILLY	10MG	N021411	002	Nov 26, 2002	Jun	CTEC
	18MG	N021411	003	Nov 26, 2002	Jun	CTEC
	25MG	N021411	004	Nov 26, 2002	Jun	CTEC
	40MG	N021411	005	Nov 26, 2002	Jun	CTEC
+	60MG	N021411	006	Nov 26, 2002	Jun	CTEC
	80MG	N021411	007	Feb 14, 2005	Jun	CTEC
	100MG	N021411	008	Feb 14, 2005	Jun	CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 10MG BASE	A090548	001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A090548	002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A090548	003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A090548	004	May 29, 2012	May	NEWA
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650	001	Jul 17, 2012	Jul	NEWA
AB		EQ 20MG BASE	A091650	002	Jul 17, 2012	Jul	NEWA
AB		EQ 40MG BASE	A091650	003	Jul 17, 2012	Jul	NEWA
AB		EQ 80MG BASE	A202357	001	Jul 17, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226	001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A091226	002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A091226	003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A091226	004	May 29, 2012	May	NEWA
AB	SANDOZ INC	EQ 10MG BASE	A077575	001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A077575	002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A077575	003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A077575	004	May 29, 2012	May	NEWA
AB	TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A078773	002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A078773	003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A078773	004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901	001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489	001	Feb 17, 2012	Feb	NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE								
AP	+	BEDFORD	10MG/ML	A074900	001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488	001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML; 2.5MG/5ML	A087708	001	May 03, 1982	Apr	CRLD
		LOMOTIL						
		@ GD SEARLE LLC	0.025MG/5ML; 2.5MG/5ML	N012699	001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

		VIVUS	50MG	N202276	001	Apr 27, 2012	Apr	NEWA
			100MG	N202276	002	Apr 27, 2012	Apr	NEWA
	+		200MG	N202276	003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

		PFIZER	1MG	N202324	001	Jan 27, 2012	Jan	NEWA
	+		5MG	N202324	002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

	+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun	CAHN
--	---	----------------	-----	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALCON PHARMA	0.05%	A202305	001	May 31, 2012	May	NEWA
----	--	--------------	-------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

ASTEPRO

AB	+	MEDA PHARMS	EQ 0.1876MG BASE/SPRAY	N022371	001	Aug 31, 2009	Aug	CFTG
----	---	-------------	------------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

AB		APOTEX INC	EQ 0.1876MG BASE/SPRAY	A201846	001	Aug 31, 2012	Aug	NEWA
----	--	------------	------------------------	---------	-----	--------------	-----	------

AB		SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423	001	May 23, 2012	May	NEWA
----	--	-------------------	-----------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

	+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	May	NEWA
--	---	-------------	--	---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN
--	--	-------------------	-------------------	---------	-----	--------------	-----	------

	+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN
--	---	--	-------------------	---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL; 12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN
--	--	-------------------	---------------------------	---------	-----	--------------	-----	------

	+		EQ 40MG MEDOXOMIL; 25MG	N202331	002	Dec 20, 2011	Apr	CAHN
--	---	--	-------------------------	---------	-----	--------------	-----	------

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

@	PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007	Jul	DISC
@	TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
@		EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA
AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

	CNS THERAPS INC	1MG/ML	N022462 004	Jun 22, 2012	Jun	NEWA
--	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BACLOFEN

>D>	AB	MATRIX LABS LTD	10MG	A090334 001	Feb 18, 2010	Sep CAHN
>D>	AB		20MG	A090334 002	Feb 18, 2010	Sep CAHN
>A>	AB	MYLAN PHARMS INC	10MG	A090334 001	Feb 18, 2010	Sep CAHN
>A>	AB		20MG	A090334 002	Feb 18, 2010	Sep CAHN
	AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb CAHN
	AB		20MG	A077088 001	Oct 31, 2007	Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@	UCB INC	10MG	N021589 001	Oct 30, 2003	Jan	CAHN
@		20MG	N021589 002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+	SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012	Feb	NEWA
---	--------------	-------	-------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

>D>	+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Sep CPOT
>A>	+		0.08MG/ACTUATION	N202813 001	Mar 23, 2012	Sep CPOT
	+		0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

>D>	AB	NOVARTIS	5MG	N019851 001	Jun 25, 1991	Sep CAHN
>D>	AB		10MG	N019851 002	Jun 25, 1991	Sep CAHN
>D>	AB		20MG	N019851 003	Jun 25, 1991	Sep CAHN
>D>	AB	+	40MG	N019851 004	Jun 25, 1991	Sep CAHN
>A>	AB	US PHARMS HOLDINGS I	5MG	N019851 001	Jun 25, 1991	Sep CAHN
>A>	AB		10MG	N019851 002	Jun 25, 1991	Sep CAHN
>A>	AB		20MG	N019851 003	Jun 25, 1991	Sep CAHN
>A>	AB	+	40MG	N019851 004	Jun 25, 1991	Sep CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

LOTENSIN HCT

>D>	AB	NOVARTIS	5MG;6.25MG	N020033 001	May 19, 1992	Sep	CAHN
>D>	AB		10MG;12.5MG	N020033 002	May 19, 1992	Sep	CAHN
>D>	AB		20MG;12.5MG	N020033 004	May 19, 1992	Sep	CAHN
>D>	AB	+	20MG;25MG	N020033 003	May 19, 1992	Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	5MG;6.25MG	N020033 001	May 19, 1992	Sep	CAHN
>A>	AB		10MG;12.5MG	N020033 002	May 19, 1992	Sep	CAHN
>A>	AB		20MG;12.5MG	N020033 004	May 19, 1992	Sep	CAHN
>A>	AB	+	20MG;25MG	N020033 003	May 19, 1992	Sep	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@ NESHER PHARMS

100MG

A040795 001 Oct 31, 2007 Jun DISC

@

200MG

A040795 002 Oct 31, 2007 Jun DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB VALEANT INTL

5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Apr CAHN

BT

+

5%;EQ 1% BASE

N050756 002 Apr 20, 2007 Apr CAHN

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D>	AB	DOW PHARM SCIENCES	5%;EQ 1% BASE	A065443 001	Aug 11, 2009	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	5%;EQ 1% BASE	A065443 001	Aug 11, 2009	Sep	CAHN
	AB	PERRIGO ISRAEL	5%;1.2%	A090979 001	Jun 26, 2012	Jun	NEWA
		DUAC					
	AB	+	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002	Jun CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB + VALEANT INTL

5%;3%

N050557 001 Oct 26, 1984 Jan CAHN

BENZAMYCIN PAK

+ VALEANT INTL

5%;3%

N050769 001 Nov 27, 2000 Jun CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA EMCURE PHARMS LTD 50MG

A202061 001 Jan 27, 2012 Jan NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP APP PHARMS LLC 1MG/ML

A090233 001 Jul 28, 2009 May CAHN

COGENTIN

AP + OAK PHARMS AKORN 1MG/ML

N012015 001 Feb CAHN

TABLET; ORAL

BENZTROPINE MESYLATE

@ LANNETT HOLDINGS INC 0.5MG

A088877 001 Apr 11, 1985 Jan DISC

@ 1MG

A088894 001 Apr 11, 1985 Jan DISC

@ 2MG

A088895 001 Apr 11, 1985 Jan DISC

AA PROSAM LABS 0.5MG

A040699 001 Feb 14, 2008 Feb CMFD

AA 1MG

A040705 001 Feb 14, 2008 Feb CMFD

TABLET; ORAL

BENZTROPINE MESYLATE

AA		PROSAM LABS	2MG	A040706 001	Feb 14, 2008	Feb	CMFD
AA	+	USL PHARMA	0.5MG	A040103 001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103 002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103 003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ SCHERING

0.6MG/5ML

N014215 002

May DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137 001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	-------------	--------------	-----	------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215 001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276 001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	-------------	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502 001	Jun 05, 2001	Jan	CAHN
----	--	----------------	------------------	-------------	--------------	-----	------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516 001	Jun 16, 2005	Jan	CAHN
----	--	----------------	------------------	-------------	--------------	-----	------

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010 001	Dec 08, 2000	Feb	CAHN
----	---	---------------	------------------	-------------	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ STIEFEL

EQ 0.12% BASE

N020934 001 Feb 28, 1999 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB		TEVA WOMENS	5MG	N019982 002	Jul 31, 1992	Jan	CAHN
----	--	-------------	-----	-------------	--------------	-----	------

AB	+		10MG	N019982 001	Jul 31, 1992	Jan	CAHN
----	---	--	------	-------------	--------------	-----	------

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ MERCK SHARP DOHME

200MG

N202258 001 May 13, 2011 Mar CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL N021602 001 May 13, 2003 Jan CDFR

BOSENTAN

TABLET; ORAL
TRACLEER

ACTELION PHARMS LTD 62.5MG N021290 001 Nov 20, 2001 May CAHN
+ 125MG N021290 002 Nov 20, 2001 May CAHN

>A> BOSUTINIB MONOHYDRATE

>A> TABLET; ORAL

>A> BOSULIF

>A> WYETH PHARMS INC EQ 100MG BASE N203341 001 Sep 04, 2012 Sep NEWA

>A> + EQ 500MG BASE N203341 002 Sep 04, 2012 Sep NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

PARLODEL

>D> AB + NOVARTIS EQ 5MG BASE N017962 002 Mar 01, 1982 Sep CAHN

>A> AB + US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Sep CAHN

TABLET; ORAL

PARLODEL

>D> AB + NOVARTIS EQ 2.5MG BASE N017962 001 Sep CAHN

>A> AB + US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Sep CAHN

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT

@ ASTRAZENECA 0.16MG/INH N020441 002 Jun 24, 1997 Jun DISC

SUSPENSION; INHALATION

BUDESONIDE

>D> AN TEVA PARENTERAL 0.25MG/2ML A077519 001 Nov 18, 2008 Sep CAHN

>D> AN 0.5MG/2ML A077519 002 Nov 18, 2008 Sep CAHN

>A> AN TEVA PHARMS 0.25MG/2ML A077519 001 Nov 18, 2008 Sep CAHN

>A> AN 0.5MG/2ML A077519 002 Nov 18, 2008 Sep CAHN

AN WATSON LABS INC 0.25MG/2ML A078404 001 Jul 31, 2012 Jul NEWA

AN 0.5MG/2ML A078404 002 Jul 31, 2012 Jul NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA 0.08MG/INH;0.0045MG/INH N021929 001 Jul 21, 2006 Jan CDFR

+ 0.16MG/INH;0.0045MG/INH N021929 002 Jul 21, 2006 Jan CDFR

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

@ PACIRA PHARMS INC 133MG/10ML (13.3MG/ML) N022496 001 Oct 28, 2011 Jul DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB + ROXANE EQ 8MG BASE A078633 002 Oct 08, 2009 Aug CRLD

TABLET; SUBLINGUAL

SUBUTEX

@ RECKITT BENCKISER	EQ 2MG BASE	N020732 002	Oct 08, 2002	Aug	DISC
@	EQ 8MG BASE	N020732 003	Oct 08, 2002	Aug	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
	EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012	Aug	NEWA
+	EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN
	EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012	Aug	NEWA

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
+	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D>	AB3	IMPAX LABS	300MG	A077415 002	Dec 15, 2006	Sep	CTEC
>A>	BX		300MG	A077415 002	Dec 15, 2006	Sep	CTEC
	AB1	WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012	Aug	NEWA
	AB1		150MG	A201331 002	Aug 30, 2012	Aug	NEWA
	AB1		200MG	A201331 003	Aug 30, 2012	Aug	NEWA
		FORFIVO XL					
+		EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
		WELLBUTRIN SR					
>D>	AB1	+ GLAXOSMITHKLINE	150MG	N020358 003	Oct 04, 1996	Sep	CRLD
>A>	AB1		150MG	N020358 003	Oct 04, 1996	Sep	CRLD
>D>	AB1		200MG	N020358 004	Jun 14, 2002	Sep	CRLD
>A>	AB1	+	200MG	N020358 004	Jun 14, 2002	Sep	CRLD
		WELLBUTRIN XL					
>D>	AB3	+ VALEANT INTL	150MG	N021515 001	Aug 28, 2003	Sep	CRLD
>A>	AB3		150MG	N021515 001	Aug 28, 2003	Sep	CRLD
>D>	AB3		300MG	N021515 002	Aug 28, 2003	Sep	CRLD
>A>	AB3	+	300MG	N021515 002	Aug 28, 2003	Sep	CRLD

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

	@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
	@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
	@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
	@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
	@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
	@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
	@ NESHER PHARMS	5MG	A075572 001	Feb 27, 2002	Jun	DISC
	@	10MG	A075572 002	Feb 27, 2002	Jun	DISC
	@	15MG	A075572 003	Feb 27, 2002	Jun	DISC
	@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
AB		5MG	A075388 001	May 09, 2002	Feb	CMFD
	@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
	@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB		15MG	A075388 003	May 09, 2002	Feb	CMFD

TABLET; ORAL

	BUSPIRONE HYDROCHLORIDE								
AB	PROSAM LABS	30MG	A078302	001	Dec 17, 2007	Feb	CMFD		

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

	BUTOCONAZOLE NITRATE								
	@ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Apr	NEWA		

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

	CAFCIT								
AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jan	CAHN		

	CAFFEINE CITRATE								
AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827	001	Aug 29, 2012	Aug	NEWA		

SOLUTION; ORAL

	CAFCIT								
AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan	CAHN		

	CAFFEINE CITRATE								
AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102	001	Aug 29, 2012	Aug	NEWA		

CALCIPOTRIENE

CREAM; TOPICAL

	CALCIPOTRIENE								
AB	TOLMAR	0.005%	A200935	001	May 30, 2012	May	NEWA		

	DOVONEX								
AB	+ LEO PHARMA AS	0.005%	N020554	001	Jul 22, 1996	May	CFTG		

SOLUTION; TOPICAL

	CALCIPOTRIENE								
AT	FOUGERA PHARMS	0.005%	A078305	001	May 06, 2008	Jan	CAHN		

CALCIUM ACETATE

CAPSULE; ORAL

	CALCIUM ACETATE								
AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312	001	Jun 01, 2012	May	NEWA		

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL								
>D>	@ ENDO LABS	12.5MG	A074418	001	Feb 13, 1996	Sep	CAHN		

>D>	@	25MG	A074418	002	Feb 13, 1996	Sep	CAHN		
-----	---	------	---------	-----	--------------	-----	------	--	--

>D>	@	50MG	A074418	003	Feb 13, 1996	Sep	CAHN		
-----	---	------	---------	-----	--------------	-----	------	--	--

>D>	@	100MG	A074418	004	Feb 13, 1996	Sep	CAHN		
-----	---	-------	---------	-----	--------------	-----	------	--	--

>A>	@ VINTAGE PHARMS LLC	12.5MG	A074418	001	Feb 13, 1996	Sep	CAHN		
-----	----------------------	--------	---------	-----	--------------	-----	------	--	--

>A>	@	25MG	A074418	002	Feb 13, 1996	Sep	CAHN		
-----	---	------	---------	-----	--------------	-----	------	--	--

>A>	@	50MG	A074418	003	Feb 13, 1996	Sep	CAHN		
-----	---	------	---------	-----	--------------	-----	------	--	--

>A>	@	100MG	A074418	004	Feb 13, 1996	Sep	CAHN		
-----	---	-------	---------	-----	--------------	-----	------	--	--

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	CAPTOPRIL AND HYDROCHLOROTHIAZIDE								
>D>	@ ENDO LABS	25MG;15MG	A074788	001	Dec 29, 1997	Sep	CAHN		

>D>	@	25MG;25MG	A074788	002	Dec 29, 1997	Sep	CAHN		
-----	---	-----------	---------	-----	--------------	-----	------	--	--

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

>D>	@ ENDO LABS	50MG;15MG	A074788 004	Dec 29, 1997	Sep	CAHN
>D>	@	50MG;25MG	A074788 003	Dec 29, 1997	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	25MG;15MG	A074788 001	Dec 29, 1997	Sep	CAHN
>A>	@	25MG;25MG	A074788 002	Dec 29, 1997	Sep	CAHN
>A>	@	50MG;15MG	A074788 004	Dec 29, 1997	Sep	CAHN
>A>	@	50MG;25MG	A074788 003	Dec 29, 1997	Sep	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A>	AB	TEVA PHARMS	100MG	A078592 001	Sep 20, 2012	Sep	NEWA
>A>	AB		200MG	A078592 002	Sep 20, 2012	Sep	NEWA
>A>	AB		300MG	A078592 003	Sep 20, 2012	Sep	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
	STALEVO 100					
AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
	STALEVO 150					
AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA

PARAPLATIN

@ CORDEN PHARMA

@

@

	@ CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989	Feb	CAHN
	@	150MG/VIAL	N019880 002	Mar 03, 1989	Feb	CAHN
	@	450MG/VIAL	N019880 003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+	ONYX PHARMS	60MG/VIAL	N202714	001	Jul 20, 2012	Jul	NEWA
---	-------------	-----------	---------	-----	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	---------	-----	--------------	-----	------

CEFACTOR

CAPSULE; ORAL

CEFACTOR

@ RANBAXY

EQ 250MG BASE

A064156	001	Aug 28, 1997	Apr	DISC
---------	-----	--------------	-----	------

@

EQ 500MG BASE

A064156	002	Aug 28, 1997	Apr	DISC
---------	-----	--------------	-----	------

FOR SUSPENSION; ORAL

CEFACTOR

@ RANBAXY

EQ 125MG BASE/5ML

A064166	001	Oct 02, 1997	Apr	DISC
---------	-----	--------------	-----	------

AB	+		EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Feb	CTEC
----	---	--	-------------------	---------	-----	--------------	-----	------

EQ 187MG BASE/5ML

A064165	001	Oct 02, 1997	Apr	DISC
---------	-----	--------------	-----	------

EQ 187MG BASE/5ML

A064165	001	Oct 02, 1997	Feb	CTEC
---------	-----	--------------	-----	------

AB	+		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Apr	DISC
----	---	--	-------------------	---------	-----	--------------	-----	------

EQ 250MG BASE/5ML

A064164	001	Oct 02, 1997	Apr	DISC
---------	-----	--------------	-----	------

EQ 375MG BASE/5ML

A064155	001	Oct 02, 1997	Apr	DISC
---------	-----	--------------	-----	------

AB	+		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Feb	CTEC
----	---	--	-------------------	---------	-----	--------------	-----	------

EQ 375MG BASE/5ML

A064155	001	Oct 02, 1997	Feb	CTEC
---------	-----	--------------	-----	------

AB		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Feb	NEWA
----	--	-----------------	-------------------	---------	-----	--------------	-----	------

EQ 187MG BASE/5ML

A065412	002	Feb 17, 2012	Feb	NEWA
---------	-----	--------------	-----	------

EQ 250MG BASE/5ML

A065412	003	Feb 17, 2012	Feb	NEWA
---------	-----	--------------	-----	------

AB			EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Feb	NEWA
----	--	--	-------------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD

EQ 125MG BASE

A065092	001	Dec 22, 2003	Apr	DISC
---------	-----	--------------	-----	------

@

EQ 187MG BASE

A065092	002	Dec 22, 2003	Apr	DISC
---------	-----	--------------	-----	------

@

EQ 250MG BASE

A065092	003	Dec 22, 2003	Apr	DISC
---------	-----	--------------	-----	------

@

EQ 375MG BASE

A065092	004	Dec 22, 2003	Apr	DISC
---------	-----	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD

EQ 500MG BASE

A065015	001	Jun 22, 1999	Apr	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

CEFADROXIL

@ RANBAXY

EQ 1GM BASE

A065018	001	Apr 23, 1999	Apr	DISC
---------	-----	--------------	-----	------

+ TEVA PHARMS

EQ 1GM BASE

A062774	001	Apr 08, 1987	Aug	CAHN
---------	-----	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 2GM BASE/VIAL

N050779	003	Jan 13, 2012	May	NEWA
---------	-----	--------------	-----	------

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

200MG

N021222	001	Aug 29, 2001	Mar	CAHN
---------	-----	--------------	-----	------

+

400MG

N021222	002	Jul 21, 2008	Mar	CAHN
---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA

CEFIXIME

CAPSULE; ORAL

SUPRAX

+	LUPIN LTD	400MG	N203195 001	Jun 01, 2012	Jun	NEWA
---	-----------	-------	-------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP	+ SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+	EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

@

CEFZIL

@ CORDEN PHARMA

@

		250MG	A065198 001	Dec 13, 2006	Apr	DISC
		500MG	A065198 002	Dec 13, 2006	Apr	DISC
		250MG	N050664 001	Dec 23, 1991	Feb	CAHN
		500MG	N050664 002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+ COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+	1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+	2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+	6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA

+		EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
+		EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
+		EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012	Aug	NEWA
AP	+ SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+	EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ RANBAXY LABS LTD

@

@

EQ 125MG BASE

EQ 250MG BASE

EQ 500MG BASE

A065043 003 Feb 15, 2002 Apr DISC

A065043 002 Feb 15, 2002 Apr DISC

A065043 001 Feb 15, 2002 Apr DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

AB	+ COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZINACEF

AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

AP	+	EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
----	---	--------------------	-------------	--------------	-----	------

ZINACEF IN PLASTIC CONTAINER

+ COVIS PHARMA

EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Apr CAHN

+

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 Apr CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

@ SHIONOGI INC

@

@

EQ 100MG BASE/ML

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

N050406 003 Jul CAHN

N050406 001 Jul CAHN

N050406 002 Jul CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ RANBAXY LABS LTD

AA	SILARX	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
----	--------	---------	-------------	--------------	-----	------

5MG/5ML

A078876 001 May 11, 2012 Apr NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+ ASPEN GLOBAL INC

2MG

N010669 002 May CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--------------------	---	-------------	--------------	-----	------

>A> CHOLINE C-11

>A> INJECTABLE; INTRAVENOUS

>A> CHOLINE C-11

>A>	+	MCPRF	4-33.1mCi	N203155 001	Sep 12, 2012	Sep	NEWA
-----	---	-------	-----------	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
+		0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

AB	GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA
----	-------------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501 001	Jul 26, 2012	Jul	NEWA
----	-------------------	-----------------	-------------	--------------	-----	------

AP	MYLAN LLC	EQ 75MG BASE/ML	A201276 001	Jun 27, 2012	Jun	NEWA
----	-----------	-----------------	-------------	--------------	-----	------

VISTIDE

AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996	Jun	CFTG
----	---	---------------------	-----------------	-------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>D>	AB	ALPHAPHARM	50MG	A077019 001	Nov 23, 2004	Sep	CAHN
-----	----	------------	------	-------------	--------------	-----	------

>D>	AB		100MG	A077019 002	Nov 23, 2004	Sep	CAHN
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB	BIOKEY	50MG	A077722 001	Sep 24, 2012	Sep	NEWA
-----	----	--------	------	-------------	--------------	-----	------

>A>	AB		100MG	A077831 001	Sep 24, 2012	Sep	NEWA
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB	MYLAN PHARMS INC	50MG	A077019 001	Nov 23, 2004	Sep	CAHN
-----	----	------------------	------	-------------	--------------	-----	------

>A>	AB		100MG	A077019 002	Nov 23, 2004	Sep	CAHN
-----	----	--	-------	-------------	--------------	-----	------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	@	ENDO PHARMS	200MG	A074281 001	May 17, 1994	Sep	CAHN
-----	---	-------------	-------	-------------	--------------	-----	------

>D>	@		300MG	A074281 002	May 17, 1994	Sep	CAHN
-----	---	--	-------	-------------	--------------	-----	------

>D>	@		400MG	A074281 003	May 17, 1994	Sep	CAHN
-----	---	--	-------	-------------	--------------	-----	------

>D>	@		800MG	A074329 001	May 17, 1994	Sep	CAHN
-----	---	--	-------	-------------	--------------	-----	------

TABLET; ORAL

CIMETIDINE

>A>	@ VINTAGE PHARMS LLC	200MG	A074281 001	May 17, 1994	Sep	CAHN
>A>	@	300MG	A074281 002	May 17, 1994	Sep	CAHN
>A>	@	400MG	A074281 003	May 17, 1994	Sep	CAHN
>A>	@	800MG	A074329 001	May 17, 1994	Sep	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

>D>	@ ENDO PHARMS	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994	Sep	CAHN
	@ HOSPIRA	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995	Jun	DISC
	@	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995	Jun	DISC
>A>	@ VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994	Sep	CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

>D>	@ ENDO PHARMS	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994	Sep	CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@ TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
@	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008	Jun	DISC
@	400MG/200ML	A077888 002	Mar 18, 2008	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
@	EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
@	EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
@	EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
	NIMBEX					
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
	NIMBEX PRESERVATIVE FREE					
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+ ABBOTT	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062	001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

>D>	ALPHAPHARM	EQ 10MG BASE	A077668	001	Feb 28, 2007	Sep	CAHN
>D>		EQ 20MG BASE	A077668	002	Feb 28, 2007	Sep	CAHN
>D>	+	EQ 40MG BASE	A077668	003	Feb 28, 2007	Sep	CAHN
>A>	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Sep	CAHN
>A>		EQ 20MG BASE	A077668	002	Feb 28, 2007	Sep	CAHN
>A>	+	EQ 40MG BASE	A077668	003	Feb 28, 2007	Sep	CAHN

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	ALPHAPHARM	EQ 10MG BASE	A077037	001	Nov 05, 2004	Sep	CAHN
>D>	AB		EQ 20MG BASE	A077037	002	Nov 05, 2004	Sep	CAHN
>D>	AB		EQ 40MG BASE	A077037	003	Nov 05, 2004	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	Sep	CAHN
>A>	AB		EQ 20MG BASE	A077037	002	Nov 05, 2004	Sep	CAHN
>A>	AB		EQ 40MG BASE	A077037	003	Nov 05, 2004	Sep	CAHN
		@ SANDOZ	EQ 10MG BASE	A077035	001	Oct 28, 2004	Aug	DISC
		@	EQ 20MG BASE	A077035	002	Oct 28, 2004	Aug	DISC
		@	EQ 40MG BASE	A077035	003	Oct 28, 2004	Aug	DISC
	AB	TEVA PHARMS	EQ 10MG BASE	A077048	001	Nov 16, 2004	Aug	CAHN
	AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Aug	CAHN
	AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET; 3.5GM/PACKET; 10MG/PAC KET	N202535	001	Jul 16, 2012	Jul	NEWA
---	-------------------	--	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489	001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489	002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

@	SANDOZ	500MG	A065250	001	Aug 25, 2005	Aug	DISC
---	--------	-------	---------	-----	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

>D>	AB	MATRIX LABS LTD	EQ 75MG BASE	A091225	001	May 31, 2011	Sep	CAHN
>D>	AB		EQ 150MG BASE	A091225	002	May 31, 2011	Sep	CAHN
>D>	AB		EQ 300MG BASE	A091225	003	May 31, 2011	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	Sep	CAHN
>A>	AB		EQ 150MG BASE	A091225	002	May 31, 2011	Sep	CAHN
>A>	AB		EQ 300MG BASE	A091225	003	May 31, 2011	Sep	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	LYNE	EQ 75MG BASE/5ML	A201821	001	Aug 28, 2012	Aug	NEWA
----	------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	May	CFTG
----	---	----------------------	----------------	---------	-----	--------------	-----	------

AP	+		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	May	CFTG
----	---	--	-----------------	---------	-----	--------------	-----	------

AP	+		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	May	CFTG
----	---	--	-----------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692	001	May 31, 2012	May	NEWA
----	--	------------	----------------	---------	-----	--------------	-----	------

AP			EQ 12MG BASE/ML	A201692	002	May 31, 2012	May	NEWA
----	--	--	-----------------	---------	-----	--------------	-----	------

AP			EQ 18MG BASE/ML	A201692	003	May 31, 2012	May	NEWA
----	--	--	-----------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A065067	001	Jan 31, 2002	Jan	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	@	COREPHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep	CAHN
-----	---	------------	------------	---------	-----	--------------	-----	------

AT		FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

>A>	@	RENAISSANCE PHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep	CAHN
-----	---	--------------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803	001	Jul 16, 2010	May	CRLD
----	---	-------------	-------------	---------	-----	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC

5MG

N202067	001	Oct 21, 2011	Mar	CAHN
---------	-----	--------------	-----	------

10MG

N202067	002	Oct 21, 2011	Mar	CAHN
---------	-----	--------------	-----	------

+

20MG

N202067	003	Oct 21, 2011	Mar	CAHN
---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		PERRIGO ISRAEL	0.05%	A077763	001	Mar 10, 2008	Jul	CTEC
-----	--	----------------	-------	---------	-----	--------------	-----	------

AB2			0.05%	A201402	001	Aug 14, 2012	Jul	NEWA
-----	--	--	-------	---------	-----	--------------	-----	------

OLUX

AB1	+	STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	Jul	CTEC
-----	---	------------------	-------	---------	-----	--------------	-----	------

OLUX E

AB2	+	STIEFEL LABS INC	0.05%	N022013	001	Jan 12, 2007	Jul	CFTG
-----	---	------------------	-------	---------	-----	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ G AND W LABS INC

0.05%

A074139	001	Aug 03, 1994	Jun	CAHN
---------	-----	--------------	-----	------

@ RENAISSANCE PHARMA

0.05%

A075338	001	Feb 09, 2001	Aug	CAHN
---------	-----	--------------	-----	------

CREAM; TOPICAL

		CLOBETASOL PROPIONATE (EMOLLIENT)					
AB2	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	Jan	CAHN
	@ RENAISSANCE PHARMA	0.05%	A075733	001	Aug 22, 2001	Aug	CAHN
		TEMOVATE					
AB1	+ FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jan	CAHN
		GEL; TOPICAL					
		CLOBETASOL PROPIONATE					
AB	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	Jan	CAHN
		TEMOVATE					
AB	+ FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	Jan	CAHN
		LOTION; TOPICAL					
		CLOBETASOL PROPIONATE					
AB	TARO	0.05%	A200302	001	Jul 02, 2012	Jun	NEWA
		OINTMENT; TOPICAL					
		CLOBETASOL PROPIONATE					
AB	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Jan	CAHN
	@ RENAISSANCE PHARMA	0.05%	A075057	001	Aug 12, 1998	Aug	CAHN
		TEMOVATE					
AB	+ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CAHN
		SHAMPOO; TOPICAL					
		CLOBETASOL PROPIONATE					
AB	PERRIGO ISRAEL	0.05%	A090974	001	Aug 09, 2012	Jul	NEWA
		SOLUTION; TOPICAL					
		CLOBETASOL PROPIONATE					
AT	FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN
	@ G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Jun	CAHN
		TEMOVATE					
AT	+ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>D>	AB	ALPHAPHARM	0.5MG	A074940	001	Oct 30, 1997	Sep	CAHN
>D>	AB		1MG	A074940	002	Oct 30, 1997	Sep	CAHN
>D>	AB		2MG	A074940	003	Oct 30, 1997	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Sep	CAHN
>A>	AB		1MG	A074940	002	Oct 30, 1997	Sep	CAHN
>A>	AB		2MG	A074940	003	Oct 30, 1997	Sep	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN
AP	+	5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

	SHIONOGI INC	0.2MG	N022331	004	Sep 28, 2010	May	CMFD
--	--------------	-------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr	NEWA

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	GATE PHARMS	EQ 300MG BASE	A091216 001	May 17, 2012	Apr	NEWA	
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012	Apr	NEWA	
AB		EQ 300MG BASE	A077665 002	May 17, 2012	Apr	NEWA	
AB	ROXANE	EQ 75MG BASE	A078004 001	May 17, 2012	Apr	NEWA	
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr	NEWA	
AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr	NEWA	
AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr	NEWA	
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr	NEWA	
AB	WOCKHARDT LTD	EQ 75MG BASE	A202266 001	Aug 14, 2012	Jul	NEWA	
>A>	AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686 001	Oct 10, 2012	Sep	NEWA

PLAVIX

AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar	CTEC
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

	@ LUNDBECK LLC	3.75MG	N017105 001		Mar	CAHN
	@	7.5MG	N017105 002		Mar	CAHN
	@	15MG	N017105 003		Mar	CAHN

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105 006		Mar	CAHN
AB		7.5MG	N017105 007		Mar	CAHN
AB	+	15MG	N017105 008		Mar	CAHN
	TRANXENE SD					
	@ LUNDBECK LLC	11.25MG	N017105 005		Mar	CAHN
	@	22.5MG	N017105 004		Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

	JAZZ	12.5MG	N021590 004	May 30, 2007	Apr	CAHN
		25MG	N021590 001	Feb 10, 2004	Apr	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+		100MG	N021590 002	Feb 10, 2004	Apr	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+		100MG	N021590 002	Feb 10, 2004	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100 001	Aug 27, 2012	Aug	NEWA
---	---------------------	-------------------------	-------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386	001	Jun 29, 2012	Jun	NEWA
----	--	-----------------	---------------------	---------	-----	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

>A>	AP	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Sep	NEWA
-----	----	-------------------	--------------------	---------	-----	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+		TEVA WOMENS	309MG/COPPER	N018680	001	Nov 15, 1984	May	CAHN
---	--	-------------	--------------	---------	-----	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

>D>	AP	INNOPHARMA INC	0.25MG/VIAL	A202147	001	Jun 29, 2012	Sep	CAHN
	AP		0.25MG/VIAL	A202147	001	Jun 29, 2012	Jun	NEWA
>A>	AP	SANDOZ	0.25MG/VIAL	A202147	001	Jun 29, 2012	Sep	CAHN

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@		KING PFIZER	0.8MG/INH	N018887	001	Dec 05, 1985	Jun	DISC
---	--	-------------	-----------	---------	-----	--------------	-----	------

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN
AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479	001	Feb 29, 1996	Jun	CAHN

SOLUTION; INHALATION

CROMOLYN SODIUM

>D>	AN	+	TEVA PARENTERAL	10MG/ML	A075271	001	Jan 18, 2000	Sep	CAHN
>A>	AN	+	TEVA PHARMS	10MG/ML	A075271	001	Jan 18, 2000	Sep	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	5MG	A073144	002	Feb 03, 2006	Jul	CRLD	
AB	+		10MG	A073144	001	May 30, 1991	Jul	CRLD	
AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN	
AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN	
		FLEXERIL							
		@	JANSSEN RES AND DEV	5MG	N017821	001		Jul	DISC
		@		10MG	N017821	002		Jul	DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Apr	CRLD
AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Apr	CRLD
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	WATSON LABS INC	25MG	A065044 002	Dec 20, 2000	May	CAHN
AB1		100MG	A065044 001	Dec 20, 2000	May	CAHN

SOLUTION; ORAL

CYCLOSPORINE

>D>	AB1	ABBOTT	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN
>A>	AB1	ABBVIE	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	ONCO THERAPIES LTD	100MG/ML	A201784 001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------	-------------	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		Mar	CAHN
----	---	--------------	------------	-------------	--	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

	@	MIKAH PHARMA	25MG	A076686 001	Oct 24, 2005	Jul	CAHN
	@		50MG	A076686 002	Oct 24, 2005	Jul	CAHN
	@		100MG	A076686 003	Oct 24, 2005	Jul	CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

	@	FERA PHARMS	0.5%	N019849 001	Dec 31, 1990	Jul	CTNA
--	---	-------------	------	-------------	--------------	-----	------

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011	Feb	CAHN
---	---------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

PREZISTA

	JANSSEN PRODS	EQ 75MG BASE	N021976 004	Dec 18, 2008	Feb	CAHN
		EQ 150MG BASE	N021976 005	Dec 18, 2008	Feb	CAHN
	@	EQ 300MG BASE	N021976 001	Jun 23, 2006	Feb	CAHN
		EQ 400MG BASE	N021976 003	Oct 21, 2008	Feb	CAHN
+		EQ 600MG BASE	N021976 002	Feb 25, 2008	Feb	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

	@	COREPHARMA	150MG	N050261 002		Jul	DISC
	@		300MG	N050261 003		Jul	DISC

DEMECLOCYCLINE HYDROCHLORIDE

AB	+	AMNEAL PHARM	300MG	A065425 002	Feb 27, 2008	Jul	CRLD
----	---	--------------	-------	-------------	--------------	-----	------

DESFLURANELIQUID; INHALATION
SUPRANE

+ BAXTER HLTHCARE 99.9% N020118 001 Sep 18, 1992 Jul CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB BELCHER PHARMS 5MG A078355 001 Apr 19, 2012 Apr NEWA
AB MYLAN PHARMS INC 5MG A078351 001 Feb 10, 2012 Jan NEWADESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB + SANOFI AVENTIS US 0.01% N017922 001 Mar CFTG

DESMOPRESSIN ACETATE

AB SUN PHARM INDS 0.01% A077212 001 Apr 12, 2012 Mar NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

>D> AB VINTAGE 0.15MG;0.03MG A076675 001 Feb 25, 2011 Sep CAHN

>A> AB VINTAGE PHARMS LLC 0.15MG;0.03MG A076675 001 Feb 25, 2011 Sep CAHN

MIRCETTE

AB + TEVA BRANDED PHARM 0.15MG,N/A;0.02MG,0.01MG N020713 001 Apr 22, 1998 Jun CAHN

VIORELE

AB GLENMARK GENERICS 0.15MG,N/A;0.02MG,0.01MG A091346 001 Apr 02, 2012 Mar NEWA

DESONIDE

LOTION; TOPICAL

DESONIDE

AB FOUGERA PHARMS 0.05% A075860 001 Mar 19, 2002 Jan CAHN

OINTMENT; TOPICAL

DESONIDE

AB FOUGERA PHARMS 0.05% A075751 001 Mar 12, 2001 Jan CAHN

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB FOUGERA PHARMS 0.25% A078369 001 Jun 29, 2010 Jan CAHN

TOPICORT

+ TARO 0.05% A073210 001 Nov 30, 1990 Apr CTNA

>D> + 0.25% A073193 001 Nov 30, 1990 Sep CTEC

>A> AB + 0.25% A073193 001 Nov 30, 1990 Sep CTEC

+ 0.25% A073193 001 Nov 30, 1990 Apr CTNA

@ TARO PHARMS NORTH 0.25% N017856 001 Apr DISC

TOPICORT LP

@ TARO PHARMS NORTH 0.05% N018309 001 Apr DISC

GEL; TOPICAL

TOPICORT

AB + TARO 0.05% A074904 001 Jul 14, 1998 Apr CTNA

@ TARO PHARMS NORTH 0.05% N018586 001 Mar 29, 1982 Apr DISC

OINTMENT; TOPICAL

DESOXIMETASONE

>A> AB FOUGERA PHARMS 0.25% A078657 001 Sep 28, 2012 Sep NEWA

OINTMENT; TOPICAL

>A> DESOXIMETASONE

AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD
----	---	------	-------	---------	-----	--------------	-----	------

TOPICORT

>D>	+	TARO	0.25%	A074286	001	Jun 07, 1996	Sep	CTEC
>A>	AB	+	0.25%	A074286	001	Jun 07, 1996	Sep	CTEC
		+	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
		@ TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD
----	---	----------------	----------------------	---------	-----	--------------	-----	------

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN
---	----------------	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>D>	@	ENDO PHARMS	5MG	A040299	001	May 13, 1999	Sep	CAHN
>A>	@	VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999	Sep	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	---------------------	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

@	HIKMA MAPLE	5MG/ML	A070312	001	Dec 16, 1985	Jul	CAHN
@		5MG/ML	A070311	001	Dec 16, 1985	Jul	CAHN
@		5MG/ML	A070313	001	Dec 16, 1985	Jul	CAHN
@		5MG/ML	A071309	001	Jul 17, 1987	Jul	CAHN
@		5MG/ML	A071310	001	Jul 17, 1987	Jul	CAHN
@		5MG/ML	A071308	001	Jul 17, 1987	Jul	CAHN
@	HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Jun	CAHN
---	-------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB	ALPHAPHARM	50MG	A075281	002	Feb 12, 2002	Sep	CAHN
>D>	AB		75MG	A075281	003	Feb 12, 2002	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	50MG	A075281	002	Feb 12, 2002	Sep	CAHN
>A>	AB		75MG	A075281	003	Feb 12, 2002	Sep	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	GD SEARLE LLC	50MG;0.2MG	N020607 001	Dec 24, 1997	Jun	CFTG
AB	+	75MG;0.2MG	N020607 002	Dec 24, 1997	Jun	CFTG

DICLOFENAC SODIUM AND MISOPROSTOL

AB	WATSON LABS INC	50MG;0.2MG	A201089 001	Jul 09, 2012	Jun	NEWA
AB		75MG;0.2MG	A201089 002	Jul 09, 2012	Jun	NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

>D>	AB	MATRIX LABS LTD	125MG	A090788 001	Apr 08, 2010	Sep	CAHN
>D>	AB		200MG	A090788 002	Apr 08, 2010	Sep	CAHN
>D>	AB		250MG	A090788 003	Apr 08, 2010	Sep	CAHN
>D>	AB		400MG	A090788 004	Apr 08, 2010	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	125MG	A090788 001	Apr 08, 2010	Sep	CAHN
>A>	AB		200MG	A090788 002	Apr 08, 2010	Sep	CAHN
>A>	AB		250MG	A090788 003	Apr 08, 2010	Sep	CAHN
>A>	AB		400MG	A090788 004	Apr 08, 2010	Sep	CAHN

TABLET, CHEWABLE; ORAL

DIDANOSINE

AUROBINDO

	100MG	A077275 001	Aug 14, 2012	Jul	NEWA
	150MG	A077275 002	Aug 14, 2012	Jul	NEWA
	200MG	A077275 003	Aug 14, 2012	Jul	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187 001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	EMCURE PHARMS USA	500MG	A202845 001	Mar 08, 2012	Feb	NEWA	
AB	+	TEVA	500MG	A073673 001	Jul 31, 1992	Feb	CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP	HIKMA MAPLE	0.25MG/ML	A083391 001		Jul	CAHN
	@ HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

@ MYLAN PHARMS INC

@

	0.125MG	A040282 001	Dec 23, 1999	Jul	CAHN
	0.25MG	A040282 002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB4	ACTAVIS ELIZABETH	120MG	A091022 001	Sep 28, 2012	Sep	NEWA
-----	-----	-------------------	-------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB4	ACTAVIS ELIZABETH	180MG	A091022 002	Sep 28, 2012	Sep	NEWA
>A>	AB4		240MG	A091022 003	Sep 28, 2012	Sep	NEWA
>A>	AB4		300MG	A091022 004	Sep 28, 2012	Sep	NEWA
>A>	AB4		360MG	A091022 005	Sep 28, 2012	Sep	NEWA
>A>	AB4		420MG	A091022 006	Sep 28, 2012	Sep	NEWA

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>A>	AP	AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999	Sep	CAHN
>D>	AP	APOTEX INC	5MG/ML	A075375 001	Sep 30, 1999	Sep	CAHN
	AP	HIKMA FARMACEUTICA	5MG/ML	A202651 001	Aug 09, 2012	Jul	NEWA
	AP	HIKMA MAPLE	5MG/ML	A078538 001	Dec 17, 2008	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Jan	DISC

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

	+	FERRING CONTROLLED	10MG	N020411 001	Mar 30, 1995	Jul	CAHN
--	---	--------------------	------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

		@ MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC
--	--	---------------	---------	-------------	--	-----	------

BENADRYL PRESERVATIVE FREE

		@ MCNEIL CONS	50MG/ML	N009486 001		Mar	DISC
--	--	---------------	---------	-------------	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	BAXTER HLTHCARE	50MG/ML	A080817 002		Apr	CRLD
		@ HIKMA MAPLE	50MG/ML	A083183 001		Jul	CAHN
AP	+		50MG/ML	A080817 002		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP		HIKMA MAPLE	5MG/ML	A074521 001	Oct 18, 1996	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

		@ NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
--	--	-----------------	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB		REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC
	MONODOX					
AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
	@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
	@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul	CAHN
AP	PFIZER	EQ 100MG BASE/VIAL	A091406 001	Aug 21, 2012	Aug	NEWA
	DOXYCYCLINE HYCLATE					
	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD	
	TABLET, DELAYED RELEASE; ORAL						
	DORYX						
AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
	DOXYCYCLINE HYCLATE						
AB	MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA	

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

	BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123 001	Aug 10, 2011	Apr	CAIN
---	---------------------	--------------------------	-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb	DISC
@		2.5MG	A075496	001	Aug 22, 2000	Jan	DISC
@		5MG	A075621	002	Aug 22, 2000	Feb	DISC
@		5MG	A075496	002	Aug 22, 2000	Jan	DISC
@		10MG	A075621	003	Aug 22, 2000	Feb	DISC
@		10MG	A075459	001	Aug 22, 2000	Jan	DISC
@		20MG	A075621	004	Aug 22, 2000	Feb	DISC
@		20MG	A075459	002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
@		10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN	+	BAXTER HLTHCARE	99.9%	N017087	001		Jul	CAHN
----	---	-----------------	-------	---------	-----	--	-----	------

ENTACAPONE

TABLET; ORAL

COMTAN

AB	+	ORION PHARMA	200MG	N020796	001	Oct 19, 1999	Jul	CFTG
	+		200MG	N020796	001	Oct 19, 1999	May	CAHN

ENTACAPONE

AB		SUN PHARMA GLOBAL	200MG	A090690	001	Jul 16, 2012	Jul	NEWA
AB		WOCKHARDT LTD	200MG	A078941	001	Aug 16, 2012	Jul	NEWA

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

>A>	+	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Sep	CAHN
>D>	+	MEDIVATION	40MG	N203415	001	Aug 31, 2012	Sep	CAHN
	+		40MG	N203415	001	Aug 31, 2012	Aug	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
----	--	----------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENACLICK

BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN

AUVI-Q

BX	+	INTELLIJECT	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Aug	NEWA
BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Aug	NEWA

TWINJECT 0.15

BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Mar	CAHN
----	---	------------	--------------------	---------	-----	--------------	-----	------

INJECTABLE; IM-SC

TWINJECT 0.3

BX	+	COREPHARMA	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Mar	CAHN
----	---	------------	-------------------	-------------	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D>		@ ELKINS SINN	0.01MG/ML;1%	A080406 001		Sep	CAHN
>D>		@	0.01MG/ML;2%	A080406 002		Sep	CAHN
>A>		@ HIKMA MAPLE	0.01MG/ML;1%	A080406 001		Sep	CAHN
>A>		@	0.01MG/ML;2%	A080406 002		Sep	CAHN

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048 001		May	CRLD
		XYLOCAINE DENTAL WITH EPINEPHRINE					
		@ DENTSPLY PHARM	0.01MG/ML;2%	N021381 001		May	DISC
		@	0.02MG/ML;2%	N021381 002		May	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	200MG/100ML (2MG/ML)	A065361 002	Oct 22, 2007	Mar	CAHN
AP			50MG/25ML (2MG/ML)	A065361 001	Oct 22, 2007	Mar	CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	CAHN
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012	Mar	NEWA
AP			200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012	Mar	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

		ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260 002	Jun 28, 2012	Jun	NEWA
	+		EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008	May	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB		WARNER CHILCOTT LLC	250MG	A062338 001		Jun	CAHN
----	--	---------------------	-------	-------------	--	-----	------

GEL; TOPICAL

E-GLADES

		@ COREPHARMA	2%	A065009 001	Mar 18, 2002	Jul	DISC
		@ RENAISSANCE PHARMA	2%	A065009 001	Mar 18, 2002	Aug	CAHN

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

		@ RENAISSANCE PHARMA	2%	A064127 001	Feb 14, 1997	Aug	CAHN
--	--	----------------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYCETE

		@ JOHNSON AND JOHNSON	2%	N050594 001	Feb 15, 1985	Apr	CAHN
--	--	-----------------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

>D>		@ COREPHARMA	2%	A064128 001	Jul 03, 1996	Sep	CAHN
AT	+	FOUGERA PHARMS	2%	A065320 001	Jul 25, 2006	Jan	CAHN
>A>		@ RENAISSANCE PHARMA	2%	A064128 001	Jul 03, 1996	Sep	CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227 001	Mar 14, 2012	Feb	NEWA
AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062 001	Apr 02, 2012	Mar	NEWA
AA	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221 001	Jun 12, 2012	May	NEWA
AA	TARO	EQ 5MG BASE/5ML	A079121 001	May 03, 2012	Apr	NEWA

LEXAPRO

AA	+ FOREST LABS	EQ 5MG BASE/5ML	N021365 001	Nov 27, 2002	Feb	CFTG
----	---------------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	ACCORD HLTHCARE	EQ 5MG BASE	A202389 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202389 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202389 003	Sep 11, 2012	Aug	NEWA
AB	APOTEX INC	EQ 5MG BASE	A078777 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078777 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078777 003	Sep 11, 2012	Aug	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A090432 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090432 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090432 003	Sep 11, 2012	Aug	NEWA
AB	HIKMA PHARMS	EQ 5MG BASE	A078766 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078766 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078766 003	Sep 11, 2012	Aug	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A078604 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078604 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078604 003	Sep 11, 2012	Aug	NEWA
AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765 001	Mar 14, 2012	Feb	NEWA
AB		EQ 10MG BASE	A076765 002	Mar 14, 2012	Feb	NEWA
AB		EQ 20MG BASE	A076765 003	Mar 14, 2012	Feb	NEWA
AB	JUBILANT ORGANOSYS	EQ 5MG BASE	A202280 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202280 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202280 003	Sep 12, 2012	Aug	NEWA
AB	LUPIN LTD	EQ 5MG BASE	A078169 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078169 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078169 003	Sep 11, 2012	Aug	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202210 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202210 003	Sep 11, 2012	Aug	NEWA
AB	STI PHARMA LLC	EQ 5MG BASE	A077512 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077512 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077512 003	Sep 12, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE	A090939 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090939 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090939 003	Sep 11, 2012	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077734 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077734 003	Sep 11, 2012	Aug	NEWA
	LEXAPRO					
AB	FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002	Feb	CFTG
AB		EQ 10MG BASE	N021323 002	Aug 14, 2002	Feb	CFTG
AB	+	EQ 20MG BASE	N021323 003	Aug 14, 2002	Feb	CFTG

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

AP	+	BAXTER HLTHCARE	10MG/ML	N019386 006	Feb 25, 2003	Jun	CAHN
		@	10MG/ML	N019386 003	Aug 15, 1988	Jun	CAHN
		@	20MG/ML	N019386 007	May 28, 2003	Jun	CAHN
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003	Jun	CAHN
		BREVIBLOC IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001	Jun	CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011	Jun	NEWA
			EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011	Jun	NEWA

ESTRADIOL

CREAM; VAGINAL

ESTRACE

	+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984	Jun	CAHN
--	---	--------------------	-------	-------------	--------------	-----	------

GEL, METERED; TRANSDERMAL

ELESTRIN

>D>	+	JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Sep	CAHN
	+		0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Jun	CAHN
>A>	+	JAZZ PHARMS II	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Sep	CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

		WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003	May	CAHN
	+		EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003	May	CAHN

TABLET; ORAL

FEMTRACE

		WARNER CHILCOTT LLC	0.45MG	N021633 001	Aug 20, 2004	Jun	CAHN
			0.9MG	N021633 002	Aug 20, 2004	Jun	CAHN
	+		1.8MG	N021633 003	Aug 20, 2004	Jun	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012	Feb	NEWA
----	--	-----------------	-------------	-------------	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

		TEVA BRANDED PHARM	0.3MG	N020992 001	Jun 21, 2002	Jun	CAHN
			0.45MG	N020992 005	Feb 05, 2004	Jun	CAHN
			0.625MG	N020992 002	Mar 24, 1999	Jun	CAHN
			0.9MG	N020992 003	Mar 24, 1999	Jun	CAHN
	+		1.25MG	N020992 004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD
AB		LOSEASONIQUE		N022262	001	Oct 24, 2008	Jun	CAHN
		LYBREL		N021864	001	May 22, 2007	May	DISC
		@ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC
		PREVEN EMERGENCY CONTRACEPTIVE KIT		N020946	001	Sep 01, 1998	Jun	CAHN
		@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN
AB	+	SEASONALE		N021544	001	Sep 05, 2003	Jul	CAHN
		TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN
AB	+	SEASONIQUE		N021840	001	May 25, 2006	Jun	CAHN
		TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN

TABLET; ORAL-21

NORDETTE-21

@ TEVA BRANDED PHARM 0.03MG;0.15MG

N018668 001 May 10, 1982 Jun CAHN

TABLET; ORAL-28

FALMINA

AB1 NOVAST LABS LTD 0.02MG;0.1MG

A090721 001 Mar 28, 2012 Mar NEWA

MARLISSA

AB GLENMARK GENERICS 0.03MG;0.15MG

A091452 001 Feb 29, 2012 Feb NEWA

MYZILRA

>D> AB VINTAGE PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG A077502 001 Nov 23, 2011 Sep CAHN

AB 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG A077502 001 Nov 23, 2011 May CDFR

>A> AB VINTAGE PHARMS LLC 0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG A077502 001 Nov 23, 2011 Sep CAHN

NORDETTE-28

AB + TEVA BRANDED PHARM 0.03MG;0.15MG

N018782 001 Jul 21, 1982 Jun CAHN

ORSYTHIA

>D> AB1 VINTAGE PHARMS 0.02MG;0.1MG A077099 001 May 11, 2011 Sep CAHN

>A> AB1 VINTAGE PHARMS LLC 0.02MG;0.1MG A077099 001 May 11, 2011 Sep CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+ JANSSEN PHARMS 0.75MG;6MG

N021180 001 Nov 20, 2001 Jun CPOT

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB GLENMARK GENERICS 0.035MG;1MG

A091634 001 Jan 19, 2012 Jan NEWA

ALYACEN 7/7/7

AB GLENMARK GENERICS 0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG A091636 001 Jan 19, 2012 Jan NEWA

CYCLAFEM 1/35

>D> AB VINTAGE 0.035MG;1MG A076337 001 Nov 12, 2010 Sep CAHN

>A> AB VINTAGE PHARMS LLC 0.035MG;1MG A076337 001 Nov 12, 2010 Sep CAHN

CYCLAFEM 7/7/7

>D> AB VINTAGE 0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG A076338 001 Nov 16, 2010 Sep CAHN

>A> AB VINTAGE PHARMS LLC 0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG A076338 001 Nov 16, 2010 Sep CAHN

OVCON-35

AB + WARNER CHILCOTT LLC 0.035MG;0.4MG

N017716 001 Jun CAHN

TABLET; ORAL-28

OVCON-50

	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576 001		Jun	CAHN
--	---	---------------------	------------	-------------	--	-----	------

WERA

AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204 001	Mar 27, 2012	Mar	NEWA
----	--	-----------------	---------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490 001	Nov 14, 2003	Jun	CAHN
----	---	---------------------	---------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065 001	Jan 14, 2005	Jun	CAHN
--	--	---------------------	----------------	-------------	--------------	-----	------

AB	+		0.005MG;1MG	N021065 002	Oct 15, 1999	Jun	CAHN
----	---	--	-------------	-------------	--------------	-----	------

LO LOESTRIN FE

	+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN
--	---	---------------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL-21

ESTROSTEP 21

		@ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
--	--	-----------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN 21 1.5/30

AB		WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875 001		Jun	CAHN
----	--	---------------------	--------------	-------------	--	-----	------

LOESTRIN 21 1/20

AB		WARNER CHILCOTT LLC	0.02MG;1MG	N017876 001		Jun	CAHN
----	--	---------------------	------------	-------------	--	-----	------

TABLET; ORAL-28

ESTROSTEP FE

AB	+	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
----	---	---------------------	-----------------------------------	-------------	--------------	-----	------

GILDESS FE 1.5/30

>D>	AB	VINTAGE	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Sep	CAHN
-----	----	---------	--------------	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Sep	CAHN
-----	----	--------------------	--------------	-------------	--------------	-----	------

GILDESS FE 1/20

>D>	AB	VINTAGE	0.02MG;1MG	A077077 001	May 20, 2005	Sep	CAHN
-----	----	---------	------------	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077 001	May 20, 2005	Sep	CAHN
-----	----	--------------------	------------	-------------	--------------	-----	------

LOESTRIN FE 1.5/30

AB	+	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN
----	---	---------------------	--------------	-------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

AB		NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
----	--	-----------------	----------------	-------------	--------------	-----	------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
----	--	-------------------	----------------	-------------	--------------	-----	------

AB		LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
----	--	--------------	---	-------------	--------------	-----	------

PREVIFEM

>D>	AB	VINTAGE	0.035MG;0.25MG	A076334 001	Jan 09, 2004	Sep	CAHN
-----	----	---------	----------------	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334 001	Jan 09, 2004	Sep	CAHN
-----	----	--------------------	----------------	-------------	--------------	-----	------

TRI-LINYAH

AB		NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
----	--	-----------------	---	-------------	--------------	-----	------

TRI-PREVIFEM

>D>	AB	VINTAGE	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004	Sep	CAHN
-----	----	---------	---	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004	Sep	CAHN
-----	----	--------------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	-------------	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

>A>	AB	ZYDUS PHARMS USA INC	250MG	A200892 001	Sep 25, 2012	Sep	NEWA
-----	----	----------------------	-------	-------------	--------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+	LUNDBECK LLC	250MG	N010841 001		Aug	CAHN
---	--------------	-------	-------------	--	-----	------

@		500MG	N010841 003		Aug	CAHN
---	--	-------	-------------	--	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

>D>	@	ENDO PHARMS	200MG	A074842 001	Jul 17, 1997	Sep	CAHN
-----	---	-------------	-------	-------------	--------------	-----	------

>D>	@		300MG	A074842 002	Jul 17, 1997	Sep	CAHN
-----	---	--	-------	-------------	--------------	-----	------

>A>	@	VINTAGE PHARMS LLC	200MG	A074842 001	Jul 17, 1997	Sep	CAHN
-----	---	--------------------	-------	-------------	--------------	-----	------

>A>	@		300MG	A074842 002	Jul 17, 1997	Sep	CAHN
-----	---	--	-------	-------------	--------------	-----	------

TABLET; ORAL

ETODOLAC

>D>	@	ENDO PHARMS	400MG	A074841 001	Jun 27, 1997	Sep	CAHN
-----	---	-------------	-------	-------------	--------------	-----	------

AB	PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

AB		500MG	A074819 002	Apr 28, 1998	Feb	CMFD
----	--	-------	-------------	--------------	-----	------

>A>	@	VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997	Sep	CAHN
-----	---	--------------------	-------	-------------	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	MYLAN INSTITUTIONAL	2MG/ML	A091297 001	Jun 20, 2012	Jun	NEWA
----	---------------------	--------	-------------	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

@	CORDEN PHARMA	50MG	N019557 001	Dec 30, 1986	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

@		100MG	N019557 002	Dec 30, 1986	Feb	CAHN
---	--	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ETOPOSIDE

AP	+	APP PHARMS LLC	20MG/ML	A074983 001	Sep 30, 1998	Mar	CRLD
----	---	----------------	---------	-------------	--------------	-----	------

AP		BEDFORD	20MG/ML	A074290 001	Jul 17, 1995	Mar	CRLD
----	--	---------	---------	-------------	--------------	-----	------

@	CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983	Feb	CAHN
---	---------------	---------	-------------	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

	JANSSEN R AND D	25MG	N022187 003	Mar 26, 2012	Mar	NEWA
--	-----------------	------	-------------	--------------	-----	------

		100MG	N022187 001	Jan 18, 2008	Feb	CAHN
--	--	-------	-------------	--------------	-----	------

+		200MG	N022187 002	Dec 22, 2010	Feb	CAHN
---	--	-------	-------------	--------------	-----	------

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS	7.5MG	N022334 004	Mar 30, 2012	Apr	NEWA
----------	-------	-------------	--------------	-----	------

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM	2MG	N203985 001	Aug 29, 2012	Aug	NEWA
----------------	-----	-------------	--------------	-----	------

	3MG	N203985 002	Aug 29, 2012	Aug	NEWA
--	-----	-------------	--------------	-----	------

+	5MG	N203985 003	Aug 29, 2012	Aug	NEWA
---	-----	-------------	--------------	-----	------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+	AMYLIN	2MG/VIAL	N022200 001	Jan 27, 2012	Jan	NEWA
---	--------	----------	-------------	--------------	-----	------

EZETIMIBE

TABLET; ORAL

ZETIA

+	MSD INTL GMBH	10MG	N021445 001	Oct 25, 2002	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

+	MSP SINGAPORE	10MG	N021445 001	Oct 25, 2002	Jan	CAHN
---	---------------	------	-------------	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL	10MG;10MG	N021687 001	Jul 23, 2004	Jan	CAHN
----------	-----------	-------------	--------------	-----	------

	10MG;20MG	N021687 002	Jul 23, 2004	Jan	CAHN
--	-----------	-------------	--------------	-----	------

	10MG;40MG	N021687 003	Jul 23, 2004	Jan	CAHN
--	-----------	-------------	--------------	-----	------

+	10MG;80MG	N021687 004	Jul 23, 2004	Jan	CAHN
---	-----------	-------------	--------------	-----	------

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE	50MG	N022345 001	Jun 10, 2011	May	CAHN
-----------------	------	-------------	--------------	-----	------

	200MG	N022345 002	Jun 10, 2011	May	CAHN
--	-------	-------------	--------------	-----	------

	300MG	N022345 003	Jun 10, 2011	May	CAHN
--	-------	-------------	--------------	-----	------

+	400MG	N022345 004	Jun 10, 2011	May	CAHN
---	-------	-------------	--------------	-----	------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
----	---------------------	-------	-------------	--------------	-----	------

AB		250MG	A201022 002	Jan 12, 2012	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

AB		500MG	A201022 003	Jan 12, 2012	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	+	HIKMA MAPLE	10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN
----	---	-------------	---------	-------------	--------------	-----	------

AP	+		10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN
----	---	--	---------	-------------	--------------	-----	------

FAMOTIDINE PRESERVATIVE FREE

AP	+	HIKMA MAPLE	10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN
----	---	-------------	---------	-------------	--------------	-----	------

AP	+		10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
----	---	--	---------	-------------	--------------	-----	------

TABLET; ORAL

PEPCID

AB	MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
----	-----------------	------	-------------	--------------	-----	------

TABLET; ORAL

PEPCID

AB	+	MARATHON PHARMS	40MG	N019462	002	Oct 15, 1986	Jan	CAHN
----	---	-----------------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	@	UCB INC	20MG	N021712	001	Sep 24, 2004	Jan	CAHN
--	---	---------	------	---------	-----	--------------	-----	------

	@		40MG	N021712	002	Sep 24, 2004	Jan	CAHN
--	---	--	------	---------	-----	--------------	-----	------

FEBUXOSTAT

TABLET; ORAL

ULORIC

		TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Apr	CAHN
--	--	-------------------	------	---------	-----	--------------	-----	------

+			80MG	N021856	002	Feb 13, 2009	Apr	CAHN
---	--	--	------	---------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>D>	AB	ENDO PHARMS	2.5MG	A200815	001	Oct 28, 2011	Sep	CAHN
-----	----	-------------	-------	---------	-----	--------------	-----	------

>D>	AB		5MG	A200815	002	Oct 28, 2011	Sep	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		10MG	A200815	003	Oct 28, 2011	Sep	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	2.5MG	A200815	001	Oct 28, 2011	Sep	CAHN
-----	----	--------------------	-------	---------	-----	--------------	-----	------

>A>	AB		5MG	A200815	002	Oct 28, 2011	Sep	CAHN
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	AB		10MG	A200815	003	Oct 28, 2011	Sep	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

	AB	WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012	Jul	NEWA
--	----	---------------	-------	---------	-----	--------------	-----	------

	AB		5MG	A091484	002	Aug 15, 2012	Jul	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

	AB		10MG	A091484	003	Aug 15, 2012	Jul	NEWA
--	----	--	------	---------	-----	--------------	-----	------

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB		LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Feb	CFTG
----	--	----------------	------	---------	-----	--------------	-----	------

AB	+		130MG	N021695	003	Nov 30, 2004	Feb	CFTG
----	---	--	-------	---------	-----	--------------	-----	------

FENOFIBRATE (MICRONIZED)

AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

AB			130MG	A090859	002	Mar 01, 2012	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

FENOFIBRATE

AB		IMPAX LABS	160MG	A076509	002	Mar 26, 2008	May	CRLD
----	--	------------	-------	---------	-----	--------------	-----	------

AB	+		160MG	A076509	002	Mar 26, 2008	Mar	CRLD
----	---	--	-------	---------	-----	--------------	-----	------

AB		TEVA	54MG	A076433	001	May 13, 2005	May	CMFD
----	--	------	------	---------	-----	--------------	-----	------

	@		54MG	A076433	001	May 13, 2005	Mar	DISC
--	---	--	------	---------	-----	--------------	-----	------

AB	+		160MG	A076433	002	May 13, 2005	May	CMFD
----	---	--	-------	---------	-----	--------------	-----	------

	@		160MG	A076433	002	May 13, 2005	Mar	DISC
--	---	--	-------	---------	-----	--------------	-----	------

AB		VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

AB			145MG	A090715	002	Apr 05, 2012	Mar	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+	XSPIRE	EQ 200MG BASE	N017604	003			Aug	CAHN
---	--------	---------------	---------	-----	--	--	-----	------

	@	EQ 300MG BASE	N017604	002			Aug	CAHN
--	---	---------------	---------	-----	--	--	-----	------

		EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug	CAHN
--	--	---------------	---------	-----	--------------	-----	------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

	FENTANYL-100								
AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jun	CAHN		
	FENTANYL-25								
AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jun	CAHN		
	FENTANYL-50								
AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jun	CAHN		
	FENTANYL-75								
AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jun	CAHN		

SPRAY; SUBLINGUAL

SUBSYS

	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT		
		0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA		
		0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT		
		0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA		
+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT		
+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA		
		0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT		
		0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA		
		0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT		
		0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA		

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

	ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT		
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT		

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN		
AB		EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN		
AB		EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN		
AB		EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN		
AB		EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN		
AB		EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN		

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

	@ AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996	Jun	DISC		
--	-------------------	-------------------	---------	-----	--------------	-----	------	--	--

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG	
		FEXOFENADINE HYDROCHLORIDE							
AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	Jul	NEWA	

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Jun	CPOT		
+		10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012	Apr	NEWA		
+		10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Apr	NEWA		

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012	Apr	NEWA
---	----------------------	----------------------	---------	-----	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug	CAHN
	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Jul	CAHN
AB		100MG	A078423	002	Mar 07, 2011	Jul	CAHN
AB		150MG	A078423	003	Mar 07, 2011	Jul	CAHN
AB		200MG	A078423	004	Mar 07, 2011	Jul	CAHN
	@ PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC
	@	100MG	A076424	002	Jul 29, 2004	Feb	DISC
	@	150MG	A076424	003	Jul 29, 2004	Feb	DISC
	@	200MG	A076424	004	Jul 29, 2004	Feb	DISC
	@ RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004	Apr	DISC
	@	100MG	A076386	002	Jul 29, 2004	Apr	DISC
	@	150MG	A076386	003	Jul 29, 2004	Apr	DISC
	@	200MG	A076386	004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@ GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC
----------------	-----------	---------	-----	--------------	-----	------

FLUDARABINE PHOSPHATE

AP	+ HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD
----	-----------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

OFORTA

@ SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	May	DISC
---------------------	------	---------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jul	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jul	CAHN
AP	SAGENT PHARMS	0.5MG/5ML (0.1MG/ML)	A090584	001	Aug 28, 2012	Aug	NEWA
AP		1MG/10ML (0.1MG/ML)	A090584	002	Aug 28, 2012	Aug	NEWA
	@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC
	@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Jul	CPOT
---	--------------	------------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL
FLUNISOLIDE

AB HI TECH PHARMA CO 0.025MG/SPRAY A077704 001 Aug 03, 2006 Aug CAHN

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC
FLUOCINOLONE ACETONIDE

AT IDENTI PHARMS INC 0.01% A091306 001 Oct 17, 2011 Jan CPOT

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

>D> AB1 ACTAVIS MID ATLANTIC 0.05% A073085 001 Feb 14, 1992 Sep CAHN

>A> AB1 G AND W LABS INC 0.05% A073085 001 Feb 14, 1992 Sep CAHN

FLUOCINONIDE EMULSIFIED BASE

AB2 FOUGERA PHARMS 0.05% A076586 001 Jun 23, 2004 Jan CAHN

@ G AND W LABS INC 0.05% A074204 001 Jun 13, 1995 May CAHN

OINTMENT; TOPICAL

FLUOCINONIDE

AB FOUGERA PHARMS 0.05% A074905 001 Aug 26, 1997 Jan CAHN

SOLUTION; TOPICAL

FLUOCINONIDE

>D> AT ACTAVIS MID ATLANTIC 0.05% A071535 001 Dec 02, 1988 Sep CAHN

>A> AT G AND W LABS INC 0.05% A071535 001 Dec 02, 1988 Sep CAHN

FLUOROURACIL

CREAM; TOPICAL

CARAC

+ VALEANT INTL 0.5% N020985 001 Oct 27, 2000 Jul CAHN

FLUOROPLEX

+ AQUA PHARMS 1% N016988 001 Jan CAHN

INJECTABLE; INJECTION

FLUOROURACIL

AP ONCO THERAPIES LTD 500MG/10ML (50MG/ML) A202668 001 Jul 17, 2012 Jul NEWA

AP 1GM/20ML (50MG/ML) A202668 002 Jul 17, 2012 Jul NEWA

AP 2.5GM/50ML (50MG/ML) A202669 001 Jul 17, 2012 Jul NEWA

AP 5GM/100ML (50MG/ML) A202669 002 Jul 17, 2012 Jul NEWA

>A> @ SPECTRUM PHARMS 50MG/ML A087792 001 Oct 13, 1982 Sep CAHN

>D> @ WATSON LABS 50MG/ML A087792 001 Oct 13, 1982 Sep CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D> AB1 ALPHAPHARM EQ 10MG BASE A075577 001 Jan 29, 2002 Sep CAHN

>D> AB1 EQ 20MG BASE A075577 002 Jan 29, 2002 Sep CAHN

>A> AB1 HERITAGE PHARMS INC EQ 10MG BASE A201336 001 Oct 01, 2012 Sep NEWA

>A> AB1 EQ 20MG BASE A201336 002 Oct 01, 2012 Sep NEWA

>A> AB EQ 40MG BASE A201336 003 Oct 01, 2012 Sep NEWA

>A> AB1 MYLAN PHARMS INC EQ 10MG BASE A075577 001 Jan 29, 2002 Sep CAHN

>A> AB1 EQ 20MG BASE A075577 002 Jan 29, 2002 Sep CAHN

PROZAC

AB1 ELI LILLY AND CO EQ 10MG BASE N018936 006 Dec 23, 1992 Apr CAHN

AB1 EQ 20MG BASE N018936 001 Dec 29, 1987 Apr CAHN

AB + EQ 40MG BASE N018936 003 Jun 15, 1999 Apr CAHN

@ EQ 60MG BASE N018936 004 Jun 15, 1999 Apr CAHN

CAPSULE; ORAL

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
AB2 +		EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
		EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
+		EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
AB		EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA

SYMBYAX

AB	LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
AB +		EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806 003		Aug	CRLD
		0.025%	N012806 003		Jul	CAHN
+		0.05%	N012806 002		Aug	CRLD
		0.05%	N012806 002		Jul	CAHN
	WATSON PHARMS	0.05%	N012806 002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
---	-------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@	AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
@		0.05%	N012806 001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
AB		SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD
>D>	AB	WATSON LABS	125MG	A075820 001	Sep 18, 2001	Sep	CAHN
>A>	AB	WATSON LABS INC FL	125MG	A075820 001	Sep 18, 2001	Sep	CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
AB		FLUTICASONE PROPIONATE					
AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
	@	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASON PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
LESCOL						
AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
+		150MG	N022033 002	Feb 28, 2008	Jun	CAHN

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

>A>	AP	MYLAN LLC	1.5GM/1.5ML (1GM/ML)	A078639 001	Mar 03, 2008	Sep	CAHN
>D>	AP	SYNERX PHARMA	1.5GM/1.5ML (1GM/ML)	A078639 001	Mar 03, 2008	Sep	CAHN

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFORMIST

>D>	+	DEY PHARMA	0.02MG/2ML	N022007 001	May 11, 2007	Sep	CAHN
>A>	+	MYLAN SPECLT	0.02MG/2ML	N022007 001	May 11, 2007	Sep	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
@		20MG	A076580 002	Apr 23, 2004	Apr	DISC
@		40MG	A076580 003	Apr 23, 2004	Apr	DISC
MONOPRIL						
@	BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
@		20MG	N019915 003	May 16, 1991	Mar	DISC
@		40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
	@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUMSOLUTION; INTRAVENOUS
LUSEDRA

@ EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC
-------------	-----------------------	-------------	--------------	-----	------

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

>D>	@ BAXTER HLTHCARE	10MG/ML	A071439 001	Sep 14, 1990	Sep	CAHN
>D>	@	10MG/ML	N018267 001		Sep	CAHN
>A>	@ HIKMA MAPLE	10MG/ML	A071439 001	Sep 14, 1990	Sep	CAHN
>A>	@	10MG/ML	N018267 001		Sep	CAHN
	@ HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC

GABAPENTINSOLUTION; ORAL
GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA

TABLET; ORAL
GABAPENTIN

>D>	AB	MATRIX LABS LTD	600MG	A090335 001	Jun 01, 2010	Sep	CAHN
>D>	AB		800MG	A090335 002	Jun 01, 2010	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	600MG	A090335 001	Jun 01, 2010	Sep	CAHN
>A>	AB		800MG	A090335 002	Jun 01, 2010	Sep	CAHN

GANCICLOVIRCAPSULE; ORAL
GANCICLOVIR

@ RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
@	500MG	A076457 002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063 001	Sep 11, 2012	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A202063 002	Sep 11, 2012	Aug	NEWA
AP	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663 001	Sep 10, 2012	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A090663 002	Sep 10, 2012	Aug	NEWA
+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA

GENTAMICIN SULFATEINJECTABLE; INJECTION
GENTAMICIN SULFATE

>D>	@ BAXTER HLTHCARE	EQ 10MG BASE/ML	A062251 002		Sep	CAHN
>D>	@	EQ 40MG BASE/ML	A062251 001		Sep	CAHN
>A>	@ HIKMA MAPLE	EQ 10MG BASE/ML	A062251 002		Sep	CAHN
>A>	@	EQ 40MG BASE/ML	A062251 001		Sep	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
	@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
	@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
	@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
	@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+	TAKEDA PHARMS USA	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
		4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>D>	@ ENDO PHARMS	5MG	A074378 001	Nov 28, 1994	Sep	CAHN
>D>	@	10MG	A074378 002	Nov 28, 1994	Sep	CAHN
>A>	@ VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994	Sep	CAHN
>A>	@	10MG	A074378 002	Nov 28, 1994	Sep	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	DR REDDYS LABS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
>D>	AB		2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
>D>	AB		5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN
>A>	AB	HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
>A>	AB		2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
>A>	AB		5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

+	MERZ PHARMS	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN
---	-------------	---------	-------------	--------------	-----	------

TABLET; ORAL

GLYCOPYRROLATE

>A>	AA	EXCELLIUM	1MG	A090195 001	Sep 21, 2012	Sep	NEWA
>A>	AA		2MG	A090195 002	Sep 21, 2012	Sep	NEWA
	AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007	Sep	CAHN
-----	----	-----------------	----------------------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
>A>	HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007	Sep	CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
TABLET; ORAL						
GRIFULVIN V						
	@ VALEANT INTL	125MG	A062279 001		Jul	CAHN
	@	250MG	A062279 002		Jul	CAHN
	+	500MG	A062279 003		Jul	CAHN

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A200881 001	Oct 05, 2012	Sep	NEWA
>A>	AB		EQ 2MG BASE	A200881 002	Oct 05, 2012	Sep	NEWA
>A>	AB		EQ 3MG BASE	A200881 003	Oct 05, 2012	Sep	NEWA
>A>	AB		EQ 4MG BASE	A200881 004	Oct 05, 2012	Sep	NEWA
INTUNIV							
>D>		SHIRE	EQ 1MG BASE	N022037 001	Sep 02, 2009	Sep	CFTG
>A>	AB		EQ 1MG BASE	N022037 001	Sep 02, 2009	Sep	CFTG
>D>			EQ 2MG BASE	N022037 002	Sep 02, 2009	Sep	CFTG
>A>	AB		EQ 2MG BASE	N022037 002	Sep 02, 2009	Sep	CFTG
>D>			EQ 3MG BASE	N022037 003	Sep 02, 2009	Sep	CFTG
>A>	AB		EQ 3MG BASE	N022037 003	Sep 02, 2009	Sep	CFTG
>D>	+		EQ 4MG BASE	N022037 004	Sep 02, 2009	Sep	CFTG
>A>	AB	+	EQ 4MG BASE	N022037 004	Sep 02, 2009	Sep	CFTG

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
OINTMENT; TOPICAL						
HALOBETASOL PROPIONATE						
AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + B BRAUN 4,000 UNITS/100ML N019952 001 Jul 20, 1992 Jul CRLD

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5,000 UNITS/100ML N018814 003 Jul 09, 1985 Mar DISC

@ 10,000 UNITS/100ML N018814 004 Jul 02, 1987 Mar DISC

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + B BRAUN 5,000 UNITS/100ML N019952 004 Jul 20, 1992 Jul CRLD

AP + 10,000 UNITS/100ML N019952 005 Jul 20, 1992 Jul CRLD

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010 May CAHN

HYALURONIDASEINJECTABLE; INJECTION

HYDASE

@ AKORN INC 150 UNITS/ML N021716 001 Oct 25, 2005 Jun DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB LANNETT HOLDINGS INC 12.5MG A091662 001 Jan 27, 2012 Jan NEWA

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>A> AB ACCORD HLTHCARE 12.5MG A202556 001 Sep 24, 2012 Sep NEWA

>A> AB 25MG A202556 002 Sep 24, 2012 Sep NEWA

>A> AB 50MG A202556 003 Sep 24, 2012 Sep NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB + SANOFI AVENTIS 12.5MG;150MG N020758 002 Sep 30, 1997 Mar CFTG

AB + 12.5MG;300MG N020758 003 Aug 31, 1998 Mar CFTG

+ 12.5MG;300MG N020758 003 Aug 31, 1998 Feb CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A> AB DR REDDYS LABS LTD 12.5MG;150MG A203500 001 Sep 27, 2012 Sep NEWA

>A> AB 12.5MG;300MG A203500 002 Sep 27, 2012 Sep NEWA

>A> AB MACLEODS PHARMS LTD 12.5MG;150MG A202414 001 Sep 27, 2012 Sep NEWA

>A> AB 12.5MG;300MG A202414 002 Sep 27, 2012 Sep NEWA

>A> AB MYLAN PHARMS INC 12.5MG;150MG A077969 001 Sep 27, 2012 Sep NEWA

>A> AB 12.5MG;300MG A077969 002 Sep 27, 2012 Sep NEWA

>A> AB SANDOZ 12.5MG;150MG A077446 001 Sep 27, 2012 Sep NEWA

>A> AB 12.5MG;300MG A077446 002 Sep 27, 2012 Sep NEWA

AB TEVA 12.5MG;150MG A077369 001 Mar 30, 2012 Mar NEWA

AB 12.5MG;300MG A077369 002 Mar 30, 2012 Mar NEWA

@ 25MG;300MG A077369 003 Mar 30, 2012 Apr DISC

25MG;300MG A077369 003 Mar 30, 2012 Mar NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D> AB ALEMBIC LTD 12.5MG;50MG A091617 001 Feb 17, 2012 Sep CAHN

AB 12.5MG;50MG A091617 001 Feb 17, 2012 Feb NEWA

>D> AB 12.5MG;100MG A091617 002 Feb 17, 2012 Sep CAHN

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;100MG	A091617	002	Feb 17, 2012	Feb	NEWA	
>D>	AB	25MG;100MG	A091617	003	Feb 17, 2012	Sep	CAHN	
	AB	25MG;100MG	A091617	003	Feb 17, 2012	Feb	NEWA	
>A>	AB	ALEMBIC PHARMS LTD	12.5MG;50MG	A091617	001	Feb 17, 2012	Sep	CAHN
>A>	AB	12.5MG;100MG	A091617	002	Feb 17, 2012	Sep	CAHN	
>A>	AB	25MG;100MG	A091617	003	Feb 17, 2012	Sep	CAHN	
>A>	AB	CADISTA PHARMS	12.5MG;50MG	A201845	001	Sep 18, 2012	Sep	NEWA
>A>	AB	12.5MG;100MG	A201845	002	Sep 18, 2012	Sep	NEWA	
>A>	AB	25MG;100MG	A201845	003	Sep 18, 2012	Sep	NEWA	
	AB	MACLEODS PHARMS LTD	12.5MG;50MG	A202289	001	Aug 09, 2012	Jul	NEWA
	AB	12.5MG;100MG	A202289	002	Aug 09, 2012	Jul	NEWA	
	AB	25MG;100MG	A202289	003	Aug 09, 2012	Jul	NEWA	

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jan	CMFD
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jan	CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Apr	CRLD
		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

>D>	AB	NOVARTIS	25MG;50MG	N018303	001	Dec 31, 1984	Sep	CAHN
>D>	AB	+	25MG;100MG	N018303	002	Dec 31, 1984	Sep	CAHN
>D>		@	50MG;100MG	N018303	003	Dec 31, 1984	Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	25MG;50MG	N018303	001	Dec 31, 1984	Sep	CAHN
>A>	AB	+	25MG;100MG	N018303	002	Dec 31, 1984	Sep	CAHN
>A>		@	50MG;100MG	N018303	003	Dec 31, 1984	Sep	CAHN

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654	002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654	003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ PADOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Jan	DISC
	@	12.5MG;15MG	A090096	002	Sep 25, 2008	Jan	DISC
	@	25MG;15MG	A090096	003	Sep 25, 2008	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

>D>		NOVARTIS	12.5MG;80MG	N020818	001	Mar 06, 1998	Sep	CFTG
>A>	AB		12.5MG;80MG	N020818	001	Mar 06, 1998	Sep	CFTG
>D>			12.5MG;160MG	N020818	002	Mar 06, 1998	Sep	CFTG
>A>	AB		12.5MG;160MG	N020818	002	Mar 06, 1998	Sep	CFTG
>D>			12.5MG;320MG	N020818	004	Apr 28, 2006	Sep	CFTG
>A>	AB		12.5MG;320MG	N020818	004	Apr 28, 2006	Sep	CFTG
>D>			25MG;160MG	N020818	003	Jan 17, 2002	Sep	CFTG
>A>	AB		25MG;160MG	N020818	003	Jan 17, 2002	Sep	CFTG

TABLET; ORAL

		DIOVAN HCT							
>D>	+	NOVARTIS	25MG;320MG	N020818	005	Apr 28, 2006	Sep	CFTG	
>A>	AB	+	25MG;320MG	N020818	005	Apr 28, 2006	Sep	CFTG	
>A>		VALSARTAN AND HYDROCHLOROTHIAZIDE							
>A>	AB	MYLAN PHARMS INC	12.5MG;80MG	A078020	001	Sep 21, 2012	Sep	NEWA	
>A>	AB		12.5MG;160MG	A078020	002	Sep 21, 2012	Sep	NEWA	
>A>	AB		12.5MG;320MG	A078020	004	Sep 21, 2012	Sep	NEWA	
>A>	AB		25MG;160MG	A078020	003	Sep 21, 2012	Sep	NEWA	
>A>	AB		25MG;320MG	A078020	005	Sep 21, 2012	Sep	NEWA	

HYDROCORTISONE

CREAM; TOPICAL

		HYTONE							
>D>	@	SANOFI AVENTIS US	1%	A080472	003		Sep	CAHN	
>D>	@		2.5%	A080472	004		Sep	CAHN	
>A>	@	VALEANT INTL	1%	A080472	003		Sep	CAHN	
>A>	@		2.5%	A080472	004		Sep	CAHN	
		NUTRACORT							
	@	DOW PHARM	0.5%	A080442	002		Jun	CAHN	
	@		1%	A080442	003		Jun	CAHN	

LOTION; TOPICAL

		CETACORT							
	@	DOW PHARM	0.5%	A080426	002		Jun	CAHN	
	@		1%	A080426	001		Jun	CAHN	
		HYDROCORTISONE							
AT	+	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Jan	CAHN	
		HYTONE							
>D>	@	SANOFI AVENTIS US	1%	A080473	003		Sep	CAHN	
>D>	@		2.5%	A080473	004	Nov 30, 1982	Sep	CAHN	
>A>	@	VALEANT INTL	1%	A080473	003		Sep	CAHN	
>A>	@		2.5%	A080473	004	Nov 30, 1982	Sep	CAHN	
		NUTRACORT							
	@	DOW PHARM	0.5%	A080443	002		Jun	CAHN	
AT			1%	A080443	003		Jun	CAHN	
AT			2.5%	A087644	001	Aug 24, 1982	Jun	CAHN	

OINTMENT; TOPICAL

		HYDROCORTISONE							
AT	+	FOUGERA PHARMS	1%	A080692	001		Jan	CAHN	

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

		CARMOL HC							
AT		FOUGERA PHARMS	1%;10%	A080505	001		Jan	CAHN	

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

		LOCOID							
AB	+	PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Jun	CAHN	
		LOCOID LIPOCREAM							
	+	PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Jun	CAHN	
		LOTION; TOPICAL							
		LOCOID							
	+	PRECISION DERMAT	0.1%	N022076	001	May 18, 2007	May	CAHN	

OINTMENT; TOPICAL

LOCOID

AB	+	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	May	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

LOCOID

AT	+	PRECISION DERMAT	0.1%	N019116	001	Feb 25, 1987	Jun	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB	+	TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
----	---	------	------	---------	-----	--------------	-----	------

WESTCORT

@	RANBAXY	0.2%	N017950	001			Mar	DISC
---	---------	------	---------	-----	--	--	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>D>	AT	ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Sep	CAHN
-----	----	-------	-------------------------------------	---------	-----	--------------	-----	------

>A>	AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Sep	CAHN
-----	----	------------------	-------------------------------------	---------	-----	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN
----	---	-----------	------	---------	-----	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@	NESHER PHARMS	2MG	A077311	001	Nov 09, 2005	Jun	DISC
---	---------------	-----	---------	-----	--------------	-----	------

@		4MG	A077311	002	Nov 09, 2005	Jun	DISC
---	--	-----	---------	-----	--------------	-----	------

@		8MG	A077311	003	Nov 09, 2005	Jun	DISC
---	--	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

EXALGO

		MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Aug	NEWA
--	--	------------------	------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@	STI PHARMA LLC	10MG/5ML	A086880	001		Feb	CAHN
---	----------------	----------	---------	-----	--	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@	MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Jul	CAHN
---	--------------	------	---------	-----	--------------	-----	------

@		25MG	A040602	001	Dec 28, 2004	Jul	CAHN
---	--	------	---------	-----	--------------	-----	------

@		50MG	A040604	001	Dec 28, 2004	Jul	CAHN
---	--	------	---------	-----	--------------	-----	------

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

@	PFIZER	EQ 25MG HCL/5ML	N011795	001		Jul	DISC
---	--------	-----------------	---------	-----	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
IBANDRONATE SODIUM							
AB		APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
AB		MUTUAL PHARM CO INC	EQ 150MG BASE	A078996 001	Aug 15, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	@	NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
	@		600MG	A078132 002	Sep 10, 2007	Jun	DISC
	@		800MG	A078132 003	Sep 10, 2007	Jun	DISC
	@	OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

	+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
--	---	--------------	------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

	+	AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
--	---	-------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>A>	AP	ONCO THERAPIES LTD	1MG/ML	A200144 001	Oct 11, 2012	Sep	NEWA
	@	TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
	@		10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
	@		20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB		PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB			25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB			50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB		APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB		FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB		GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

>D>	AB	ALPHAPHARM	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
>D>	AB		2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
>A>	AB		2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>A>	AB	HETERO LABS LTD III	75MG	A201807 001	Sep 28, 2012	Sep	NEWA
-----	----	---------------------	------	-------------	--------------	-----	------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

		LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
	+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

	@	LILLY	50 UNITS/ML;50 UNITS/ML	N021018 003	Dec 22, 1999	Jun	DISC
--	---	-------	-------------------------	-------------	--------------	-----	------

HUMALOG MIX 75/25 PEN

	@	LILLY	75 UNITS/ML;25 UNITS/ML	N021017 003	Dec 22, 1999	Jun	DISC
--	---	-------	-------------------------	-------------	--------------	-----	------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

	@	LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998	Jun	DISC
--	---	-------	--------------	-------------	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN	TEVA PARENTERAL	0.02%	A075313 001	Feb 07, 2000	Sep	CAHN
>A>	AN	TEVA PHARMS	0.02%	A075313 001	Feb 07, 2000	Sep	CAHN

IRBESARTAN

TABLET; ORAL

AVAPRO

	AB	SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
	AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
	AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

>A>	AB	AUROBINDO PHARMA LTD	75MG	A203081 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A203081 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A203081 003	Sep 27, 2012	Sep	NEWA
>A>	AB	DR REDDYS LABS LTD	75MG	A203161 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A203161 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A203161 003	Sep 27, 2012	Sep	NEWA

TABLET; ORAL

IRBESARTAN

>A>	AB	HETERO LABS LTD V	75MG	A202910 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A202910 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A202910 003	Sep 27, 2012	Sep	NEWA
>A>	AB	MACLEODS PHARMS LTD	75MG	A202254 001	Oct 03, 2012	Sep	NEWA
>A>	AB		150MG	A202254 002	Oct 03, 2012	Sep	NEWA
>A>	AB		300MG	A202254 003	Oct 03, 2012	Sep	NEWA
>A>	AB	MYLAN PHARMS INC	75MG	A200461 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A200461 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A200461 003	Sep 27, 2012	Sep	NEWA
>A>	AB	PRINSTON INC	75MG	A203071 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A203071 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A203071 003	Sep 27, 2012	Sep	NEWA
>A>	AB	SANDOZ	75MG	A077466 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A077466 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A077466 003	Sep 27, 2012	Sep	NEWA
	AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
	AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
	AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA
>A>	AB	WATSON LABS INC	75MG	A090720 001	Oct 12, 2012	Sep	NEWA
>A>	AB		150MG	A090720 002	Oct 12, 2012	Sep	NEWA
>A>	AB		300MG	A090720 003	Oct 12, 2012	Sep	NEWA
>A>	AB	ZYDUS PHARMS USA INC	75MG	A079213 001	Sep 27, 2012	Sep	NEWA
>A>	AB		150MG	A079213 002	Sep 27, 2012	Sep	NEWA
>A>	AB		300MG	A079213 003	Sep 27, 2012	Sep	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP		CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP			100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP		EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP			100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP		HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP			100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP		TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP			100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP			500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
		@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

AN	+	BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
----	---	-----------------	-------	-------------	--	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB		ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Jun	CAHN
		@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

>D>		CIPHER	10MG	N021951 001	May 25, 2012	Sep	CTEC
-----	--	--------	------	-------------	--------------	-----	------

CAPSULE; ORALABSORICA

>A>	BX	CIPHER	10MG	N021951 001	May 25, 2012	Sep	CTEC
			10MG	N021951 001	May 25, 2012	May	NEWA
>D>			20MG	N021951 002	May 25, 2012	Sep	CTEC
>A>	BX		20MG	N021951 002	May 25, 2012	Sep	CTEC
			20MG	N021951 002	May 25, 2012	May	NEWA
>D>			30MG	N021951 003	May 25, 2012	Sep	CTEC
>A>	BX		30MG	N021951 003	May 25, 2012	Sep	CTEC
			30MG	N021951 003	May 25, 2012	May	NEWA
>D>			40MG	N021951 004	May 25, 2012	Sep	CTEC
>A>	BX		40MG	N021951 004	May 25, 2012	Sep	CTEC
			40MG	N021951 004	May 25, 2012	May	NEWA

MYORISAN

AB		DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB			20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB			40MG	A076485 003	Jan 19, 2012	Jan	NEWA

ITRACONAZOLECAPSULE; ORALITRACONAZOLE

AB		MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012	Jul	NEWA
----	--	------------------	-------	-------------	--------------	-----	------

IVACAFTORTABLET; ORALKALYDECO

+		VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	--	---------------	-------	-------------	--------------	-----	------

IVERMECTINLOTION; TOPICALSKLICE

+		SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
---	--	----------------	------	-------------	--------------	-----	------

KANAMYCIN SULFATEINJECTABLE; INJECTIONKANAMYCIN

>D>	@	BAXTER HLTHCARE	EQ 75MG BASE/2ML	A062324 001		Sep	CAHN
>D>	@		EQ 500MG BASE/2ML	A062324 002		Sep	CAHN
>D>	@		EQ 1GM BASE/3ML	A062324 003		Sep	CAHN
>A>	@	HIKMA MAPLE	EQ 75MG BASE/2ML	A062324 001		Sep	CAHN
>A>	@		EQ 500MG BASE/2ML	A062324 002		Sep	CAHN
>A>	@		EQ 1GM BASE/3ML	A062324 003		Sep	CAHN

KETOCONAZOLECREAM; TOPICALKETOCONAZOLE

AB		FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

KETOPROFENCAPSULE; ORALKETOPROFEN

		DORADO PHARMA	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
AB			50MG	A074014 002	Jan 29, 1993	Jul	CAHN
AB			75MG	A074014 003	Jan 29, 1993	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORALKETOPROFEN

AB	ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997	Jun	CAHN
----	----------------------	-------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINEINJECTABLE; INJECTIONKETOROLAC TROMETHAMINE

>D>	AP	BAXTER HLTHCARE	15MG/ML	A075772	001	Jul 21, 2004	Sep	CAHN
>D>	AP		30MG/ML	A075772	002	Jul 21, 2004	Sep	CAHN
>D>	AP	BAXTER HLTHCARE CORP	15MG/ML	A075299	001	Nov 03, 1999	Sep	CAHN
>D>	AP		30MG/ML	A075299	002	Nov 03, 1999	Sep	CAHN
>A>	AP	HIKMA MAPLE	15MG/ML	A075772	001	Jul 21, 2004	Sep	CAHN
>A>	AP		15MG/ML	A075299	001	Nov 03, 1999	Sep	CAHN
>A>	AP		30MG/ML	A075299	002	Nov 03, 1999	Sep	CAHN
>A>	AP		30MG/ML	A075772	002	Jul 21, 2004	Sep	CAHN

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTIONLABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699	001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	---------	-----	--------------	-----	------

TABLET; ORALLABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908	001	Jul 10, 2012	Jun	NEWA
AB		200MG	A200908	002	Jul 10, 2012	Jun	NEWA
AB		300MG	A200908	003	Jul 10, 2012	Jun	NEWA

LACTULOSEFOR SOLUTION; ORALLACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Jun	CAHN
+		20GM/PACKET	A074712	002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORALLACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503	001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

SOLUTION; ORAL, RECTALLACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502	001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

LAMIVUDINE; ZIDOVUDINETABLET; ORALLAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418	001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246	001	May 15, 2012	Apr	NEWA

LAMOTRIGINETABLET; ORALLAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169	001	May 12, 2012	Apr	NEWA
AB		100MG	A090169	002	May 12, 2012	Apr	NEWA
AB		150MG	A090169	003	May 12, 2012	Apr	NEWA
AB		200MG	A090169	004	May 12, 2012	Apr	NEWA
BX	UPSHER SMITH	25MG	A078310	001	Feb 04, 2009	Aug	CTEC
BX		100MG	A078310	002	Feb 04, 2009	Aug	CTEC
BX		150MG	A078310	003	Feb 04, 2009	Aug	CTEC
BX		200MG	A078310	004	Feb 04, 2009	Aug	CTEC

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
LANSOPRAZOLE

>D>	AB	MATRIX LABS LTD	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
>D>	AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
>A>	AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
	AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
	AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA
		PREVACID					
	AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
	AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

		@ TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
		@	30MG	A078730 002	Oct 15, 2010	Mar	DISC
		PREVACID					
		TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
		+	30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
FOSRENOL

		@ SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
			EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
			EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
		+	EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
LATANOPROST

>A>	AT	AKORN	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN
>D>	AT	PADDOCK LLC	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN

LENALIDOMIDE

CAPSULE; ORAL
REVLIMID

>D>	+	CELGENE	15MG	N021880 003	Jun 29, 2006	Sep	CRLD
>A>			15MG	N021880 003	Jun 29, 2006	Sep	CRLD

LETROZOLE

TABLET; ORAL
LETROZOLE

	AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
>D>	AB	ENDO PHARMS	2.5MG	A090789 001	Jun 03, 2011	Sep	CAHN

TABLET; ORAL

LETROZOLE

>A>	AB	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Sep	CAHN
-----	----	--------------------	-------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ TEVA PARENTERAL

EQ 50MG BASE/VIAL

A081278 001 Sep 28, 1993 Mar DISC

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A200753	001	Sep 06, 2012	Aug	NEWA
AP		EQ 100MG BASE/VIAL	A200753	002	Sep 06, 2012	Aug	NEWA
AP		EQ 200MG BASE/VIAL	A200753	003	Sep 06, 2012	Aug	NEWA
AP		EQ 350MG BASE/VIAL	A200855	001	Sep 06, 2012	Aug	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+ ABBOTT ENDOCRINE

3.75MG/VIAL

N020011 001 Oct 22, 1990 May CAHN

+

7.5MG/VIAL

N019732 001 Jan 26, 1989 May CAHN

+

11.25MG/VIAL

N020708 001 Mar 07, 1997 May CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	May	CAHN
AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869	001	Apr 06, 2012	Mar	NEWA
AP	LUITPOLD	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Aug	CAHN
AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Jan	NEWA
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	LOTUS PHARM CO LTD	500MG	A090906	001	Nov 05, 2010	Jul	CAHN
AB	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797	003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797	004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	BOCA PHARMA	500MG	A201464	001	May 25, 2012	May	NEWA
AB		750MG	A201464	002	May 25, 2012	May	NEWA
AB	ROUSES POINT PHARMS	500MG	A202524	001	Aug 27, 2012	Aug	NEWA
AB		750MG	A202524	002	Aug 27, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012	May	NEWA
AB		750MG	A091338	002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264	001	Jun 29, 2012	Jun	NEWA
----	---------------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA
AB	ZYDUS PHARMS USA INC	250MG	A077652 001	Sep 07, 2012	Aug	NEWA
AB		500MG	A077652 002	Sep 07, 2012	Aug	NEWA
AB		750MG	A077652 003	Sep 07, 2012	Aug	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS

EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)

N020140 003 Apr 29, 2011 Jun DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB	WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA
	PLAN B					
AB	+ TEVA BRANDED PHARM	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
	@	0.75MG	N021045 001	Jul 28, 1999	May	CAHN
	PLAN B ONE-STEP					
AB	+ DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

AB	WATSON LABS INC	5%	A200675 001	Aug 23, 2012	Aug	NEWA
	LIDODERM					
AB	+ TEIKOKU PHARMA USA	5%	N020612 001	Mar 19, 1999	Aug	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	@ BAXTER HLTHCARE	1%	A080407 001		Sep	CAHN
>D>	@	2%	A080407 002		Sep	CAHN
>A>	@ HIKMA MAPLE	1%	A080407 001		Sep	CAHN
>A>	@	2%	A080407 002		Sep	CAHN
>A>	AP PFIZER	0.5%	A091058 001	Sep 30, 2010	Sep	CAHN
>A>	AP	0.5%	A091056 001	Dec 08, 2010	Sep	CAHN
>A>	AP	1%	A091056 002	Dec 08, 2010	Sep	CAHN
>A>	AP	1%	A091058 002	Sep 30, 2010	Sep	CAHN
>D>	AP STRIDES ARCOLAB LTD	0.5%	A091056 001	Dec 08, 2010	Sep	CAHN
>D>	AP	0.5%	A091058 001	Sep 30, 2010	Sep	CAHN
>D>	AP	1%	A091056 002	Dec 08, 2010	Sep	CAHN
>D>	AP	1%	A091058 002	Sep 30, 2010	Sep	CAHN

INJECTABLE; INJECTION

	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
>D>	@ BAXTER HLTHCARE	1%	A084625 001	Sep	CAHN
>D>	@	2%	A084625 002	Sep	CAHN
>A>	@ HIKMA MAPLE	1%	A084625 001	Sep	CAHN
>A>	@	2%	A084625 002	Sep	CAHN
>A>	AP PFIZER	2%	A090665 001	Sep 27, 2010	Sep CAHN
>D>	AP STRIDES ARCOLAB LTD	2%	A090665 001	Sep 27, 2010	Sep CAHN
	XYLOCAINE DENTAL				
	@ DENTSPLY PHARM	2%	N021380 001	May	DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003	Jan CAHN
----	----------------	-----------	-------------	--------------	----------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+	GALDERMA LABS LP	7%;7%	N021717 001	Jun 29, 2006	Jun CTNA
---	------------------	-------	-------------	--------------	----------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

	FOREST LABS INC	145MCG	N202811 001	Aug 30, 2012	Aug NEWA
+		290MCG	N202811 002	Aug 30, 2012	Aug NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan NEWA
		2.5MG;850MG	N201281 002	Jan 30, 2012	Jan NEWA
+		2.5MG;1GM	N201281 003	Jan 30, 2012	Jan NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun NEWA
AP	+ ZYVOX PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588 001		Jun CMFD
	@	10MG	N017588 001		May DISC
		40MG	N017588 002		Jun CMFD
	@	40MG	N017588 002		May DISC
+		100MG	N017588 003		Jun CMFD
	@	100MG	N017588 003		May DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA HI-TECH PHARMA CO 2MG/ML A200169 001 Jan 30, 2012 Jan NEWA

INJECTABLE; INJECTION

LORAZEPAM

>D> @ BAXTER HLTHCARE 2MG/ML A074496 001 Sep 28, 1998 Sep CAHN
 >D> @ 4MG/ML A074496 002 Sep 28, 1998 Sep CAHN
 @ BEDFORD 2MG/ML A077076 001 Jul 13, 2005 Jun DISC
 @ 4MG/ML A077076 002 Jul 13, 2005 Jun DISC
 >A> @ HIKMA MAPLE 2MG/ML A074496 001 Sep 28, 1998 Sep CAHN
 >A> @ 4MG/ML A074496 002 Sep 28, 1998 Sep CAHN
 @ HOSPIRA 2MG/ML A074300 001 Apr 12, 1994 Jun DISC

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+ ARENA PHARMS INC 10MG N022529 001 Jun 27, 2012 Jun NEWA
 + EISAI INC 10MG N022529 001 Jun 27, 2012 Jul CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

>A> AB CADISTA PHARMS 25MG A201170 001 Sep 18, 2012 Sep NEWA
 >A> AB 50MG A201170 002 Sep 18, 2012 Sep NEWA
 >A> AB 100MG A201170 003 Sep 18, 2012 Sep NEWA
 AB MACLEODS PHARMS LTD 25MG A202230 001 May 30, 2012 May NEWA
 AB 50MG A202230 002 May 30, 2012 May NEWA
 AB 100MG A202230 003 May 30, 2012 May NEWA
 >A> AB MICRO LABS LTD INDIA 25MG A091541 001 Sep 24, 2012 Sep NEWA
 >A> AB 50MG A091541 002 Sep 24, 2012 Sep NEWA
 >A> AB 100MG A091541 003 Sep 24, 2012 Sep NEWA

LOTEPREDNOL ETABONATE

>A> GEL; OPHTHALMIC
 >A> LOTEMAX
 >A> + BAUSCH AND LOMB 0.5% N202872 001 Sep 28, 2012 Sep NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

@ MIKAH PHARMA EQ 5MG BASE A076868 001 Aug 04, 2005 Jul CAHN
 @ EQ 10MG BASE A076868 002 Aug 04, 2005 Jul CAHN
 @ EQ 25MG BASE A076868 003 Aug 04, 2005 Jul CAHN
 @ EQ 50MG BASE A076868 004 Aug 04, 2005 Jul CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+ DISCOVERY LABS 8.5ML N021746 001 Mar 06, 2012 Apr NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

+ SUNOVION PHARMS INC 20MG N200603 003 Dec 07, 2011 Aug CRLD

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Apr	NEWA
		40MG	N200603 001	Oct 28, 2010	Aug	CRLD
+		40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

	@ EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004	Jun	DISC
--	--------------	------------	-------------	--------------	-----	------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+	MYLAN LLC	EQ 85MG BASE/GM	N016763 001		Jun	CAHN
---	-----------	-----------------	-------------	--	-----	------

FOR SOLUTION; TOPICAL

SULFAMYLON

+	MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jun	CAHN
---	-----------	----	-------------	--------------	-----	------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

	@ SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009	Jun	DISC
	@	343MG;40MG;750MG	N022456 002	Dec 04, 2009	Jun	DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
		40GM/1000ML(40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
AT	SUVEN LIFE	0.5%	A091559 001	May 23, 2012	May	NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010	May	CAHN
---	---------------	----------------------------	-------------	--------------	-----	------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA	
AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA	
>A>	AA	MYLAN PHARMS INC	12.5MG	A202640 001	Sep 17, 2012	Sep	NEWA
>A>	AA		25MG	A202640 002	Sep 17, 2012	Sep	NEWA

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	AA	MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012	Sep	NEWA
-----	----	------------------	------	-------------	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

		@ TEVA PARENTERAL	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC
--	--	-------------------	----------	-------------	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

>A>	AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270 001	Jun 09, 2009	Sep	CAHN
>D>	AP	SYNERX	EQ 50MG BASE/VIAL	A090270 001	Jun 09, 2009	Sep	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

		@ ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012	Mar	DISC
AB			5MG	A090044 001	Mar 12, 2012	Feb	NEWA
		@	10MG	A090044 002	Mar 12, 2012	Mar	DISC
AB			10MG	A090044 002	Mar 12, 2012	Feb	NEWA
		NAMENDA					
		FOREST LABS	5MG	N021487 001	Oct 16, 2003	Mar	CTEC
AB			5MG	N021487 001	Oct 16, 2003	Feb	CTEC
	+		10MG	N021487 002	Oct 16, 2003	Mar	CTEC
AB	+		10MG	N021487 002	Oct 16, 2003	Feb	CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE CORP	25MG/ML	A080455 007		Sep	CAHN
>D>	AP		50MG/ML	A080455 008		Sep	CAHN
>D>	AP		75MG/ML	A080455 009		Sep	CAHN
>D>	AP		100MG/ML	A080455 010		Sep	CAHN
>D>	AP	ELKINS SINN	25MG/ML	A080445 001		Sep	CAHN
>D>	AP		50MG/ML	A080445 002		Sep	CAHN
>D>	AP		75MG/ML	A080445 003		Sep	CAHN
>D>	AP		100MG/ML	A080445 004		Sep	CAHN
>A>	AP	HIKMA MAPLE	25MG/ML	A080445 001		Sep	CAHN
>A>	AP		25MG/ML	A080455 007		Sep	CAHN
>A>	AP		50MG/ML	A080455 008		Sep	CAHN
>A>	AP		50MG/ML	A080445 002		Sep	CAHN
>A>	AP		75MG/ML	A080455 009		Sep	CAHN
>A>	AP		75MG/ML	A080445 003		Sep	CAHN
>A>	AP		100MG/ML	A080455 010		Sep	CAHN
>A>	AP		100MG/ML	A080445 004		Sep	CAHN
		MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE					
>D>	AP	BAXTER HLTHCARE CORP	10MG/ML	A081002 001	Jul 30, 1993	Sep	CAHN
>A>	AP	HIKMA MAPLE	10MG/ML	A081002 001	Jul 30, 1993	Sep	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

		@ DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984	May	DISC
--	--	------------------	----	-------------	--------------	-----	------

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@ AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999	Jun	DISC
---------------	----------	-------------	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@ APTALIS PHARMA US	500MG	N021252 001	Jan 05, 2001	Jul	CAHN
	1GM	N021252 002	Nov 05, 2004	Jul	CAHN

ROWASA

@ MEDA PHARMS	500MG	N019919 001	Dec 18, 1990	Jan	CAHN
---------------	-------	-------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
----	---------------------	----------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	ALPHAPHARM	500MG	A075969 001	Jan 29, 2002	Sep	CAHN
>D>	AB		850MG	A075969 002	Jan 29, 2002	Sep	CAHN
>D>	AB		1GM	A075969 003	Jan 29, 2002	Sep	CAHN
	AB	MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
	AB		850MG	A090888 002	Mar 12, 2012	Feb	NEWA
	AB		1GM	A090888 003	Mar 12, 2012	Feb	NEWA
>A>	AB	MYLAN PHARMS INC	500MG	A075969 001	Jan 29, 2002	Sep	CAHN
>A>	AB		850MG	A075969 002	Jan 29, 2002	Sep	CAHN
>A>	AB		1GM	A075969 003	Jan 29, 2002	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	AUROBINDO PHARMA LTD	500MG	A079118 001	Jul 20, 2012	Jul	NEWA
AB		750MG	A079118 002	Jul 20, 2012	Jul	NEWA
AB1	INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
AB2	MYLAN PHARMS INC	500MG	A200690 001	Aug 01, 2012	Jul	NEWA
AB		1GM	A200690 002	Aug 01, 2012	Jul	NEWA
	@ RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Apr	DISC
	@	750MG	A077211 001	Jun 29, 2005	Apr	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA PHARMS USA	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Aug	CAHN
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009	Aug	CAHN
+		1GM;EQ 30MG BASE	N022024 002	May 12, 2009	Aug	CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010	Apr	CAIN
		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

+	BRISTOL MYERS SQUIBB	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAIN
---	----------------------	-----------------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989	001		Mar	CMFD
AA		750MG	A086988	001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	---------	-----	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	AP	+	BIONICHE PHARMA USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Sep	CAHN
>D>	AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Sep	CAHN
	AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Feb	CAHN
>A>	AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Sep	CAHN
>A>	AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Sep	CAHN
	AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	NEWA
	AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	NEWA
	AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	NEWA
	AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar	NEWA
	AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Mar	NEWA

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

>A>	AA	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012	Sep	NEWA
>A>	AA		5MG	A200602 002	Sep 24, 2012	Sep	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM 2.5MG

N012524 001 Mar DISC

@ 5MG

N012524 004 Mar DISC

METHYCLOTHIAZIDE

AB	+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	---	------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL 50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

>D>	AP	+	NOVARTIS	0.2MG/ML	N006035 004	Sep	CAHN
-----	----	---	----------	----------	-------------	-----	------

>A>	AP	+	US PHARMS HOLDINGS I	0.2MG/ML	N006035 004	Sep	CAHN
-----	----	---	----------------------	----------	-------------	-----	------

TABLET; ORAL

METHERGINE

>D>	AB	+	NOVARTIS	0.2MG	N006035 003	Sep	CAHN
-----	----	---	----------	-------	-------------	-----	------

>A>	AB	+	US PHARMS HOLDINGS I	0.2MG	N006035 003	Sep	CAHN
-----	----	---	----------------------	-------	-------------	-----	------

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS 8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+ 12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS 12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB	UCB INC	10MG	N021259 003	May 27, 2003	Jul	CFTG
----	---------	------	-------------	--------------	-----	------

AB2		20MG	N021259 001	Apr 03, 2001	Jul	CFTG
-----	--	------	-------------	--------------	-----	------

AB2		30MG	N021259 002	Jun 19, 2003	Jul	CFTG
-----	--	------	-------------	--------------	-----	------

AB2		40MG	N021259 004	Feb 19, 2006	Jul	CFTG
-----	--	------	-------------	--------------	-----	------

AB		50MG	N021259 005	Feb 19, 2006	Jul	CFTG
----	--	------	-------------	--------------	-----	------

AB	+	60MG	N021259 006	Feb 19, 2006	Jul	CFTG
----	---	------	-------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

AB1	ACTAVIS	20MG	A078458 001	Dec 01, 2011	Jul	CTEC
-----	---------	------	-------------	--------------	-----	------

AB1		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
-----	--	------	-------------	--------------	-----	------

AB1		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
-----	--	------	-------------	--------------	-----	------

AB1	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jul	CTEC
-----	---------------	------	-------------	--------------	-----	------

AB		20MG	A079031 001	Jul 13, 2012	Jun	NEWA
----	--	------	-------------	--------------	-----	------

AB1		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
-----	--	------	-------------	--------------	-----	------

AB		30MG	A079031 002	Jul 13, 2012	Jun	NEWA
----	--	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	BARR LABS INC	40MG	A079031 003	Jul 13, 2012	Jul	CTEC
AB		40MG	A079031 003	Jul 13, 2012	Jun	NEWA
AB	TEVA PHARMS	10MG	A077707 001	Jul 19, 2012	Jul	NEWA
AB2		20MG	A077707 002	Jul 19, 2012	Jul	NEWA
AB2		30MG	A077707 003	Jul 19, 2012	Jul	NEWA
AB2		40MG	A078873 001	Jul 19, 2012	Jul	NEWA
AB		50MG	A078873 002	Jul 19, 2012	Jul	NEWA
AB		60MG	A078873 003	Jul 19, 2012	Jul	NEWA

RITALIN LA

AB1	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
AB1 +		40MG	N021284 003	Jun 05, 2002	Jul	CTEC

>A> FOR SUSPENSION, EXTENDED RELEASE; ORAL

>A> QUILLIVANT XR

>A>	+	NEXTWAVE PHARMS	5MG/ML	N202100 001	Sep 27, 2012	Sep	NEWA
-----	---	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@	UCB INC	10MG	A040306 001	Oct 20, 1999	Jul	DISC
---	---------	------	-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

@	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
@		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
---	-----------------	----------------	-------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012	Jul	NEWA
AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012	Jul	NEWA
	@ NESHER PHARMS	EQ 100MG TARTRATE	A076640 002	May 18, 2007	Jun	DISC
	@	EQ 200MG TARTRATE	A076640 001	May 18, 2007	Jun	DISC
AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012	Jul	NEWA
AB		EQ 200MG BASE	A078889 002	Aug 15, 2012	Jul	NEWA
	@ SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
	@	EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

@ SANDOZ	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
@	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

>D>	AB	NOVARTIS	50MG	N017963 001	Sep	CAHN
>D>	AB		100MG	N017963 002	Sep	CAHN
>A>	AB	US PHARMS HOLDINGS I	50MG	N017963 001	Sep	CAHN
>A>	AB		100MG	N017963 002	Sep	CAHN

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
	+	NORITATE					
		VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE

>D>		@ ELKINS SINN	500MG/100ML	N018907 001	Mar 30, 1984	Sep	CAHN
>A>		@ HIKMA MAPLE	500MG/100ML	N018907 001	Mar 30, 1984	Sep	CAHN

LOTION; TOPICAL

METRONIDAZOLE

AB		FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

	+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
--	---	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METOPIRONE

	@	HRA PHARMA	250MG	N012911 001		Jun	CAHN
--	---	------------	-------	-------------	--	-----	------

METYROSINE

CAPSULE; ORAL

DEMSEER

	+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
--	---	----------------------	-------	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
>D>	AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN
>D>	AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
>D>	AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN
	AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
	AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA
>A>	AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
>A>	AP		EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
>A>	AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN
>A>	AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB	SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+	5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB		10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
---	----------------	-------	-------------	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>D>	AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	A075530 001	May 28, 2002	Sep	CAHN
>D>		@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075852 001	May 28, 2002	Sep	CAHN
>A>	AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075530 001	May 28, 2002	Sep	CAHN
>A>		@	EQ 1MG BASE/ML	A075852 001	May 28, 2002	Sep	CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>		@ BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002	Sep	CAHN
>A>		@ HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002	Sep	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
	@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN
AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	RANBAXY LABS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012	Jul	NEWA
		EQ 67.5MG BASE	N201922 002	Jul 11, 2012	Jul	NEWA
		EQ 90MG BASE	N201922 003	Jul 11, 2012	Jul	NEWA
		EQ 112.5MG BASE	N201922 004	Jul 11, 2012	Jul	NEWA
	+	EQ 135MG BASE	N201922 005	Jul 11, 2012	Jul	NEWA

INJECTABLE; INJECTION

MINOCIN

+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN
---	------------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

MINOCIN

	@ PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN
--	--------------------	------------------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	BARR LABS INC	EQ 65MG BASE	A065485 004	May 18, 2012	Sep	NEWA
>A>	AB		EQ 115MG BASE	A065485 005	May 18, 2012	Sep	NEWA
>D>	AB	MATRIX LABS LTD	EQ 45MG BASE	A090911 001	Jul 20, 2010	Sep	CAHN
>D>	AB		EQ 90MG BASE	A090911 002	Jul 20, 2010	Sep	CAHN
>D>	AB		EQ 135MG BASE	A090911 003	Jul 20, 2010	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 45MG BASE	A090911 001	Jul 20, 2010	Sep	CAHN
>A>	AB		EQ 90MG BASE	A090911 002	Jul 20, 2010	Sep	CAHN
>A>	AB		EQ 135MG BASE	A090911 003	Jul 20, 2010	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

>D>		MEDICIS	EQ 65MG BASE	N050808 004	Jul 23, 2009	Sep	CFTG
>A>	AB		EQ 65MG BASE	N050808 004	Jul 23, 2009	Sep	CFTG
>D>			EQ 115MG BASE	N050808 005	Jul 23, 2009	Sep	CFTG
>A>	AB		EQ 115MG BASE	N050808 005	Jul 23, 2009	Sep	CFTG

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

		APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA
		+	50MG	N202611 002	Jun 28, 2012	Jun	NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>D>	AB	ALPHAPHARM	15MG	A076176 001	Jun 19, 2003	Sep	CAHN
>D>	AB		30MG	A076176 002	Jun 19, 2003	Sep	CAHN
>D>	AB		45MG	A076176 003	Jun 19, 2003	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	15MG	A076176 001	Jun 19, 2003	Sep	CAHN
>A>	AB		30MG	A076176 002	Jun 19, 2003	Sep	CAHN
>A>	AB		45MG	A076176 003	Jun 19, 2003	Sep	CAHN

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

AB		NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA
AB			0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

		+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
--	--	---	---------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

MITOMYCIN

>D>	AP	BAXTER HLTHCARE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
>D>	AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN
>A>	AP	HIKMA MAPLE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
>A>	AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

	@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC
	@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC
	@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

	@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	Jun	CAHN
--	---	---------------------	----------------	-------------	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

>A>	AB	AUROBINDO PHARMA LTD	100MG	A202566 001	Sep 27, 2012	Sep	NEWA
>A>	AB		200MG	A202566 002	Sep 27, 2012	Sep	NEWA
>A>	AB	HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012	Sep	NEWA
>A>	AB		200MG	A090543 002	Sep 26, 2012	Sep	NEWA
	AB	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012	Jun	NEWA
	AB		200MG	A076594 002	Jul 16, 2012	Jun	NEWA
>A>	AB	ORCHID HLTHCARE	100MG	A078963 001	Sep 26, 2012	Sep	NEWA
>A>	AB		200MG	A078963 002	Sep 26, 2012	Sep	NEWA
		PROVIGIL					
	AB	CEPHALON	100MG	N020717 001	Dec 24, 1998	Jun	CFTG
	AB	+	200MG	N020717 002	Dec 24, 1998	Jun	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987	Jun	CAHN
		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN

LOTION; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019796 001	Mar 30, 1989	Jul	CAHN
		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN

OINTMENT; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987	May	CAHN
		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

>A>	AB	DR REDDYS LABS LTD	EQ 4MG BASE/PACKET	A202906 001	Sep 17, 2012	Sep	NEWA
	AB	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955 001	Aug 03, 2012	Jul	NEWA
		SINGULAIR					
	AB	+	EQ 4MG BASE/PACKET	N021409 001	Jul 26, 2002	Jul	CFTG

TABLET; ORAL

MONTELUKAST SODIUM

>A>	AB	ACCORD HLTHCARE	EQ 10MG BASE	A202717 001	Sep 21, 2012	Sep	NEWA
	AB	APOTEX CORP	EQ 10MG BASE	A201294 001	Aug 03, 2012	Jul	NEWA
	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468 001	Aug 03, 2012	Jul	NEWA
	AB	DR REDDYS LABS LTD	EQ 10MG BASE	A201582 001	Aug 06, 2012	Jul	NEWA
	AB	ENDO PHARMS	EQ 10MG BASE	A091576 001	Aug 03, 2012	Jul	NEWA
	AB	GLENMARK GENERICS	EQ 10MG BASE	A090926 001	Aug 03, 2012	Jul	NEWA
	AB	KUDCO IRELAND	EQ 10MG BASE	A201522 001	Aug 03, 2012	Jul	NEWA
	AB	MYLAN PHARMS INC	EQ 10MG BASE	A079103 001	Aug 03, 2012	Jul	NEWA
	AB	ROXANE	EQ 10MG BASE	A090655 001	Aug 03, 2012	Jul	NEWA
	AB	SANDOZ INC	EQ 10MG BASE	A200889 001	Aug 03, 2012	Jul	NEWA
	AB	TEVA PHARMS	EQ 10MG BASE	A078605 001	Aug 03, 2012	Jul	NEWA
	AB	TORRENT PHARMS LTD	EQ 10MG BASE	A201515 001	Aug 03, 2012	Jul	NEWA
		SINGULAIR					
	AB	+	EQ 10MG BASE	N020829 002	Feb 20, 1998	Jul	CFTG

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	APOTEX INC	EQ 4MG BASE	A201508 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A201508 002	Aug 03, 2012	Jul	NEWA
AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A202096 002	Aug 03, 2012	Jul	NEWA
AB	DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012	Jul	NEWA
AB		EQ 5MG BASE	A201581 002	Aug 06, 2012	Jul	NEWA
AB	ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
AB	KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
AB	ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA
	SINGULAIR					
AB	MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

	ACTAVIS ELIZABETH	40MG	N020616 009	Jul 09, 2012	Jul	NEWA
		70MG	N020616 010	Jul 09, 2012	Jul	NEWA
		130MG	N020616 011	Jul 09, 2012	Jul	NEWA
		150MG	N020616 012	Jul 09, 2012	Jul	NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN
		INFUMORPH					
+		HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
+			25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

	@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA		PADDOCK LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul	NEWA
----	--	-------------	-----------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>D>	AB	ENDO PHARMS	15MG	A075295 001	Oct 28, 1998	Sep	CAHN
>D>	AB		30MG	A075295 002	Oct 28, 1998	Sep	CAHN
>D>	AB		60MG	A075295 003	Oct 28, 1998	Sep	CAHN
>D>	AB		100MG	A075295 004	Sep 15, 2000	Sep	CAHN
>D>	AB		200MG	A075295 005	Sep 15, 2000	Sep	CAHN
	AB	RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB	RANBAXY LABS LTD	30MG	A078761 002	May 11, 2012	Apr	NEWA
AB		60MG	A078761 003	May 11, 2012	Apr	NEWA
AB		100MG	A078761 004	May 11, 2012	Apr	NEWA
AB		200MG	A078761 005	May 11, 2012	Apr	NEWA
>A>	VINTAGE PHARMS LLC	15MG	A075295 001	Oct 28, 1998	Sep	CAHN
>A>		30MG	A075295 002	Oct 28, 1998	Sep	CAHN
>A>		60MG	A075295 003	Oct 28, 1998	Sep	CAHN
>A>		100MG	A075295 004	Sep 15, 2000	Sep	CAHN
>A>		200MG	A075295 005	Sep 15, 2000	Sep	CAHN
	ORAMORPH SR					
	@ XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
	@	30MG	N019977 001	Aug 15, 1991	May	DISC
	@	60MG	N019977 002	Aug 15, 1991	May	DISC
	@	100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	ENDO PHARMS	250MG	A090111 001	Dec 22, 2009	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	250MG	A090111 001	Dec 22, 2009	Sep	CAHN
>D>	AB	ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009	Sep	DISC
>A>	@		250MG	A065433 001	May 04, 2009	Sep	DISC

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	ENDO PHARMS	500MG	A090606 001	Jul 16, 2010	Sep	CAHN
>A>	AB	VINTAGE PHARMS LLC	500MG	A090606 001	Jul 16, 2010	Sep	CAHN
>D>	AB	ZYDUS PHARMS USA INC	500MG	A065477 001	May 04, 2009	Sep	DISC
>A>	@		500MG	A065477 001	May 04, 2009	Sep	DISC

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB	APOTEX INC	180MG	A091558 001	Aug 21, 2012	Aug	NEWA
AB	NOVARTIS	180MG	N050791 001	Feb 27, 2004	Aug	CFTG

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB	MATRIX LABS LTD	500MG	A090516 001	Jul 12, 2010	Sep	CAHN
>D>	AB		750MG	A090516 002	Jul 12, 2010	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	500MG	A090516 001	Jul 12, 2010	Sep	CAHN
>A>	AB		750MG	A090516 002	Jul 12, 2010	Sep	CAHN
	AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
	AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	ANTIBIOTICE	EQ 1GM BASE	A090560 001	Oct 03, 2011	Aug	CAHN
AP		EQ 2GM BASE	A090560 002	Oct 03, 2011	Aug	CAHN
AP	ASTRAL PHARM INDS	EQ 1GM BASE/VIAL	A090582 001	Aug 24, 2012	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A090582 002	Aug 24, 2012	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A090580 001	Aug 24, 2012	Aug	NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	HIKMA MAPLE	0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN

NALOXONE HYDROCHLORIDE

@	HIKMA MAPLE	0.02MG/ML	A071272 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071287 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071273 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071274 001	May 24, 1988	Jun	CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

>D>	AB	ALPHAPHARM	375MG	A075390 001	Apr 19, 2001	Sep	CAHN
>D>	AB		500MG	A075390 002	Apr 19, 2001	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	375MG	A075390 001	Apr 19, 2001	Sep	CAHN
>A>	AB		500MG	A075390 002	Apr 19, 2001	Sep	CAHN

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN
----	-------------------	---------------	-------------	--	-----	------

ANAPROX DS

AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN
----	---	-------------------	---------------	-------------	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TRESIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
---	--------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
----	------------------	-------------	-------------	--------------	-----	------

TABLET; ORALNARATRIPTAN

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA

NATEGLINIDETABLET; ORALNATEGLINIDE

	@ TEVA PHARMS	60MG	A077467 001	Sep 09, 2009	Jul	DISC
	@	120MG	A077467 002	Sep 09, 2009	Jul	DISC

NEDOCROMIL SODIUMSOLUTION/DROPS; OPHTHALMICALOCRIIL

AT	+ ALLERGAN	2%	N021009 001	Dec 08, 1999	Aug	CFTG
AT	NEDOCROMIL SODIUM					
AT	AKORN	2%	A090638 001	Aug 22, 2012	Aug	NEWA

NEVIRAPINESUSPENSION; ORALNEVIRAPINE

AA	AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
AA	+ BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG

TABLET; ORALNEVIRAPINE

AB	APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
AB	AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
AB	CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
AB	HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
AB	MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
AB	MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
AB	MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
AB	PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
AB	SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May	NEWA
AB	STRIDES	200MG	A078195 001	May 22, 2012	May	NEWA
AB	VIRAMUNE					
AB	+ BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May	CFTG

NIFEDIPINETABLET, EXTENDED RELEASE; ORALNIFEDIPINE

AB1	ACTAVIS	90MG	A077899 003	May 25, 2012	May	NEWA
-----	---------	------	-------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORALMACRODANTIN

AB	ALMATICA	25MG	N016620 003		Jul	CAHN
AB		50MG	N016620 001		Jul	CAHN
AB	+	100MG	N016620 002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE; ORALMACROBID

AB	+ ALMATICA	75MG;25MG	N020064 001	Dec 24, 1991	Jul	CAHN
----	------------	-----------	-------------	--------------	-----	------

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ RANBAXY LABS LTD 75MG;25MG

A076951 001 Mar 30, 2005 Apr DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1 MEDICIS 0.1MG/HR

A089771 001 Aug 30, 1996 Jul CAHN

AB1 0.2MG/HR

A089772 001 Aug 30, 1996 Jul CAHN

AB1 0.4MG/HR

A089773 001 Aug 30, 1996 Jul CAHN

AB1 0.6MG/HR

A089774 001 Aug 30, 1996 Jul CAHN

OINTMENT; INTRA-ANAL

RECTIV

+ APTALIS PHARMA 0.4%

N021359 001 Jun 21, 2011 Jan CAHN

NIZATIDINE

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM 150MG

N019508 001 Apr 12, 1988 Mar DISC

@ 300MG

N019508 002 Apr 12, 1988 Mar DISC

NIZATIDINE

@ MYLAN PHARMS INC 150MG

A075934 001 Jul 09, 2002 Apr DISC

@ 300MG

A075934 002 Jul 09, 2002 Apr DISC

AB + 300MG

A075806 002 Jul 05, 2002 Apr CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP CLARIS LIFESCIENCES EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 May CAHN

AP SINTEGICA EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 Mar NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB AMNEAL PHARMS 5MG

A200275 001 Jul 30, 2012 Jul NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT FOUGERA PHARMS 100,000 UNITS/GM

A062129 001 Jan CAHN

AT + TARO 100,000 UNITS/GM

A064022 001 Jan 29, 1993 Aug CRLD

OINTMENT; TOPICAL

NYSTATIN

AT + FOUGERA PHARMS 100,000 UNITS/GM

A062124 002 Sep 23, 1982 Jan CAHN

POWDER; TOPICAL

NYSTATIN

@ NESHER PHARMS 100,000 UNITS/GM

A065321 001 Aug 18, 2006 Jun DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062367 001 May 28, 1985 Jun CAHN

OINTMENT; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062733 001 Mar 09, 1987 Jun CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

@ SANDOZ	0.3%	A076848 001	Nov 25, 2008	Aug	DISC
----------	------	-------------	--------------	-----	------

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003	Apr	DISC
@	300MG	A076220 002	Sep 02, 2003	Apr	DISC
@	400MG	A076220 003	Sep 02, 2003	Apr	DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

>A>	AP	LUITPOLD	10MG/VIAL	A201741 001	Mar 20, 2012	Sep	CAHN
>D>	AP	PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Sep	CAHN
	AP		10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
	AP	SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN

TABLET; ORAL

OLANZAPINE

AB	APOTEX INC	2.5MG	A090798 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A090798 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A090798 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A090798 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A090798 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A090798 006	Apr 23, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A202050 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202050 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202050 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202050 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202050 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202050 006	Apr 23, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A076255 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076255 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076255 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076255 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076133 001	Apr 23, 2012	Apr	NEWA
AB	MYLAN	2.5MG	A076866 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076866 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076866 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076866 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076866 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A076866 006	Apr 23, 2012	Apr	NEWA
AB	ORCHID HLTHCARE	2.5MG	A202287 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202287 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202287 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202287 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287 006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038 006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012	Apr	NEWA

TABLET; ORAL

OLANZAPINE

AB	TORRENT PHARMS LTD	5MG	A091434 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	JUBILANT ORGANOSYS	5MG	A200221 001	Sep 12, 2012	Aug	NEWA
AB		10MG	A200221 002	Sep 12, 2012	Aug	NEWA
AB		15MG	A200221 003	Sep 12, 2012	Aug	NEWA
AB		20MG	A200221 004	Sep 12, 2012	Aug	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA
AB	SANDOZ	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

	@ NESHER PHARMS	4MG	A077717 001	Jun 25, 2007	Jun	DISC
	@	8MG	A077717 002	Jun 25, 2007	Jun	DISC
	@ PAR PHARM	4MG	A076506 001	Dec 26, 2006	Aug	DISC
	@	8MG	A076506 002	Dec 26, 2006	Aug	DISC
	@	16MG	A077406 001	Dec 26, 2006	Aug	DISC
	@	24MG	A077406 002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA	
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN	
	@ SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007	Aug	DISC	
>D>	ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER						
>D>	AP	+ BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006	Sep	DISC
>A>		@	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006	Sep	DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN	

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

>A>	DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006	Sep	NEWA
	@ PAR PHARM	EQ 4MG BASE	A077303 001	Jun 25, 2007	Aug	DISC
	@	EQ 8MG BASE	A077303 002	Jun 25, 2007	Aug	DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

		@ PAR PHARM	EQ 24MG BASE	A077303 004	Jun 25, 2007	Aug	DISC
>D>	AB	WEST WARD	EQ 4MG BASE	A077545 001	Sep 06, 2007	Sep	DISC
>D>	AB		EQ 8MG BASE	A077545 002	Sep 06, 2007	Sep	DISC
>D>	AB		EQ 24MG BASE	A077545 003	Sep 06, 2007	Sep	DISC
>A>		@ WEST WARD PHARM CORP	EQ 4MG BASE	A077545 001	Sep 06, 2007	Sep	DISC
>A>		@	EQ 8MG BASE	A077545 002	Sep 06, 2007	Sep	DISC
>A>		@	EQ 24MG BASE	A077545 003	Sep 06, 2007	Sep	DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB		CNTY LINE PHARMS	100MG	A040249 001	Jan 29, 1999	Jul	CAHN
AB		INVAGEN PHARMS	100MG	A091158 001	Jul 27, 2012	Jul	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+		ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	--	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP		SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP			EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP			EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP		ACTAVIS TOTOWA	50MG/VIAL	A078803 001	Aug 08, 2012	Jul	NEWA
AP			100MG/VIAL	A078803 002	Aug 08, 2012	Jul	NEWA
AP		ONCO THERAPIES LTD	50MG/10ML (5MG/ML)	A091358 001	Aug 07, 2012	Jul	NEWA
AP			50MG/VIAL	A200979 001	Aug 08, 2012	Jul	NEWA
AP			100MG/VIAL	A200979 002	Aug 08, 2012	Jul	NEWA
AP			100MG/20ML (5MG/ML)	A091358 002	Aug 07, 2012	Jul	NEWA
AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+		100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB		AMNEAL PHARMS	300MG/5ML	A202961 001	Sep 17, 2012	Aug	NEWA
>A>	AB	ROXANE	300MG/5ML	A201193 001	Oct 03, 2012	Sep	NEWA

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+		FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	--	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+		WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
+			600MG	A086742 001		Jun	CAHN

OXYBUTYNYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

	+	ARROW INTL	3%	N202513	001	Dec 07, 2011	Apr	CAHN
	+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Feb	CAHN

OXYBUTYNYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS 5MG

N017577 001 Mar DISC

OXYBUTYNYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079	001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Mar	NEWA
----	--	------------------	------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB		COASTAL PHARMS	5MG	A203107	001	Jul 26, 2012	Jul	NEWA
----	--	----------------	-----	---------	-----	--------------	-----	------

AB	+	LEHIGH VALLEY	5MG	N200534	001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----	---------	-----	--------------	-----	------

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535	001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----------	---------	-----	--------------	-----	------

+ VISTAPHARM 5MG/5ML

N201194 001 Jan 12, 2012 Jan NEWA

AA			100MG/5ML	A202537	001	Jul 30, 2012	Jul	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758	003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS 5MG

N021610 001 Jun 22, 2006 May DISC

@ 10MG

N021610 002 Jun 22, 2006 May DISC

@ 20MG

N021610 003 Jun 22, 2006 May DISC

@ 30MG

N021610 007 Feb 29, 2008 May DISC

+ 40MG

N201655 007 Dec 09, 2011 Aug CRLD

@ 40MG

N021610 004 Jun 22, 2006 May DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS 5MG

A079087 001 Jun 14, 2010 May CTEC

10MG

A079087 003 Jun 14, 2010 May CTEC

20MG

A079087 005 Jun 14, 2010 May CTEC

30MG

A079087 006 Jul 22, 2010 May CTEC

40MG

A079087 007 Jun 14, 2010 May CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL 10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 Jan DISC

@ 100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 Mar DISC

PITOCIN

JHP PHARMS 500USP UNITS/50ML (10USP UNITS/ML)

N018261 003 Sep 05, 2012 Aug NEWA

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@	CORDEN PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Mar	CAHN
---	---------------	--------	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@	NOVARTIS	30MG/VIAL	N020036	001	Oct 31, 1991	Mar	DISC
---	----------	-----------	---------	-----	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	ABBOTT LABS	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725	004	Jul 12, 2011	Jun	NEWA
--	-------------	---	---------	-----	--------------	-----	------

		30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009	Feb	CAHN
--	--	--	---------	-----	--------------	-----	------

		60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009	Feb	CAHN
--	--	---	---------	-----	--------------	-----	------

+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009	Feb	CAHN
---	--	--	---------	-----	--------------	-----	------

PERTZYE

	DIGESTIVE CARE INC	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175	001	May 17, 2012	May	NEWA
--	--------------------	--	---------	-----	--------------	-----	------

+		60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175	002	May 17, 2012	May	NEWA
---	--	---	---------	-----	--------------	-----	------

ULTRESA

	APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	Mar	NEWA
--	-------------------	---	---------	-----	--------------	-----	------

		41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	Mar	NEWA
--	--	---	---------	-----	--------------	-----	------

+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	Mar	NEWA
---	--	---	---------	-----	--------------	-----	------

ZENPEP

	APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011	Apr	NEWA
--	-------------------	--	---------	-----	--------------	-----	------

		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr	CRLD
--	--	--	---------	-----	--------------	-----	------

+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr	NEWA
---	--	--	---------	-----	--------------	-----	------

TABLET; ORAL

VIOKACE

	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar	NEWA
--	-------------------	---	---------	-----	--------------	-----	------

+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar	NEWA
---	--	---	---------	-----	--------------	-----	------

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	APOTEX INC	EQ 20MG BASE	A090807	001	May 02, 2012	Apr	NEWA
----	------------	--------------	---------	-----	--------------	-----	------

AB		EQ 40MG BASE	A090807	002	May 02, 2012	Apr	NEWA
----	--	--------------	---------	-----	--------------	-----	------

>A>	AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A202038	001	Sep 28, 2012	Sep	NEWA
-----	----	----------------------	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 40MG BASE	A202038	002	Sep 28, 2012	Sep	NEWA
-----	----	--	--------------	---------	-----	--------------	-----	------

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	Jan	NEWA
----	---------------------	--------------	---------	-----	--------------	-----	------

AB		EQ 40MG BASE	A200821	002	Feb 16, 2012	Jan	NEWA
----	--	--------------	---------	-----	--------------	-----	------

>D>	AB	MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Sep	CAHN
-----	----	-----------------	--------------	---------	-----	--------------	-----	------

>D>	AB		EQ 40MG BASE	A090970	002	Jan 19, 2011	Sep	CAHN
-----	----	--	--------------	---------	-----	--------------	-----	------

>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A090970	001	Jan 19, 2011	Sep	CAHN
-----	----	------------------	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 40MG BASE	A090970	002	Jan 19, 2011	Sep	CAHN
-----	----	--	--------------	---------	-----	--------------	-----	------

AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	NEWA
----	------------------	--------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	RANBAXY LABS LTD	EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA
----	------------------	--------------	-------------	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
	AB		EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
>D>	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
>D>	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
>D>	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN
	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD
>D>	AB	ALPHAPHARM	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
>D>	AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
>D>	AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
>D>	AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
>A>	AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
>A>	AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
>A>	AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
>A>	AB	PROSAM LABS	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
>A>	AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
>A>	AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
>A>	AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

>D>	AP	APP PHARMS	5,000,000 UNITS/VIAL	A065448 001	Aug 18, 2009	Sep	CAHN
>D>	AP		20,000,000 UNITS/VIAL	A065448 002	Aug 18, 2009	Sep	CAHN
>A>	AP	IBI	5,000,000 UNITS/VIAL	A065448 001	Aug 18, 2009	Sep	CAHN

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

>A>	AP	IBI	20,000,000 UNITS/VIAL	A065448 002	Aug 18, 2009	Sep	CAHN
-----	----	-----	-----------------------	-------------	--------------	-----	------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

	+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
--	---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB		XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB			4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+		8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
----	---	------------------	------	-------------	--	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

AB		ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA
----	--	--------	------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA	ELITE LABS	15MG	A202248 001	Sep 28, 2012	Sep	NEWA
>A>	AA		30MG	A202248 002	Sep 28, 2012	Sep	NEWA
	AA	LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
		@ MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
		@	30MG	A040227 001	Jun 18, 1997	Jul	CAHN
		@	30MG	A040448 001	Jan 22, 2003	Jul	CAHN
		@	37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

		@ MIKAH PHARMA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
>A>	AA	MIRROR PHARMS	37.5MG	A091451 001	Sep 21, 2012	Sep	NEWA
		@ SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD
	+		37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS

			EQ 3.75MG BASE;23MG	N022580 001	Jul 17, 2012	Jul	NEWA
			EQ 7.5MG BASE;46MG	N022580 002	Jul 17, 2012	Jul	NEWA
			EQ 11.25MG BASE;69MG	N022580 003	Jul 17, 2012	Jul	NEWA
	+		EQ 15MG BASE;92MG	N022580 004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE	50MG/ML	A084307 001		Jun	CAHN
----	---	-------------	---------	-------------	--	-----	------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
----	---	-----------------	-----------	-------------	--	-----	------

TABLET; ORAL

MEPHYTON

+	VALEANT PHARMS	5MG	N010104 003		Jun	CAHN
---	----------------	-----	-------------	--	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

@	MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992	May	CAHN
---	------------------	-----	-------------	--------------	-----	------

@		10MG	A074018 001	Sep 24, 1992	May	CAHN
---	--	------	-------------	--------------	-----	------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB		TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Aug	CFTG
----	--	-------------------	--------------	-------------	--------------	-----	------

			EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
--	--	--	--------------	-------------	--------------	-----	------

AB			EQ 30MG BASE	N021073 002	Jul 15, 1999	Aug	CFTG
----	--	--	--------------	-------------	--------------	-----	------

			EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
--	--	--	--------------	-------------	--------------	-----	------

AB	+		EQ 45MG BASE	N021073 003	Jul 15, 1999	Aug	CFTG
----	---	--	--------------	-------------	--------------	-----	------

+			EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN
---	--	--	--------------	-------------	--------------	-----	------

PIOGLITAZONE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 15MG BASE	A076801 001	Aug 17, 2012	Aug	NEWA
----	--	------------------	--------------	-------------	--------------	-----	------

AB			EQ 30MG BASE	A076801 002	Aug 17, 2012	Aug	NEWA
----	--	--	--------------	-------------	--------------	-----	------

AB			EQ 45MG BASE	A076801 003	Aug 17, 2012	Aug	NEWA
----	--	--	--------------	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

>D>	AA	PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769 001	Jun 07, 2010	Sep	DISC
-----	----	-------------	--	-------------	--------------	-----	------

>A>		@	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769 001	Jun 07, 2010	Sep	DISC
-----	--	---	--	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

>D>	AA	PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712 001	Feb 25, 2010	Sep	DISC
-----	----	-------------	--	-------------	--------------	-----	------

>A>		@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712 001	Feb 25, 2010	Sep	DISC
-----	--	---	--	-------------	--------------	-----	------

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL							
K+10							
	@ FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987	Mar	DISC
KAON CL-10							
	@ SAVAGE LABS	10MEQ	N017046	002		Mar	DISC
KLOR-CON M20							
AB	+ UPSHER SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Mar	CRLD
KLOTRIX							
	@ APOTHECON	10MEQ	N017850	001		Mar	DISC
POTASSIUM CHLORIDE							
	@ NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002	Mar	DISC
	@ SCHERING	10MEQ	N019439	002	Jun 13, 1986	Mar	DISC
	@	20MEQ	N019439	001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL							
POTASSIUM CITRATE							
	@ NOVA K	10MEQ/PACKET	N019647	002	Oct 13, 1988	Feb	CAHN
	@	20MEQ/PACKET	N019647	001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
AB	APOTEX INC	0.125MG	A090151	001	Apr 30, 2012	Apr	NEWA
AB		0.25MG	A090151	002	Apr 30, 2012	Apr	NEWA
AB		0.5MG	A090151	003	Apr 30, 2012	Apr	NEWA
AB		0.75MG	A090151	006	Apr 30, 2012	Apr	NEWA
AB		1MG	A090151	004	Apr 30, 2012	Apr	NEWA
AB		1.5MG	A090151	005	Apr 30, 2012	Apr	NEWA
>A>	AB	MACLEODS PHARMS LTD	A202164	001	Sep 20, 2012	Sep	NEWA
>A>	AB		A202164	002	Sep 20, 2012	Sep	NEWA
>A>	AB		A202164	003	Sep 20, 2012	Sep	NEWA
>A>	AB		A202164	004	Sep 20, 2012	Sep	NEWA
>A>	AB		A202164	005	Sep 20, 2012	Sep	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL							
PRAVASTATIN SODIUM							
	@ PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006	Jun	DISC
	@	20MG	A077730	002	Nov 21, 2006	Jun	DISC
	@	30MG	A077730	003	Nov 21, 2006	Jun	DISC
	@	40MG	A077730	005	Nov 21, 2006	Jun	DISC
	@ RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007	Apr	DISC
	@	20MG	A076445	002	Apr 23, 2007	Apr	DISC
	@	40MG	A076445	003	Apr 23, 2007	Apr	DISC
	@	80MG	A076445	004	Apr 23, 2007	Apr	DISC

PREDNICARBATE

CREAM; TOPICAL							
PREDNICARBATE							
AB	FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Jan	CAHN
OINTMENT; TOPICAL							
PREDNICARBATE							
AB	FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Jan	CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	+	HI TECH PHARMA CO	15MG/5ML	A040401	001	Feb 27, 2003	Jul	CRLD
		@ NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001	Jun	DISC
		@	15MG/5ML	A040364	001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

>A>	AA	+	SETON PHARM	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Sep	CAHN
>D>	AA	+	UCB INC	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Sep	CAHN
			PREDNISOLONE SODIUM PHOSPHATE						
		+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jul	CAHN
			@ NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005	Jun	DISC

PREDNISONE

TABLET, DELAYED RELEASE; ORAL

RAYOS

			HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Jul	NEWA
				2MG	N202020	002	Jul 26, 2012	Jul	NEWA
		+		5MG	N202020	003	Jul 26, 2012	Jul	NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB			PF PRISM	25MG	N021446	001	Dec 30, 2004	Jun	CFTG
				25MG	N021446	001	Dec 30, 2004	Jan	CAHN
AB				50MG	N021446	002	Dec 30, 2004	Jun	CFTG
				50MG	N021446	002	Dec 30, 2004	Jan	CAHN
AB				75MG	N021446	003	Dec 30, 2004	Jun	CFTG
				75MG	N021446	003	Dec 30, 2004	Jan	CAHN
				100MG	N021446	004	Dec 30, 2004	Jan	CAHN
AB				150MG	N021446	005	Dec 30, 2004	Jun	CFTG
				150MG	N021446	005	Dec 30, 2004	Jan	CAHN
AB				200MG	N021446	006	Dec 30, 2004	Jun	CFTG
				200MG	N021446	006	Dec 30, 2004	Jan	CAHN
AB				225MG	N021446	007	Dec 30, 2004	Jun	CFTG
				225MG	N021446	007	Dec 30, 2004	Jan	CAHN
AB	+			300MG	N021446	008	Dec 30, 2004	Jun	CFTG
		+		300MG	N021446	008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB			LUPIN LTD	25MG	A091040	001	Jul 03, 2012	Jun	NEWA
AB				50MG	A091040	002	Jul 03, 2012	Jun	NEWA
AB				75MG	A091040	003	Jul 03, 2012	Jun	NEWA
AB				100MG	A091040	004	Jul 03, 2012	Jun	NEWA
AB				150MG	A091040	005	Jul 03, 2012	Jun	NEWA
AB				200MG	A091040	006	Jul 03, 2012	Jun	NEWA
AB				225MG	A091040	007	Jul 03, 2012	Jun	NEWA
AB				300MG	A091040	008	Jul 03, 2012	Jun	NEWA
AB			TEVA PHARMS	25MG	A091219	001	Jul 03, 2012	Jun	NEWA
AB				50MG	A091219	002	Jul 03, 2012	Jun	NEWA
AB				75MG	A091224	001	Jul 03, 2012	Jun	NEWA
AB				100MG	A091224	002	Jul 03, 2012	Jun	NEWA
AB				150MG	A091224	003	Jul 03, 2012	Jun	NEWA

CAPSULE; ORAL

PREGABALIN

AB	TEVA PHARMS	200MG	A091224 004	Jul 03, 2012	Jun	NEWA
AB		225MG	A091224 005	Jul 03, 2012	Jun	NEWA
AB		300MG	A091224 006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG	A091221 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091221 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091221 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091221 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091221 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091221 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091221 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091221 008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN
---	----------	---------	-------------	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

@	DENTSPLY PHARM	4%	N021382 001		May	DISC
+	SEPTODONT INC	4%	A079235 001	Sep 29, 2010	May	CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

@	HIKMA MAPLE	100MG/ML	A089029 001	Apr 17, 1986	Jun	CAHN
@		500MG/ML	A089030 001	Apr 17, 1986	Jun	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	HIKMA MAPLE	EQ 5MG BASE/ML	A089903 001	Aug 29, 1989	Jun	CAHN
	@		EQ 5MG BASE/ML	A089523 001	May 03, 1988	Jun	CAHN

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

>A>	AB	SOFGEN PHARMS	100MG	A200456 001	Sep 28, 2012	Sep	NEWA
>A>	AB		200MG	A200456 002	Sep 28, 2012	Sep	NEWA
	AB	TEVA PHARMS	100MG	A202121 001	Feb 29, 2012	Feb	NEWA
	AB		200MG	A202121 002	Feb 29, 2012	Feb	NEWA
		PROMETRIUM					
	AB	ABBOTT LABS	100MG	N019781 001	May 14, 1998	Feb	CFTG
	AB	+	200MG	N019781 002	Oct 15, 1999	Feb	CFTG

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		TRIS PHARMA INC	6.25MG/5ML	A091675 001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	------------	-------------	--------------	-----	------

PROPAPENONE HYDROCHLORIDE

TABLET; ORAL

PROPAPENONE HYDROCHLORIDE

@	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Jun	DISC
---	---------------	-------	-------------	--------------	-----	------

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ NESHER PHARMS	225MG	A076193 002	Feb 07, 2002	Jun	DISC
@	300MG	A076193 003	Feb 07, 2002	Jun	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB	APTALIS PHARMATECH	60MG	A078703 001	Jul 15, 2011	Sep	CAHN
>A>	AB		80MG	A078703 002	Jul 15, 2011	Sep	CAHN
>A>	AB		120MG	A078703 003	Jul 15, 2011	Sep	CAHN
>A>	AB		160MG	A078703 004	Jul 15, 2011	Sep	CAHN
>D>	AB	GLAXOSMITHKLINE	60MG	A078703 001	Jul 15, 2011	Sep	CAHN
>D>	AB		80MG	A078703 002	Jul 15, 2011	Sep	CAHN
>D>	AB		120MG	A078703 003	Jul 15, 2011	Sep	CAHN
>D>	AB		160MG	A078703 004	Jul 15, 2011	Sep	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@ TEVA WOMENS R AND D	5MG	N016012 001		Jul	CAHN
@	10MG	N016012 002		Jul	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	60MG	N009829 002		Jun	CAHN
----	---	--------------------	------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

AB	+	VALEANT PHARMS LLC	180MG	N011665 001		Jun	CAHN
----	---	--------------------	-------	-------------	--	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB		APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB		AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	DR REDDYS LABS LTD	EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA
SEROQUEL						
AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
@		EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
@		EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
@		EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

>D>	+	AR HOLDING CO INC	324MG	N021799 001	Aug 12, 2005	Sep	CFTG
>A>	AB	+	324MG	N021799 001	Aug 12, 2005	Sep	CFTG
>A>		QUININE SULFATE					
>A>	AB	TEVA PHARMS	324MG	A091661 001	Sep 28, 2012	Sep	NEWA

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
---	-------------------	-----	-------------	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009 Apr DISC

@

10MG

A078849 002 Mar 06, 2009 Apr DISC

TABLET; ORAL

ALTACE

@ KING PFIZER

1.25MG

N022021 001 Feb 27, 2007 Jan DISC

@

2.5MG

N022021 002 Feb 27, 2007 Jan DISC

@

5MG

N022021 003 Feb 27, 2007 Jan DISC

@

10MG

N022021 004 Feb 27, 2007 Jan DISC

RAMIPRIL

>D>	AB	MATRIX LABS LTD	1.25MG	A090650 001	Jun 30, 2011	Sep	CAHN
>D>	AB		2.5MG	A090650 002	Jun 30, 2011	Sep	CAHN
>D>	AB		5MG	A090650 003	Jun 30, 2011	Sep	CAHN
>D>	AB		10MG	A090650 004	Jun 30, 2011	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011	Sep	CAHN
>A>	AB		2.5MG	A090650 002	Jun 30, 2011	Sep	CAHN
>A>	AB		5MG	A090650 003	Jun 30, 2011	Sep	CAHN
>A>	AB		10MG	A090650 004	Jun 30, 2011	Sep	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
----	---	--------------	-----------------	-------------	--------------	-----	------

ZANTAC IN PLASTIC CONTAINER

+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
	@	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA	RANBAXY	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007	Sep	DISC
>A>		@	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007	Sep	DISC

REGORAFENIB

>A>		TABLET; ORAL					
>A>		STIVARGA					
>A>	+	BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012	Sep	NEWA

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB		PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	--	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
	@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
	+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN
---	---------------------	------	-------------	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

	NOVARTIS	13.3MG/24HR	N022083 005	Aug 31, 2012	Aug	NEWA
--	----------	-------------	-------------	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012	Aug	NEWA	
AP		100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012	Aug	NEWA	
>D>	AP	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008	Sep	CAHN
>D>	AP		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008	Sep	CAHN
>A>	AP	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008	Sep	CAHN
>A>	AP		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008	Sep	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB		EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB		EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB		EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB		EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA
AB	WOCKHARDT LTD	EQ 2MG BASE	A091395 001	Aug 27, 2012	Aug	NEWA
AB		EQ 4MG BASE	A091395 002	Aug 27, 2012	Aug	NEWA
AB		EQ 6MG BASE	A091395 003	Aug 27, 2012	Aug	NEWA
AB		EQ 8MG BASE	A091395 004	Aug 27, 2012	Aug	NEWA
AB		EQ 12MG BASE	A091395 005	Aug 27, 2012	Aug	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC

		1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
		2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
		3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
		4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
		6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+		8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

+ JAZZ EUSA PHARMA 50mCi/ML N020570 001 Mar 28, 1997 Jul CAHN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

>D> @ ENDO PHARMS 5MG A074565 001 Aug 02, 1996 Sep CAHN
>A> @ VINTAGE PHARMS LLC 5MG A074565 001 Aug 02, 1996 Sep CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+ VALEANT INTL 2% N021385 001 Dec 10, 2003 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 20MG BASE/ML A078053 001 Feb 05, 2007 Aug DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D> AB MATRIX LABS LTD EQ 25MG BASE A078626 001 Jan 31, 2008 Sep CAHN
>D> AB EQ 50MG BASE A078626 002 Jan 31, 2008 Sep CAHN
>D> AB EQ 100MG BASE A078626 003 Jan 31, 2008 Sep CAHN
>A> AB MYLAN PHARMS INC EQ 25MG BASE A078626 001 Jan 31, 2008 Sep CAHN
>A> AB EQ 50MG BASE A078626 002 Jan 31, 2008 Sep CAHN
>A> AB EQ 100MG BASE A078626 003 Jan 31, 2008 Sep CAHN
AB PROSAM LABS EQ 25MG BASE A078175 001 Jul 21, 2010 Feb CMFD
AB EQ 50MG BASE A078175 002 Jul 21, 2010 Feb CMFD
AB EQ 100MG BASE A078175 003 Jul 21, 2010 Feb CMFD

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER 10MG/ML N203109 001 Aug 30, 2012 Aug NEWA

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB THEPHARMANETWORK LLC 1% N018810 001 Dec 23, 1985 Jun CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>D> AB MATRIX LABS LTD 5MG A090868 001 Jun 08, 2010 Sep CAHN
>D> AB 10MG A090868 002 Jun 08, 2010 Sep CAHN
>D> AB 20MG A090868 003 Jun 08, 2010 Sep CAHN
>D> AB 40MG A090868 004 Jun 08, 2010 Sep CAHN
>D> AB 80MG A090868 005 Jun 08, 2010 Sep CAHN
>A> AB MYLAN PHARMS INC 5MG A090868 001 Jun 08, 2010 Sep CAHN
>A> AB 10MG A090868 002 Jun 08, 2010 Sep CAHN
>A> AB 20MG A090868 003 Jun 08, 2010 Sep CAHN
>A> AB 40MG A090868 004 Jun 08, 2010 Sep CAHN
>A> AB 80MG A090868 005 Jun 08, 2010 Sep CAHN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

>A>	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343 004	Sep 18, 2012	Sep	NEWA
>A>		20MG;EQ 50MG BASE	N202343 005	Sep 18, 2012	Sep	NEWA
>A>		40MG;EQ 50MG BASE	N202343 006	Sep 18, 2012	Sep	NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
+		EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	@ MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--	--------------------	-------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

	@ BRACCO	200uCi/ML	N013993 001		Jun	DISC
--	----------	-----------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

	@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
--	-----------------	--------	-------------	--	-----	------

SOLUTION; ORAL

SODIUM IODIDE I 123

	@ GE HEALTHCARE	2mCi/ML	N017630 002		Jul	DISC
--	-----------------	---------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

	JUBILANT DRAXIMAGE	9-100mCi	N021305 006	May 19, 2005	Feb	CAHN
--	--------------------	----------	-------------	--------------	-----	------

CAPSULE; ORAL

SODIUM IODIDE I-131

@ JUBILANT DRAXIMAGE	2-200mCi	N021305 004	Nov 18, 2004	Jan	DISC
----------------------	----------	-------------	--------------	-----	------

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE	1-1000mCi/ML	N021305 005	Apr 04, 2006	Feb	DISC
----------------------	--------------	-------------	--------------	-----	------

@	1-250mCi/0.25ML	N021305 002	Jan 24, 2003	Feb	DISC
---	-----------------	-------------	--------------	-----	------

@	1-500mCi/0.5ML	N021305 003	Jan 24, 2003	Feb	DISC
---	----------------	-------------	--------------	-----	------

+	250-1000mCi	N021305 007	Dec 05, 2011	Jan	NEWA
---	-------------	-------------	--------------	-----	------

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS	300MG/10ML (30MG/ML)	N203922 001	Feb 14, 2012	Feb	NEWA
---------------	----------------------	-------------	--------------	-----	------

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS	500MG/ML	N021196 001	Jul 17, 2002	Jun	CAHN
---------------	----------	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHARMA	454GM/BOT	A040909 001	Dec 03, 2008	Jun	DISC
----------------	-----------	-------------	--------------	-----	------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923 001	Feb 14, 2012	Feb	NEWA
---------------	------------------------	-------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK INC	5MG/1.5ML	N021148 001	Jun 20, 2000	Jul	DISC
--------------------	-----------	-------------	--------------	-----	------

@	10MG/1.5ML	N021148 002	Jun 20, 2000	Jul	DISC
---	------------	-------------	--------------	-----	------

@	15MG/1.5ML	N021148 003	Jun 20, 2000	Jul	DISC
---	------------	-------------	--------------	-----	------

>D>	NORDITROPIN NORDIFLEX				
-----	-----------------------	--	--	--	--

>D>	BX	NOVO NORDISK INC	5MG/1.5ML	N021148 004	Oct 01, 2004 Sep DISC
-----	----	------------------	-----------	-------------	-----------------------

>A>		@	5MG/1.5ML	N021148 004	Oct 01, 2004 Sep DISC
-----	--	---	-----------	-------------	-----------------------

>D>	BX		10MG/1.5ML	N021148 005	Oct 01, 2004 Sep DISC
-----	----	--	------------	-------------	-----------------------

>A>		@	10MG/1.5ML	N021148 005	Oct 01, 2004 Sep DISC
-----	--	---	------------	-------------	-----------------------

>D>			15MG/1.5ML	N021148 006	Oct 01, 2004 Sep DISC
-----	--	--	------------	-------------	-----------------------

>A>		@	15MG/1.5ML	N021148 006	Oct 01, 2004 Sep DISC
-----	--	---	------------	-------------	-----------------------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2	EPIC PHARMA INC	80MG	A077070 001	Nov 04, 2005	Jun CAHN
-----	-----------------	------	-------------	--------------	----------

AB2		120MG	A077070 002	Nov 04, 2005	Jun CAHN
-----	--	-------	-------------	--------------	----------

AB2		160MG	A077070 003	Nov 04, 2005	Jun CAHN
-----	--	-------	-------------	--------------	----------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	N022408 001	Jan 18, 2011	May CAHN
---	-------------	------	-------------	--------------	----------

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC 100MG N019998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB FOUGERA PHARMS 10% A077015 001 Nov 17, 2006 Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFATRIM

@ STI PHARMA LLC 200MG/5ML;40MG/5ML N018615 002 Jan 07, 1983 Aug CAHN

SULFATRIM PEDIATRIC

AB STI PHARMA LLC 200MG/5ML;40MG/5ML N018615 001 Jan 07, 1983 Aug CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+ JAZZ PHARMS COMMERCL 15% N006530 003 Jan 27, 1987 Mar CAHN

+ JAZZ PHARMS II 15% N006530 003 Jan 27, 1987 Jul CAHN

+ JAZZ PHARMS III 15% N006530 003 Jan 27, 1987 Jun CAHN

SUPPOSITORY; VAGINAL

AVC

@ JAZZ PHARMS COMMERCL 1.05GM N006530 004 Jan 27, 1987 Mar CAHN

@ JAZZ PHARMS II 1.05GM N006530 004 Jan 27, 1987 Jul CAHN

@ JAZZ PHARMS III 1.05GM N006530 004 Jan 27, 1987 Jun CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX MERIDIAN MEDCL EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N022377 001 Jun 29, 2010 Jun CRLD

SUMATRIPTAN SUCCINATE

AP INJECTALIA EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A090310 001 Aug 11, 2010 Mar CAHN

SUMAVEL DOSEPRO

BX + ZOGENIX INC EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N022239 001 Jul 15, 2009 Jun CTEC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB APOTEX INC EQ 25MG BASE A200263 001 Jun 19, 2012 Jun NEWA

AB EQ 50MG BASE A200263 002 Jun 19, 2012 Jun NEWA

AB EQ 100MG BASE A200263 003 Jun 19, 2012 Jun NEWA

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

>D> AB ACCORD HLTHCARE 0.5MG A091195 001 Aug 31, 2011 Sep CPOT

>A> AB EQ 0.5MG BASE A091195 001 Aug 31, 2011 Sep CPOT

>D> AB 1MG A091195 002 Aug 31, 2011 Sep CPOT

>A> AB EQ 1MG BASE A091195 002 Aug 31, 2011 Sep CPOT

>D> AB 5MG A091195 003 Aug 31, 2011 Sep CPOT

>A> AB EQ 5MG BASE A091195 003 Aug 31, 2011 Sep CPOT

>A> AB PANACEA BIOTEC LTD EQ 0.5MG BASE A090802 001 Sep 28, 2012 Sep NEWA

CAPSULE; ORAL

TACROLIMUS

>A>	AB	PANACEA BIOTEC LTD	EQ 1MG BASE	A090802 002	Sep 28, 2012	Sep	NEWA
>A>	AB		EQ 5MG BASE	A090802 003	Sep 28, 2012	Sep	NEWA

T AFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+		MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	--	-------------------	---------	-------------	--------------	-----	------

T ALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+		PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--	--------	----------------	-------------	--------------	-----	------

T AMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

		ONCOGENERIX PHARMS	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD
--	--	--------------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

TAMOXIFEN CITRATE

@		AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
---	--	--------------	--------------	-------------	--------------	-----	------

@			EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC
---	--	--	--------------	-------------	--------------	-----	------

T AZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+		STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	--	------------------	------	-------------	--------------	-----	------

T ECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@		JUBILANT DRAXIMAGE	N/A	N018035 001		May	CAHN
---	--	--------------------	-----	-------------	--	-----	------

DRAXIMAGE MDP-25

+		JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--	--------------------	-----	-------------	--------------	-----	------

T EMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB		NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
----	--	----------------	-------	-------------	--------------	-----	------

AB			22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA
----	--	--	--------	-------------	--------------	-----	------

T EMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB		MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
----	--	-------------------	-----	-------------	--------------	-----	------

AB			20MG	N021029 002	Aug 11, 1999	Jun	CAHN
----	--	--	------	-------------	--------------	-----	------

AB			100MG	N021029 003	Aug 11, 1999	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB			140MG	N021029 005	Oct 19, 2006	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB			180MG	N021029 006	Oct 19, 2006	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB	+		250MG	N021029 004	Aug 11, 1999	Jun	CAHN
----	---	--	-------	-------------	--------------	-----	------

POWDER; INTRAVENOUS

TEMODAR

+		MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
---	--	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SCOOPFUL N022577 001 Jan 18, 2012 Jan NEWA

TABLET; ORAL

VIREAD

GILEAD SCIENCES INC 150MG N021356 002 Jan 18, 2012 Apr NEWA

200MG N021356 003 Jan 18, 2012 Apr NEWA

250MG N021356 004 Jan 18, 2012 Apr NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 1MG BASE A076021 001 Aug 22, 2002 Apr DISC

@ EQ 2MG BASE A076021 002 Aug 22, 2002 Apr DISC

@ EQ 5MG BASE A076021 003 Aug 22, 2002 Apr DISC

@ EQ 10MG BASE A076021 004 Aug 22, 2002 Apr DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ TEVA PARENTERAL 1MG/ML A076853 001 Jul 20, 2004 Jan DISC

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB FOUGERA PHARMS 0.4% A076712 001 Feb 18, 2005 Jan CAHN

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB FOUGERA PHARMS 80MG A076850 001 Jul 12, 2006 Jan CAHN

>A> TERIFLUNOMIDE

>A> TABLET; ORAL

>A> AUBAGIO

>A> SANOFI AVENTIS US 7MG N202992 001 Sep 12, 2012 Sep NEWA

>A> + 14MG N202992 002 Sep 12, 2012 Sep NEWA

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

@ EMD SERONO EQ 1MG BASE/VIAL N022505 001 Nov 10, 2010 Jun DISC

+ EQ 1MG BASE/VIAL N022505 001 Nov 10, 2010 May CAHN

+ EQ 2MG BASE/VIAL N022505 002 Nov 29, 2011 Jun NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX + ABBOTT LABS 1% (50MG/5GM PACKET) N021015 002 Feb 28, 2000 Feb CPOT

1% (25MG/2.5GM PACKET) N021015 001 Feb 28, 2000 Feb CPOT

>A> ABBVIE 1.62% (20.25MG/1.25GM PACKET) N022309 002 Sep 07, 2012 Sep NEWA

>A> + 1.62% (40.5MG/2.5GM PACKET) N022309 003 Sep 07, 2012 Sep NEWA

TESTIM

BX + AUXILIUM PHARMS 1% (50MG/5GM PACKET) N021454 001 Oct 31, 2002 Feb CPOT

TESTOSTERONE

TEVA PHARMS 25MG/2.5GM PACKET N202763 001 Feb 14, 2012 Feb NEWA

	GEL; TRANSDERMAL								
	TESTOSTERONE								
	TEVA PHARMS	50MG/5GM PACKET		N202763	002	Feb 14, 2012	Feb	NEWA	
	GEL, METERED; TRANSDERMAL								
	ANDROGEL								
	+	ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015	003	Sep 26, 2003	Jun	CPOT	
	FORTESTA								
>D>	+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Sep	CPOT	
>A>	+		10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Sep	CPOT	
	PELLET; IMPLANTATION								
	TESTOPEL								
	+	ACTIENT PHARMS	75MG	A080911	001		May	CAHN	
	SOLUTION, METERED; TRANSDERMAL								
	AXIRON								
>D>	+	ELI LILLY AND CO	30MG/1.5ML ACTIVATION	N022504	001	Nov 23, 2010	Sep	CPOT	
>A>	+		30MG/1.5ML ACTIVATION	N022504	001	Nov 23, 2010	Sep	CPOT	
	<u>TESTOSTERONE CYPIONATE</u>								
	INJECTABLE; INJECTION								
	TESTOSTERONE CYPIONATE								
AO	HIKMA FARMACEUTICA	200MG/ML		A091244	001	May 01, 2012	Apr	NEWA	
AO	MYLAN INSTITUTIONAL	200MG/ML		A040652	001	Dec 11, 2006	Feb	CAHN	
	<u>TESTOSTERONE ENANTHATE</u>								
	INJECTABLE; INJECTION								
	TESTOSTERONE ENANTHATE								
>A>	AO	HIKMA FARMACEUTICA	200MG/ML	A091120	001	Sep 18, 2012	Sep	NEWA	
	AO	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Feb	CAHN	
	<u>TETRABENAZINE</u>								
	TABLET; ORAL								
	XENAZINE								
	VALEANT PHARMS	12.5MG		N021894	001	Aug 15, 2008	Apr	CAHN	
	+		25MG	N021894	002	Aug 15, 2008	Apr	CAHN	
	<u>TETRAHYDROZOLINE HYDROCHLORIDE</u>								
	SOLUTION; NASAL								
	TYZINE								
	+	FOUGERA PHARMS	0.05%	A086576	002		Jan	CAHN	
			0.1%	A086576	001		Jan	CAHN	
	SPRAY; NASAL								
	TYZINE								
	+	FOUGERA PHARMS	0.1%	A086576	003		Jan	CAHN	
	<u>THEOPHYLLINE</u>								
	CAPSULE, EXTENDED RELEASE; ORAL								
	THEO-24								
	UCB INC	100MG		A087942	001	Aug 22, 1983	May	CTEC	
		200MG		A087943	001	Aug 22, 1983	May	CTEC	
		300MG		A087944	001	Aug 22, 1983	May	CTEC	
	+		400MG	A081034	001	Feb 28, 1992	May	CRLD	
	THEOPHYLLINE								
	@	INWOOD LABS	100MG	A040052	001	Feb 14, 1994	May	DISC	
	@		125MG	A040052	002	Feb 14, 1994	May	DISC	
	@		200MG	A040052	003	Feb 14, 1994	May	DISC	
	@		300MG	A040052	004	Feb 14, 1994	May	DISC	

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC
@		40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC
@		80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC
@		160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC
@		200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC
@		320MG/100ML	N018649	006	Nov 13, 1985	Mar	DISC
@		400MG/100ML	N018649	005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

AA	+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Jun	CTEC
AA		TRIS PHARMA INC	80MG/15ML	A091586	001	Jun 15, 2012	Jun	NEWA

TABLET; ORAL

THEOLAIR

+	MEDICIS	125MG	A086399	001		Jul	CAHN
+		250MG	A086399	002		Jul	CAHN

TABLET, EXTENDED RELEASE; ORAL

UNIPHYL

>D>	@	PURDUE PHARM PRODS	400MG	A087571	001	Sep 01, 1982	Sep	CAHN
>D>	@		600MG	A040086	001	Apr 15, 1996	Sep	CAHN
>A>	@	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Sep	CAHN
>A>	@		600MG	A040086	001	Apr 15, 1996	Sep	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	100MG/ML	A091623	001	Jun 25, 2012	Jun	NEWA
----	--	---------------------	----------	---------	-----	--------------	-----	------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@	CEPHALON	6MG	N020646	006	Nov 29, 2005	Jan	DISC
@		8MG	N020646	007	Nov 29, 2005	Jan	DISC
@		10MG	N020646	008	Nov 29, 2005	Jan	DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB		MISSION PHARMA	250MG	N021618	001	May 17, 2004	Apr	CFTG
AB	+		500MG	N021618	002	May 17, 2004	Apr	CFTG

TINIDAZOLE

AB		NOVEL LABS INC	250MG	A202044	001	Apr 30, 2012	Apr	NEWA
AB			500MG	A202044	002	Apr 30, 2012	Apr	NEWA
AB		ROXANE	250MG	A201172	001	Apr 30, 2012	Apr	NEWA
AB			500MG	A201172	002	Apr 30, 2012	Apr	NEWA

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

@	LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000	Jun	DISC
---	---------------	--------------	---------	-----	--------------	-----	------

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB		APOTEX INC	EQ 2MG BASE	A078868	001	Feb 03, 2012	Jan	NEWA
----	--	------------	-------------	---------	-----	--------------	-----	------

CAPSULE; ORALTIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
<u>ZANAFLEX</u>						
AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORALTIZANIDINE HYDROCHLORIDE

>D>	AB	ALPHAPHARM	EQ 2MG BASE	A076282 001	Dec 16, 2003	Sep	CAHN
>D>	AB		EQ 4MG BASE	A076282 002	Dec 16, 2003	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003	Sep	CAHN
>A>	AB		EQ 4MG BASE	A076282 002	Dec 16, 2003	Sep	CAHN
	AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
	AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
	AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOBRAMYCIN SULFATEINJECTABLE; INJECTIONTOBRAMYCIN SULFATE

>D>	AP	AKORN STRIDES	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN
>D>	AP	APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
>A>	@		EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
>A>	AP	PFIZER	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN

TOLBUTAMIDETABLET; ORALTOLBUTAMIDE

	+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
	@	WATSON LABS	500MG	A087318 001		Mar	DISC
	@		500MG	A086109 001		Mar	DISC

TOLCAPONETABLET; ORALTASMAR

	+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
	@		200MG	N020697 002	Jan 29, 1998	May	CAHN

TOLTERODINE TARTRATETABLET; ORALDETROL

>D>		PHARMACIA AND UPJOHN	1MG	N020771 001	Mar 25, 1998	Sep	CFTG
>A>	AB		1MG	N020771 001	Mar 25, 1998	Sep	CFTG
>D>		+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG
>A>	AB	+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG
>A>		TOLTERODINE TARTRATE					
>A>	AB	APOTEX CORP	1MG	A200164 001	Sep 25, 2012	Sep	NEWA
>A>	AB		2MG	A200164 002	Sep 25, 2012	Sep	NEWA

TOPOTECAN HYDROCHLORIDEINJECTABLE; INJECTIONTOPOTECAN HYDROCHLORIDE

AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
AP	ONCO THERAPIES LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012	Aug	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB	ALPHAPHARM	50MG	A075980	001	Nov 21, 2002	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002	Sep	CAHN
		@ SANDOZ	50MG	A075968	001	Jun 25, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2		ACTAVIS	100MG	A091609	001	Jun 27, 2012	Jun	NEWA
AB2			200MG	A091609	002	Jun 27, 2012	Jun	NEWA
AB2			300MG	A091609	003	Jun 27, 2012	Jun	NEWA
AB2		ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Jun	NEWA
AB2			200MG	A200491	002	Jun 27, 2012	Jun	NEWA
AB2			300MG	A200491	003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

	+	SHIONOGI INC	50MG	N021693	001	May 05, 2005	Mar	CTNA
--	---	--------------	------	---------	-----	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP		APP PHARMS LLC	100MG/ML	A091596	001	Mar 02, 2012	May	CAHN
>A>	AP	LUITPOLD	100MG/ML	A201885	001	Aug 10, 2011	Sep	CAHN
AP		NEXUS PHARMS	100MG/ML	A091596	001	Mar 02, 2012	Feb	NEWA
>D>	AP	PHARMAFORCE	100MG/ML	A201885	001	Aug 10, 2011	Sep	CAHN

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

>D>	AB	MATRIX LABS LTD	50MG	A090514	001	Jun 02, 2009	Sep	CAHN
>D>	AB		100MG	A090514	002	Jun 02, 2009	Sep	CAHN
>D>	AB		150MG	A090514	003	Jun 02, 2009	Sep	CAHN
>D>	AB		300MG	A090514	004	Jun 02, 2009	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	Sep	CAHN
>A>	AB		100MG	A090514	002	Jun 02, 2009	Sep	CAHN
>A>	AB		150MG	A090514	003	Jun 02, 2009	Sep	CAHN
>A>	AB		300MG	A090514	004	Jun 02, 2009	Sep	CAHN

TRETINOIN

CREAM; TOPICAL

AVITA

AB		MYLAN PHARMS INC	0.025%	N020404	003	Jan 14, 1997	Jun	CAHN
----	--	------------------	--------	---------	-----	--------------	-----	------

RENOVA

	+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522	001		Jan	CAHN
AB	+		0.1%	N017340	001		Jan	CAHN

CREAM; TOPICAL

TRETINOIN

	AB	PRECISION DERMAT	0.025%	A075264 001	Dec 24, 1998	May	CAHN
		+	0.0375%	A090098 001	Mar 22, 2010	May	CAHN
	AB1		0.05%	A075265 001	Dec 24, 1998	May	CAHN
>A>			0.075%	A202209 001	Oct 11, 2012	Sep	NEWA
	AB		0.1%	A075213 001	Dec 24, 1998	May	CAHN
	AB2	SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	May	CAHN

GEL; TOPICAL

RETIN-A

	AB	+ VALEANT INTL	0.01%	N017955 001		Jan	CAHN
	AB	+	0.025%	N017579 002		Jan	CAHN

TRETINOIN

	AB	PRECISION DERMAT	0.01%	A075589 001	Jun 11, 2002	May	CAHN
	AB		0.025%	A075529 001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL

RETIN-A

	AT	+ VALEANT INTL	0.05%	N016921 001		Jan	CAHN
--	----	----------------	-------	-------------	--	-----	------

SWAB; TOPICAL

RETIN-A

@ VALEANT INTL

			0.05%	N016921 002		Jan	CAHN
--	--	--	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

@ ABBOTT

			0.1MG/INH	N018117 001	Apr 23, 1982	May	DISC
--	--	--	-----------	-------------	--------------	-----	------

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT	FOUGERA PHARMS	0.025%	A085692 001		Jan	CAHN
	AT		0.1%	A085692 003		Jan	CAHN
	AT	+	0.5%	A085692 002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT	FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN
	AT		0.1%	A040467 002	Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

	AT	FOUGERA PHARMS	0.025%	A085691 001		Jan	CAHN
	AT		0.1%	A085691 003		Jan	CAHN
	AT		0.5%	A085691 002		Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

	AB	TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar	CAHN
--	----	-------------	---------------	-------------	--------------	-----	------

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

>D>	AB	ALPHAPHARM	0.125MG	A074031 001	Mar 25, 1994	Sep	CAHN
>D>	AB		0.25MG	A074031 002	Mar 25, 1994	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	0.125MG	A074031 001	Mar 25, 1994	Sep	CAHN
>A>	AB		0.25MG	A074031 002	Mar 25, 1994	Sep	CAHN

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

>D>	AT	ALCON	1%	A074311 001	Oct 06, 1995	Sep	CAHN
-----	----	-------	----	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

>A>	AT	ALCON PHARMS LTD	1%	A074311	001	Oct 06, 1995	Sep	CAHN
-----	----	------------------	----	---------	-----	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

	@	HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987	Jun	DISC
--	---	---------	----------	---------	-----	--------------	-----	------

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

>D>	+	ALLERGAN	60MG	N022103	001	Aug 03, 2007	Sep	CFTG
-----	---	----------	------	---------	-----	--------------	-----	------

>A>	AB	+	60MG	N022103	001	Aug 03, 2007	Sep	CFTG
-----	----	---	------	---------	-----	--------------	-----	------

>A>		TROSPIUM CHLORIDE						
-----	--	-------------------	--	--	--	--	--	--

>A>	AB	WATSON LABS INC FL	60MG	A091289	001	Oct 12, 2012	Sep	NEWA
-----	----	--------------------	------	---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA
----	--------------------	---------------	---------	-----	--------------	-----	------

AB		EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA
----	--	-------------	---------	-----	--------------	-----	------

>D>	AB	MATRIX LABS LTD	EQ 500MG BASE	A078518	001	May 24, 2010	Sep	CAHN
-----	----	-----------------	---------------	---------	-----	--------------	-----	------

>D>	AB		EQ 1GM BASE	A078518	002	May 24, 2010	Sep	CAHN
-----	----	--	-------------	---------	-----	--------------	-----	------

>A>	AB	MYLAN PHARMS INC	EQ 500MG BASE	A078518	001	May 24, 2010	Sep	CAHN
-----	----	------------------	---------------	---------	-----	--------------	-----	------

>A>	AB		EQ 1GM BASE	A078518	002	May 24, 2010	Sep	CAHN
-----	----	--	-------------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	May	CAHN
---	-------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001	May	CAHN
---	-------------------	---------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG
----	------------	---------------	---------	-----	--------------	-----	------

AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG
----	---	---------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	NEWA
----	-------	---------------	---------	-----	--------------	-----	------

AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB	APP PHARMS LLC	EQ 125MG BASE	A065453	001	Jun 18, 2012	Jun	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

AB		EQ 250MG BASE	A065453	002	Jun 18, 2012	Jun	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Mar	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

AB		EQ 250MG BASE	A065490	002	Apr 09, 2012	Mar	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB	WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012	Mar	NEWA
----	-------------	---------------	---------	-----	--------------	-----	------

AB		EQ 250MG BASE	A065510	002	Apr 09, 2012	Mar	NEWA
----	--	---------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837	001	Aug 10, 2012	Jul	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Jul	NEWA
----	------------	------------------	---------	-----	--------------	-----	------

AP		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Jul	NEWA
----	--	-------------------	---------	-----	--------------	-----	------

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
+		300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
AP	+	SUN PHARMA GLOBAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP	+		A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+ LUNDBECK LLC 500MG/PACKET N022006 001 Aug 21, 2009 Apr CAHN

TABLET; ORAL

SABRIL

+ LUNDBECK LLC 500MG N020427 001 Aug 21, 2009 Apr CAHN

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VLIBRYD

+ FOREST LABS INC 10MG N022567 001 Jan 21, 2011 Apr CRLD

40MG N022567 003 Jan 21, 2011 Apr CRLD

VINCRISTINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+ TALON THERAP 5MG/5ML (1MG/ML) N202497 001 Aug 09, 2012 Aug NEWA

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

AP ONCO THERAPIES LTD EQ 10MG BASE/ML A200148 001 Aug 31, 2012 Aug NEWA

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>A> AP JIANGSU HANSON PHARM EQ 10MG BASE/ML A091106 001 Sep 26, 2012 Sep NEWA

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ GENENTECH 150MG N203388 001 Jan 30, 2012 Jan NEWA

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP + PFIZER 200MG/VIAL N021267 001 May 24, 2002 May CFTG

VORICONAZOLE

AP SANDOZ INC 200MG/VIAL A090862 001 May 30, 2012 May NEWA

TABLET; ORAL

VORICONAZOLE

AB TEVA PHARMS 50MG A091658 001 Apr 06, 2012 Mar NEWA

AB 200MG A091658 002 Apr 06, 2012 Mar NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@ JAZZ PHARMS COMMERCL 200MCG/2ML (100MCG/ML) N021060 003 Dec 28, 2004 Mar CAHN

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML) N021060 003 Dec 28, 2004 Jun CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+ JAZZ PHARMS COMMERCL 100MCG/1ML (100MCG/ML) N021060 002 Dec 28, 2004 Mar CAHN

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN
+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Jun	CAHN
+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Jun	CAHN
+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

>D>	AB	MATRIX LABS LTD	300MG	A078922 001	Feb 14, 2008	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	300MG	A078922 001	Feb 14, 2008	Sep	CAHN
		@ RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562 001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562 002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562 003	Jun 01, 2012	May	NEWA
AB			EQ 80MG BASE	A077562 004	Jun 01, 2012	May	NEWA
AB		WOCKHARDT LTD	EQ 20MG BASE	A090348 001	Sep 05, 2012	Aug	NEWA
AB			EQ 40MG BASE	A090348 002	Sep 05, 2012	Aug	NEWA
AB			EQ 60MG BASE	A090348 003	Sep 05, 2012	Aug	NEWA
AB			EQ 80MG BASE	A090348 004	Sep 05, 2012	Aug	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB		CIPLA LTD	5MG	A077388 001	Jul 30, 2012	Jul	NEWA
AB			10MG	A077388 002	Jul 30, 2012	Jul	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

>D>	AB	ALPHAPHARM	25MG	A077647 001	Dec 22, 2005	Sep	CAHN
>D>	AB		50MG	A077647 002	Dec 22, 2005	Sep	CAHN
>D>	AB		100MG	A077647 003	Dec 22, 2005	Sep	CAHN

CAPSULE; ORAL

ZONISAMIDE

>A>	AB	MYLAN PHARMS INC	25MG	A077647 001	Dec 22, 2005	Sep	CAHN
>A>	AB		50MG	A077647 002	Dec 22, 2005	Sep	CAHN
>A>	AB		100MG	A077647 003	Dec 22, 2005	Sep	CAHN

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+ MCNEIL CONS 800MG;10MG;165MG N020958 001 Oct 16, 2000 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ RANBAXY LABS LTD 5MG/5ML A090183 002 Apr 24, 2008 Jul DISC

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ RANBAXY LABS LTD 5MG/5ML A090183 001 Apr 24, 2008 Jul DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> SUN PHARM INDS LTD 5MG;120MG A090922 001 Sep 28, 2012 Sep NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION 2%;70% (0.67ML) N021555 001 Oct 07, 2002 Aug CAHN

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION 2%;70% (1.75ML) N021555 002 May 10, 2005 Aug CAHN

CHLORAPREP TRIPLE SWABSTICK

+ CAREFUSION 2%;70% (5.25ML) N021555 003 Jun 10, 2009 Aug CAHN

CHLORASCUB MAXI SWABSTICK

+ PROF DSPLS 3.15%;70% (5.1ML) N021524 003 Jun 03, 2005 Mar CAHN

CHLORASCUB SWAB

+ PROF DSPLS 3.15%;70% (1ML) N021524 001 Jun 03, 2005 Mar CAHN

CHLORASCUB SWABSTICK

+ PROF DSPLS 3.15%;70% (1.6ML) N021524 002 Jun 03, 2005 Mar CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC EQ 30MG HBR/5ML A091135 001 May 25, 2012 May NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A200888 001 Mar 05, 2012 Feb NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS 10MG N020801 001 Sep 24, 1998 Mar CAHN

+ 20MG N020801 002 Dec 17, 2007 Mar CAHN

TABLET; ORAL

PEPCID AC

MCNEIL CONS 10MG N020325 001 Apr 28, 1995 Mar CAHN

+ 20MG N020325 002 Sep 23, 2003 Mar CAHN

TABLET; ORAL

PEPCID AC (GELTAB)

MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN
-------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

	180MG	A091567	006	Feb 06, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

	180MG	A079112	006	Feb 08, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

	180MG	A091567	005	Feb 06, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

	180MG	A079112	005	Feb 08, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	---------	-----	--------------	-----	------

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	Jun	NEWA
------------------------	---------------	---------	-----	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012	Apr	NEWA
--------------------	------	---------	-----	--------------	-----	------

PERRIGO R AND D	15MG	A202319	001	May 18, 2012	Apr	NEWA
-----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	15MG	A202727	001	May 18, 2012	Apr	NEWA
---------------	------	---------	-----	--------------	-----	------

PREVACID 24 HR

+ NOVARTIS	15MG	N022327	001	May 18, 2009	Apr	CFTG
------------	------	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Jun	NEWA
-----------------	-------	---------	-----	--------------	-----	------

PLAN B

+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	May	CAHN
----------------------	--------	---------	-----	--------------	-----	------

PLAN B ONE-STEP

+ DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG
-----------	-------	---------	-----	--------------	-----	------

LORATADINE

SYRUP; ORAL

LORATADINE

@ RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004	Jul	DISC
--------------------	--------	---------	-----	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

AVEVA	7MG/24HR	A074612 002	Jul 28, 2003	Apr	NEWA
	14MG/24HR	A074612 003	Oct 20, 1997	Apr	NEWA

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

>A>	PERRIGO R AND D	EQ 2MG BASE	A203690 001	Oct 09, 2012	Sep	NEWA
>A>		EQ 4MG BASE	A203690 002	Oct 09, 2012	Sep	NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

>D>	PADDOCK LLC	17GM/SCOOPFUL	A090567 001	Oct 15, 2009	Sep	DISC
>A>	@	17GM/SCOOPFUL	A090567 001	Oct 15, 2009	Sep	DISC

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172 001	May 31, 2012	May	NEWA
SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2012

NO SEPTEMBER 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A091294 001					>A> PC	Dec 16, 2012
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP	U-1264		
	7078412	Jul 16, 2020	DS DP	U-1263		
	8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022		U-1078		
	8129362	Jul 18, 2027		U-1078		
	8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N022344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030		U-1225		
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	RE42462	Jul 29, 2018	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	RE42462	Jul 29, 2018	DS			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	8216289	May 01, 2018		U-289		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>APREPITANT - EMEND</u>						
N021549 001	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 002	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 003	>A> 8258132	Sep 26, 2027	DP U-901			
	>A> 8258132	Sep 26, 2027	DP U-1282			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE ODE PED PED	Mar 20, 2013 Mar 20, 2015 Sep 20, 2015 Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE ODE PED PED	Mar 20, 2013 Mar 20, 2015 Sep 20, 2015 Sep 20, 2013
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
	>A> 8263054	Aug 25, 2023	U-1277			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	>A> 8278353	Mar 16, 2025	DP			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 001	>A> 6002008	Mar 27, 2018	DS DP U-1284		>A> NCE	Sep 04, 2017
	>A> 7417148	Jan 23, 2026	U-1283		>A> ODE	Sep 04, 2019
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7919625	Dec 11, 2025	DP			
	>A> RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 002	>A> 6002008	Mar 27, 2018	DS DP U-1284		>A> NCE	Sep 04, 2017
	>A> 7417148	Jan 23, 2026	U-1283		>A> ODE	Sep 04, 2019
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7919625	Dec 11, 2025	DP			
	>A> RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003					NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004					NDF	Aug 30, 2013
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001	>A> 8263580	May 26, 2026	DP U-1280		>A> I-657	Sep 27, 2015
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	>A> 8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	>A> 8247400	Feb 10, 2031	DP U-282			
<u>CEVIMELINE HYDROCHLORIDE - CEVIMELINE</u>						
A091260 001					>A> PC	Apr 06, 2013
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N203155 001					>A> NCE >A> W	Sep 12, 2017 Sep 12, 2017
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665	002				PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023	001				PC	Nov 13, 2012
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100	001	>A> 5814639	Sep 29, 2015	DS DP		
		>A> 5914331	Jul 02, 2017	DS		
		>A> 5922695	Jul 25, 2017	DS	U-257	
		>A> 5935946	Jul 25, 2017	DS DP	U-257	
		>A> 5977089	Jul 25, 2017	DS DP	U-257	
		>A> 6043230	Jul 25, 2017		U-257	
		>A> 6642245	Nov 04, 2020		U-257	
		>A> 6703396	Mar 09, 2021	DS DP		
		>A> 7176220	Nov 20, 2023	DS DP	U-257	
		>A> 7635704	Jan 12, 2026	DS DP	U-257	
		>A> 8148374	Sep 03, 2029	DS DP	U-1279	
<u>COLCHICINE - COLCRYS</u>						
N022352	001	7964648	Oct 06, 2028		U-1161	
		8097655	Oct 06, 2028		U-1020	
<u>CRIZOTINIB - XALKORI</u>						
N202570	001	8217057	Nov 06, 2029	DS DP		
<u>CRIZOTINIB - XALKORI</u>						
N202570	002	8217057	Nov 06, 2029	DS DP		
<u>DAPTOMYCIN - CUBICIN</u>						
N021572	002	8129342	Nov 28, 2020	DS DP		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	001	5843946*PED	Jun 01, 2016			
		6037157	Jun 26, 2016		U-1209	
		6037157	Jun 26, 2016		U-935	
		6037157*PED	Dec 26, 2016			
		6335460	Aug 25, 2012	DS DP	U-935	
		6335460	Aug 25, 2012	DS DP	U-1209	
		6335460	Aug 25, 2012	DS DP	U-744	
		6335460	Aug 25, 2012	DS DP	U-903	
		6335460*PED	Feb 25, 2013			
		6703403	Jun 26, 2016		U-935	
		6703403	Jun 26, 2016		U-1209	
		6703403*PED	Dec 26, 2016			
		7470506	Jun 23, 2019		U-1209	
		7470506	Jun 23, 2019		U-935	
		7470506*PED	Dec 23, 2019			
		RE43596	May 09, 2017	DS DP		
		RE43596*PED	Nov 09, 2017			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016				U-1209
	6037157	Jun 26, 2016				U-935
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP			U-935
	6335460	Aug 25, 2012	DS DP			U-1209
	6335460	Aug 25, 2012	DS DP			U-744
	6335460	Aug 25, 2012	DS DP			U-903
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016				U-935
	6703403	Jun 26, 2016				U-1209
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019				U-1209
	7470506	Jun 23, 2019				U-935
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016				U-1209
	6037157	Jun 26, 2016				U-935
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP			U-935
	6335460	Aug 25, 2012	DS DP			U-1209
	6335460	Aug 25, 2012	DS DP			U-744
	6335460	Aug 25, 2012	DS DP			U-903
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016				U-935
	6703403	Jun 26, 2016				U-1209
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019				U-1209
	7470506	Jun 23, 2019				U-935
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	>A> 8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	>A> 8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	>A> 8101582	Dec 19, 2027	DP U-1082			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N021394 001	>A> 8263647	May 30, 2022	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2013	DS DP U-992			
	5223510	Jul 26, 2013	DS DP U-1261			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7160870	Nov 20, 2022	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	7160870	Nov 20, 2022	DS DP U-930			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001	>A> 7709517	Aug 13, 2027	DS DP		NCE	Aug 31, 2017
	>A> 8183274	May 15, 2026	U-1281			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
7411070	May 25, 2018	DS				
7411070*PED	Nov 25, 2018					
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
7411070	May 25, 2018	DS				
7411070*PED	Nov 25, 2018					

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001	>A> 5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	>A> 5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	>A> 6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	>A> 7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	>A> 7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002	>A> 5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	>A> 5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	>A> 6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	>A> 7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	>A> 7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003	>A> 5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	>A> 5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	>A> 6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	>A> 6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	>A> 7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	>A> 7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	003				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	004				M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	001	8124125	Oct 01, 2024	DP U-1234		
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	002	8124125	Oct 01, 2024	DP U-1234		
<u>FENTANYL - SUBSYS</u>						
N202788	001				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	002				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	003				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	004				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	005				NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	001	8092832	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	002	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	003	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	004	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	005	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569	001	8216604	Oct 03, 2024	U-767		
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569	002	8216604	Oct 03, 2024	U-767		
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266	001	7579019	Jan 22, 2020	U-767		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	Jul 03, 2022	DS	U-913		
	8088398	Jun 07, 2027	DP	U-913		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	Jul 03, 2022	DS	U-913		
	8088398	Jun 07, 2027	DP	U-913		
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	>A> 8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8062264	Apr 05, 2026	DP			
	8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
	>A> 8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
	>A> 8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021		U-1239		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 001					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 002					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 003					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 004					>A> PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 005					>A> PC	Mar 20, 2013
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 004	5702725	Jul 07, 2014	DP U-1043		>A> NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8188146	Jan 27, 2020	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	8236816	Dec 11, 2029	U-68			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	8222270	Dec 11, 2029	U-68			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>IRON SUCROSE - VENOFER</u>						
N021135 001					>A> NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 002					>A> NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 004					>A> NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024	U-1251			
	8207215*PED	Nov 28, 2024				
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N021035	002				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035	003				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035	004				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021505	001				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064	001	>A> 5698558	Jul 26, 2013	U-812		
		>A> 5698558*PED	Jan 26, 2014			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157	001	>A> 5698558	Jul 26, 2013	U-852		
		>A> 5698558*PED	Jan 26, 2014			
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623	001	6465709	Jul 07, 2020	DP		
<u>LINACLOTIDE - LINZESS</u>						
N202811	001	>A> 7304036	Jan 28, 2024	DS DP U-1278	NCE	Aug 30, 2017
		>A> 7371727	Jan 28, 2024	DS		
		>A> 7704947	Jan 28, 2024	DS DP		
		>A> 7745409	Jan 28, 2024	DS DP		
		>A> 8080526	Jan 28, 2024	DS DP		
		>A> 8110553	Jan 28, 2024	U-1278		
<u>LINACLOTIDE - LINZESS</u>						
N202811	002	>A> 7304036	Jan 28, 2024	DS DP U-1278	NCE	Aug 30, 2017
		>A> 7371727	Jan 28, 2024	DS		
		>A> 7704947	Jan 28, 2024	DS DP		
		>A> 7745409	Jan 28, 2024	DS DP		
		>A> 8080526	Jan 28, 2024	DS DP		
		>A> 8110553	Jan 28, 2024	U-1278		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		M-121	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-118	Aug 13, 2015
	6890898	Feb 02, 2019	U-493			
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1255			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004					D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 001					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 002					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 001	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 002	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 003	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	>A> 6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	>A> 6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	>A> 6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	>A> 6602911	Jan 14, 2023	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	8252776	Jun 24, 2025	U-124			
	>A> 8268804	Jun 24, 2025	U-1078			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023		U-913		
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027		U-1241		
	8158156	Jun 19, 2027		U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027		U-1241		
	8158156	Jun 19, 2027		U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027		U-1241		
	8158156	Jun 19, 2027		U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027		U-1241		
	8158156	Jun 19, 2027		U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027		U-1241		
	8158156	Jun 19, 2027		U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027		U-1241		
	8158156	Jun 19, 2027		U-1241		
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	>A> 8282966	Jun 30, 2029				U-1286
	>A> 8282966*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	>A> 8282966	Jun 30, 2029				U-1286
	>A> 8282966*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001					M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002					M-119	Aug 29, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	003				M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	004				M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	005				M-119	Aug 29, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725	004				I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175	001				NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175	002				NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222	002				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222	003				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542	002				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	001	8221747 Feb 20, 2028	DP			
		8246950 Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	002	8221747 Feb 20, 2028	DP			
		8246950 Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	003	8221747 Feb 20, 2028	DP			
		8246950 Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	004	8221747 Feb 20, 2028	DP			
		8246950 Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	005	8221747 Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210	006	8221747 Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465	001	8114885 Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465	002	8114885 Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	>A> 8263600	Apr 01, 2022	DP			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 003	8168218	Jan 07, 2028	DP U-1269			
<u>PREGABALIN - LYRICA</u>						
N021446 001	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 002	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 005	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 006	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 007	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 008	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N022488 001	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N203085 001					>A> NCE	Sep 27, 2017
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP U-1265			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	8246989	Jan 16, 2026	DP			
<u>RITONAVIR - NORVIR</u>						
N022417 001	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2925				
<u>RIVASTIGMINE - EXELON</u>						
N022083 005	>A> 5602176	Feb 11, 2014	DS DP U-322		>A> NS	Aug 31, 2015
	>A> 6316023	Jan 08, 2019	DP			
	>A> 6335031	Jan 08, 2019	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			M-61	Aug 30, 2015
					PED	Mar 01, 2016
					PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF	Nov 20, 2012
					PED	Mar 01, 2016
					PED	May 20, 2013
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109 001					NDF	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	8168637	Jun 26, 2022	DP U-1188			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	>A> 8263650	Dec 22, 2019	DP U-1102			
	>A> 8263650	Dec 22, 2019	DP U-1101			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 22, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	>A> 8267903	Mar 18, 2023	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178		
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858 001					ODE	Aug 13, 2019
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2015
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-1275			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>							
N021356 003	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013	
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015	
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015	
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013	
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017	
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017	
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015	
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014	
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013	
	5935946	Jul 25, 2017	DS DP U-999				
	5935946*PED	Jan 25, 2018					
	5977089	Jul 25, 2017	DS DP U-248				
	5977089	Jul 25, 2017	DS DP U-250				
	5977089	Jul 25, 2017	DS DP U-256				
	5977089	Jul 25, 2017	DS DP U-999				
	5977089	Jul 25, 2017	DS DP U-1275				
	5977089*PED	Jan 25, 2018					
	6043230	Jul 25, 2017		U-1275			
	6043230	Jul 25, 2017		U-248			
	6043230	Jul 25, 2017		U-250			
	6043230	Jul 25, 2017		U-256			
	6043230	Jul 25, 2017		U-999			
	6043230*PED	Jan 25, 2018					
	<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
	N021356 004	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
		5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
		5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
		5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
5922695		Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017	
5922695*PED		Jan 25, 2018			PED	Sep 24, 2017	
5935946		Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015	
5935946		Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014	
5935946		Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013	
5935946		Jul 25, 2017	DS DP U-999				
5935946*PED		Jan 25, 2018					
5977089		Jul 25, 2017	DS DP U-248				
5977089		Jul 25, 2017	DS DP U-250				
5977089		Jul 25, 2017	DS DP U-256				
5977089		Jul 25, 2017	DS DP U-999				
5977089		Jul 25, 2017	DS DP U-1275				
5977089*PED		Jan 25, 2018					
6043230		Jul 25, 2017		U-1275			
6043230		Jul 25, 2017		U-248			
6043230		Jul 25, 2017		U-250			
6043230		Jul 25, 2017		U-256			
6043230		Jul 25, 2017		U-999			
6043230*PED		Jan 25, 2018					

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-1275		PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-250			
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 001	>A> 5459163	Oct 17, 2012	DP		>A> NCE	Sep 12, 2017
	>A> 5679709	Oct 21, 2014	DP U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 002	>A> 5459163	Oct 17, 2012	DP		>A> NCE	Sep 12, 2017
	>A> 5679709	Oct 21, 2014	DP U-1285			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002	>A> 5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	>A> 6020311	May 26, 2015	DS DP U-1100			
	>A> 7144577	Jul 14, 2020	U-1100			
	>A> 7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 002					>A> NP	Apr 29, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 003					>A> NP	Apr 29, 2014
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	6455557	Nov 28, 2021		Y		
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - Hycamtin</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - Hycamtin</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	>A> 8273795	May 20, 2026	U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	>A> 8268299	Oct 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1258			
	8211880	Mar 10, 2029	U-1257			
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		>A> ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020	U-1271			
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	------------------------	-----------------------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>